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1 Fundamental concepts of nanomedicine 
1.1 Nanoparticle-based therapeutic systems 
Nanomaterials have received growing attention as therapeutic systems due to their 
favorable pharmacokinetic and pharmacodynamic profiles [1-4] which are owed to 
their unique characteristics and their targeting capability. The increasing interest in the 
development of colloidal drug delivery systems is driven by the need for safer and 
more efficient therapeutics [5,6]. The use of conventional small-molecular drugs is 
often accompanied by undesired side effects deriving from their intrinsic toxicity and 
their non-specificity, which significantly limit their applicable dose and frequency of 
treatment [7,8]. In contrast, colloidal drug delivery systems provide essential 
advantages, such as improved drug solubility, controlled drug release, prolonged 
circulation times, reduced adverse effects and their potential to specifically target 
distinct tissues [1,9-11]. Nanoparticle-based therapeutic systems (Figure 1) are typically 
degradable, biodegradable or bioeliminable structures with a colloidal size up to 
150 nm [12]. They can be loaded with a variety of payloads (e.g. small molecular drugs, 
peptides and proteins) which are usually entrapped within the particle core [13].  
 
 
 
Figure 1. Parameters for the design of colloidal therapeutic systems. Adapted from [11]. 
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An additional polymer shell can be used to endow nanocarriers with “stealth” 
properties and prolong their circulation time in the systemic blood stream [14,15]. 
Furthermore, these polymers can be functionalized with ligands or imaging modalities 
and can be used to control surface charge and hydrophobicity [11,16-18]. Their 
physicochemical properties, including composition, size, surface charge and 
chemistry, hydrophobicity or shape mainly determine their biodistribution and drug 
release profiles and have to be taken carefully into consideration for the development 
of nanoparticle-based therapeutic systems [19,20]. 
 
1.2 Biodistribution and pharmacokinetics of colloids 
Upon intravenous administration, NPs enter the systemic blood circulation and are 
either excreted from the body via different clearance pathways or distributed to organs 
and peripheral tissues. NPs smaller than approximately 8 to 10 nm in size can pass the 
glomerular filtration barrier relatively unhindered and are rapidly removed from the 
blood via the urine [21-23].  In contrast, larger particles are subjected to biliary excretion 
and biodistribution into tissues [22,24,25]. Their circulation time in the blood stream 
mainly depends on the colloidal size and their ability to evade the reticuloendothelial 
system (RES) [11,26]. The RES, or mononuclear phagocyte system (MPS), consists of 
immune cells, including macrophages and monocytes, which are responsible for 
engulfing and eliminating pathogens, xenobiotic products or cell debris from the 
blood. Sequestration of NPs by these immune cells is mediated by presentation of 
distinct plasma complement factors and immunoglobulin proteins, also referred to as 
“opsonins” [27,28]. Upon entering the blood stream, numerous biomolecules instantly 
adsorb onto the colloidal surface forming a protein corona that bestows NPs with a 
new biological identity [29]. The identity and degree of opsonization is thereby dictated 
by physicochemical characteristics of colloids such as surface chemistry, material 
composition, size, charge, shape, hydrophobicity, or roughness [30-34]. For instance, 
larger particle sizes, correlating with larger radii of curvature, and a cationic surface 
charge favor opsonin adsorption and consequently enhance clearance by the RES [35]. 
To reduce recognition and uptake of colloids by immune cells of the RES it is essential 
to “stealth” NPs using highly hydrophilic antifouling polymers such as poly(ethylene 
glycol) (PEG) [26]. PEGylation significantly reduces adsorption of biomolecules and 
therefore, prolongs their circulation time which is considered a prerequisite for efficient 
accumulation of NPs in target tissues [14,15].
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2 Targeting strategies 
2.1 Passive tissue targeting 
Passive targeting is widely exploited for the treatment of tumors because it facilitates 
accumulation of long-circulating NPs due to the pathophysiological differences 
compared to healthy tissues [36]. The basement membrane of pathological 
neovasculature is discontinuous or even absent, allowing macromolecules and NPs 
with a size smaller than 200 nm to extravasate and accumulate in the interstitium of 
the diseased tissue [37-40]. Furthermore, solid tumors lack a lymphatic system 
resulting in reduced drainage of accumulated colloids [38,41,42]. This ability of 
nanoscaled colloids to accumulate selectively and to be retained for a prolonged period 
of time in tumor tissue or other infarcted areas is commonly referred to as “enhanced 
permeation and retention” (EPR) effect [36]. As efficient EPR-mediated targeting 
requires a prolonged circulation half-life that allows time for NPs to passage from the 
systemic circulation into the diseased and permeable regions, passively targeted 
colloidal drug delivery systems are usually modified with hydrophilic polymers, such 
as PEG [15]. However, PEGylation at the same time, impedes endocytic uptake and 
endosomal escape of NPs in target cells, which consequently results in a significant loss 
in efficacy of the drug delivery system, also referred to as “PEG dilemma” [43,44]. 
Recent studies have indicated, that the EPR effect offers less than 2-fold increase in NP 
accumulation in the diseased tissue compared with critical healthy organs which often 
achieves no adequate dose for efficient therapeutic treatment [45].   
 
2.2 Active tissue targeting 
In contrast to passive targeting, which has been introduced in the previous section, 
active targeting relies on the affinity of ligands presented on the surface of 
long-circulating colloids for matrix proteins or antigen receptors expressed on target 
tissues [46]. The rationale for specific NP-cell interactions is based on significantly 
higher expression levels of antigenic receptors on the cellular membrane and the high 
specificity and high binding affinity of the ligand [11]. A general scheme of the active 
targeting concept is depicted in Figure 2. In the case of off-target cells, the receptor 
expression is low or even absent, impeding specific interactions with targeted colloids, 
whereas ligand-decorated NPs can specifically bind to the target receptors resulting in 
NP accumulation on the cellular membrane. Moreover, receptor-mediated targeting 
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can be used to trigger endocytosis into cells, which can enhance therapeutic efficacy as 
it can significantly increase intracellular concentration of drug carriers [47,48]. 
Internalized NP-receptor complexes end up in vesicles of endosomes, which 
progressively acidify and mature into late endosomes. Unless NPs are not able to 
escape the endosome, they will be subsequently degraded in lysosomes [49].  
 
 
 
Figure 2. Schematic concept of active targeting using ligand-decorated NPs. Targeted NPs can selectively 
recognize and bind to their target cells followed by endocytosis. Concomitantly, interactions with 
off-target cells that express lower levels of the receptor can be minimized. 
 
 
Active targeting can be further subdivided into homomultivalent, i.e., targeting using 
only a single type of ligand, and heteromultivalent targeting, i.e., targeting using 
multiple types of ligand which are simultaneously presented on a single particle. A 
complex example for heteromultivalent binding is the targeting sequence of viruses 
which often also includes time-dependent effects. All of these concepts will be 
introduced in the following sections. 
 
2.2.1 Homomultivalent ligand presentation 
In contrast to small molecular drugs, ligand-decorated NPs are capable of multivalent 
binding to their targets [50]. Multivalency describes simultaneous interactions of 
multiple ligands of one entity with multiple receptors of another one, which results in 
an increase in avidity compared to a single ligand-receptor interaction [51,52]. This 
mechanism can also be used to transform low-affinity monovalent ligands into a 
high-avidity multivalent construct [53]. A general obstacle originating from covalent 
ligand attachment is the considerable loss in binding affinity which can, on the one 
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hand, be attributed to steric hindrance deriving from the polymeric linker [54,55] or, 
on the other hand, be a result of chemical transformation of distinct functional groups 
that are peculiarly important for the interaction of the ligand with the complementary 
receptor binding-sites [56]. Therefore, multivalent ligand presentation can benefit from 
the avidity gain that was previously reported to overcompensate the loss in affinity 
deriving from ligand conjugation to PEG linkers [54]. 
Moreover, multivalency enhances selectivity towards the target site since multivalent 
binding requires a high receptor density, whereas the binding affinity is substantially 
alleviated with decreasing densities of the target receptor [57]. As a consequence, the 
intrinsic multivalent nature of colloids allows for discrimination between target 
surfaces with different receptor expression levels [58]. In the case of pathological 
tissues with upregulated receptor expression, the binding of multiligand-decorated 
NPs is enhanced while the interaction with healthy organs and cells expressing basal 
levels of the respective receptor is minimized [57,58]. For this reason, an adequate 
manufacturing process that allows for precise control over particle characteristics is 
key for the successful development of multivalent binding NPs. Pivotal design factors 
include the colloidal ligand density [59-61], the flexibility and length of the 
linker [62,63], and the size [64,65] of the particle that dictates the interfacial contact area. 
Ligands that are employed for active targeting include a myriad of different synthetic 
and natural compounds including monoclonal antibodies (mAbs) and their fragments, 
proteins, peptides, aptamers, sugars and small molecular drugs [11,66].  
Monoclonal antibodies are among the most commonly used targeting ligands and have 
been successfully utilized to enhance targeting efficiency of polymeric NPs. For 
example, decoration of NPs with rituximab and trastuzumab resulted in a 6-fold higher 
particle uptake compared to non-targeted NPs [67,68]. However, mAb-decorated NPs 
still encounter diverse challenges and limitations since antibodies show insufficient 
stability in organic solvents, are potentially immunogenic, severely affect surface 
hydrophobicity and “stealth” properties upon conjugation to the colloid, which 
enhances recognition by the RES and promote rapid NP clearance [69,70]. Moreover, 
due to their large size of approximately 150 kDa, corresponding to an average 
hydrodynamic size of about 15 nm, surface conjugation of mAb-moieties leads to a 
significant increase in overall colloidal size by up to 30 nm [47,71]. To overcome these 
limitations, antibody fragments, such as antigen-binding fragments and single chain 
variable fragments are preferably employed [72].  
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Many endogenous proteins can be used to accomplish selective binding to specific 
receptors on cell membranes, followed by receptor-mediated endocytosis. For 
example, the epidermal growth factor (EGF), which binds specifically to the EGF 
receptor, has been attached to different types of NPs for imaging or therapeutic 
purposes [73-75]. However, protein-decorated NPs suffer from severe drawbacks, such 
as an enhanced immunogenicity as well as a rapid clearance from the systemic 
circulation through several mechanisms in the body, which drastically limit their 
in vivo performance [11]. Moreover, cognate receptors are commonly expressed on 
healthy off-target tissues, increasing the chance of undesired side-effects [76]. 
Peptides have gained increasing popularity as targeting moieties because they are 
small in size, can be chemically synthesized and therefore, provide tailorable chemical 
functions which facilitate specific conjugation to polymers, lipids and colloids [77,78]. 
Moreover, peptides are significantly less immunogenic compared to proteins and 
possess a higher stability in both aqueous and organic solvents [79]. One of the most 
studied peptide sequences is Arg-Gly-Asp, also known as RGD, which targets ανβ3 
integrin receptors highly upregulated in tumor cells or angiogenic endothelial 
cells [80-83]. However, ανβ3 integrin receptors are also expressed in normal tissues 
including endothelial cells of the healthy vascular system [11] or renal cells such as 
podocytes [84,85]. 
Aptamers are nucleic acid ligands [86] composed of either DNA, RNA or 
oligonucleotides folded into unique secondary structures which endows them with 
high specificity against their targets [87].  However, a change in this secondary 
structure due to heat or endonuclease and exonuclease degradation severely impairs 
their stability and targeting capability [88]. 
Small molecules constitute another class of targeting ligands. Due to their small size 
(< 1000 Da), high ligand densities can be obtained. Moreover, a wide range of different 
ligands are available possessing variable solubility and different functional groups that 
can be used for conjugation [17]. Their synthesis is scalable and requires less effort 
compared to e.g. the production of antibodies and moreover, they possess only low or 
even no immunogenic potential. For these reasons, small targeting molecules, such as 
folic acid [89,90] or methotrexate [91,92], which both target the folate receptor, have 
become a standard tool for targeted drug delivery systems.  
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2.2.2 Heteromultivalent ligand presentation 
Owed to the massive increase in binding affinity, multivalent NPs can still interact with 
off-target tissues expressing lower levels of the complementary receptor if a certain 
density threshold is surpassed. Recent approaches have tried to overcome this 
limitation by simultaneous presentation of two different types of ligand [93-97].  
Kluza and colleagues [97] prepared paramagnetic liposomes, decorated with cyclic 
RGD and anginex (Anx) for selective targeting of galectin-1 and ανβ3 integrin receptors, 
respectively. In contrast to their single-targeted counterparts decorated with either 
Anx- or RGD-ligands, dual-targeted liposomes displayed enhanced intracellular 
uptake and higher inhibitory effects for angiogenesis in vitro. In a further study by 
Kluza et al. [98], Anx/RGD-targeted liposomes were administered into 
melanoma-bearing mice. Interestingly, although the specificity for melanoma 
endothelium was increased, the tumor targeting efficacy of dual-targeted colloids was 
lower compared to liposomes decorated with RGD ligands which could be attributed 
to the cationic charge of Anx-ligands that facilitated recognition and clearance of dual 
targeted colloids. These findings emphasize that colloidal stability and clearance in vivo 
have great impact on the targeting efficacy of colloidal drug delivery systems. 
Rangger and colleagues [99] constructed dual-targeted liposomes by combining 
RGD-ligands with substance P for concomitant targeting of ανβ3 integrins and 
neurokinin-a, respectively, aiming at increased specificity towards tumor tissue. 
Although the in vitro cellular uptake study displayed specific binding of 
single-targeted NPs towards two different cancer cell lines, decreased cellular binding 
was observed for heteromultivalent targeted liposomes. Moreover, in vivo 
biodistribution studies in an animal tumor model revealed only low accumulation in 
tumor xenografts using a dual-targeting approach. These results clearly demonstrate 
that the arrangement of two ligand types with regard to their densities and position 
play a pivotal role in synergistic targeting approaches and have to be optimized for 
each type of target. 
These studies demonstrate that for the development of heteromultivalent targeted 
systems a variety of design parameters have to be considered to enhance targeting 
specificity and efficacy in vivo. These considerations particularly include an 
appropriate combination of ligands and optimized ligand densities on the colloidal 
surface, as well as a surface composition diminishing interactions with serum proteins 
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that potentially enhances NP clearance from the blood. Moreover, it is often overlooked 
that by involving multiple types of ligands also the number of off-target sites in vivo is 
increased. This owed to the fact that circulating colloids can potentially encounter a 
higher number of cells or tissues that express only one of the respective target motifs 
but are earlier accessible than the target site. 
 
2.2.3 Advanced targeting strategies of viruses 
Viruses constitute prominent examples that have developed advanced strategies of 
recognizing and invading their host cells in a superselective fashion [100-102]. Virus 
binding to the cell surface and host cell entry is a highly orchestrated process that 
involves the consecutive binding of different receptor types, or even enzymatic on-site 
activation of a pro-ligand, followed by membrane fusion or receptor-mediated 
endocytosis [103-105].  
For instance, the entry process of hepatitis C virus (HCV) requires a whole series of 
binding events to specific host factors [102,105,106]. The target cell is initially 
recognized through binding to two attachment factors: low-density lipoprotein 
receptors and glycosaminoglycans which are expressed on the basolateral surface of 
hepatocytes. The close proximity to the membrane allows the virus to subsequently 
bind to the four receptors scavenger receptor class B type I, tetraspanin CD81, the tight 
junction proteins claudin 1 and occludin followed by binding to several entry factors 
such as the EGF receptor, the ephrin receptor A2, the transferrin receptor 1 and 
cholesterol transporter Niemann-Pick C1-like 1.  
Another prominent example is the influenza A virus [107,108], which possesses two 
envelope glycoproteins: hemagglutinin (HA) and neuraminidase (NA). While NA 
facilitates elution of virus replicates from the infected host cell, the trimeric 
glycoprotein HA serves as an anchor and mediates target cell adherence and virus 
entry in a unique fashion. The first step of target cell infection is the recognition of the 
target receptor molecule terminal α-sialic acid by HA [107]. Thereby, multivalent 
binding of HA moieties to multiple sialic acid receptors is mandatory to enable 
sufficiently tight attachment to the host membrane [109], because the monovalent 
interaction a single HA with sialic acid is known to be of low affinity [110]. In contrast, 
high-avidity binding of several receptor-ligand interactions results in strong binding 
of the virus particle to the host membrane. In a next step, HA must be cleaved by 
membrane-bound proteases to expose a distinct amino acid sequence that allows the 
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virus to fuse with the host membrane and enter the cytoplasm [111]. Cleavage of HA 
is a prerequisite for hijacking of host cells and serves as a checkpoint to confirm target 
cell identity [112]. For this reason, influenza A infection and replication in human is 
exclusively limited to the respiratory tract, since that is the only place where the 
respective protease is expressed.  
Few studies have tried to transfer this advanced targeting strategy to colloidal drug 
delivery systems [113-116], yet the successful development of virus-mimicking NPs is 
still in its infancy. 
 
3 The kidney as novel target for nanomedicines 
NPs have been extensively investigated as therapeutic drug delivery systems aiming 
at specific targeting of diseased tissue sites. The majority of effort is dedicated to the 
development of nanoparticle-based therapeutic systems for cancer treatment due to the 
inherent tendency of NPs to accumulate in tumor tissues [1,22]. Although the kidney 
is severely affected in various diseases, such as diabetes mellitus [117], it has been 
largely overlooked as valuable target organ for NP-mediated drug delivery. 
Diabetes mellitus has become one of the most common chronic diseases worldwide. 
Due to a change in lifestyle, e.g. low physical activity and increased obesity, the number 
of people suffering from this condition is expected to continuously raise [118]. 
Approximately one-third of all patients suffering from diabetes type 1 and 2 are 
affected by diabetic nephropathy (DN) [119], which has become the leading cause of 
end-stage renal disease (ESDR) and is predicted to become the seventh leading cause 
of death by 2030 [120,121]. Current therapies such as glycaemic control, blood pressure 
control and interception of the renin-angiotensin-aldosteron system (RAAS) aim at 
decelerating disease progression, however, the incidence of ESRD under therapy still 
remains unacceptably high [120]. For these reasons, there is a need for alternative 
therapeutic approaches with higher efficacy and fewer side effects. Targeted 
nanoparticle-based therapeutic systems would therefore be a valuable platform to 
improve treatment of various kidney diseases. However, due to the complex 
composition of the glomerular filtration barrier, colloids must possess distinct 
attributes that allows them to enter or transit distinct kidney areas [12,22]. 
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3.1 Kidney anatomy and renal function 
The kidneys are bean-shaped organs located at the posterior abdomen. They perform 
a variety of essential functions such as osmoregulation, maintenance of the fluid 
balance and secretion of hormones [12]. In addition, kidneys filter the plasma and 
thereby excrete metabolic waste products and toxins with the urine [122]. 
The functional unit of the kidney is the nephron. Each human kidney contains 
approximately one million nephrons [123]. The nephron is composed of a renal 
corpuscle and a hairpin shaped tubular system, consisting of the proximal convoluted 
tubule, the loop of Henle, a distal convoluted tubule and the collecting duct [122]. The 
renal corpuscle is composed of the glomerulus, a capillary tuft, and the Bowman’s 
capsule that surrounds the glomerulus. The renal corpuscle compromises glomerular 
endothelial cells, a glomerular basement membrane (GBM), mesangial cells, podocytes 
and parietal epithelial cells [12,124]. Approximately 180 liters of plasma are filtered 
each day [125]. The primary urine is generated in the renal corpuscle by selective 
filtration of water, ions and small molecules from the blood and the filtrate is 
subsequently reabsorbed and concentrated in different sections of the tubule system to 
produce 1.5 liters of urine. The filtrate has a similar composition as plasma but is largely 
devoid of proteins due to the selective filtration of the glomerular barrier [125]. 
 
3.2 Components of the glomerular barrier 
The glomerular filtration barrier has been intensively studied for decades, since it 
constitutes the most complex biological membrane being not only size- and but also 
charge-selective [125]. It is composed of three sequential layers that physically separate 
the vasculature from the urinary space and selectively filter blood components. These 
layers are (1) the glomerular endothelium [126], (2) the glomerular basement 
membrane (GBM) [127] and (3) podocytes with their foot processes [128] (Figure 3).  
The glomerular endothelial cells form the capillaries within the glomerulus. They are 
unusually flattened with a height of 50 to 150 nm [125]. Moreover, they possess large 
fenestrated areas with a pore size of 50 to 100 nm [129], constituting 20 to 50% of the 
entire endothelial surface [130,131]. These fenestrations allow water and small solutes 
to pass unhindered from the vasculature into the glomerulus, but they effectively 
restrict the passage of blood cells [125]. Endothelial cells are coated by a negatively 
charged glycocalyx, consisting of proteoglycans and glycosaminoglycans, that restricts 
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negatively charged biomolecules (e.g. albumin) from entering the GBM by virtue of 
electrostatic repulsion [132].  
The GBM is a 300 to 350 nm thick basal lamina which separates the endothelial from 
the epithelial layer [22]. It is mainly composed of type IV collagen and laminin, 
crosslinked with heparan sulfate and other charged proteoglycans such as agrin, 
perlecan and nidogen/entactin [22,125,133,134]. Due to its highly negative charge and 
the average pore size of 3 nm, the GBM selectively filters small molecules and colloids 
by their size and charge [135]. 
The third and outermost filtration barrier is represented by visceral epithelial cells also 
known as podocytes [136]. Podocytes and their extended foot processes enwrap the 
outer aspects of glomerular capillaries facing the urinary space [128,137]. Thereby, foot 
processes form filtration slits with an average width of 32 nm [22]. Adjacent foot 
processes are interconnected by a thin slit diaphragm, a specialized intercellular 
junction composed of unique membrane proteins (e.g. nephrin, podocin) and 
additional adherens junction proteins (e.g. P-cadherin) [138]. Both structures, podocyte 
foot processes and the slit diaphragm serve as the final filtration barrier that restricts 
proteins and macromolecules from reaching the urinary space. 
 
 
 
Figure 3. The kidney glomerulus and its filtration barrier consisting of the glomerular endothelium, the 
glomerular basement membrane (GBM), and podocytes with their foot processes and the slit diaphragm. 
Adapted from [12]. 
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Although mesangial cells are not directly assigned to the glomerular filtration barrier, 
they are an essential part of glomerulus and mandatory to maintain its filter 
function [139]. Mesangial cells and their matrix provide substantial structural support 
for glomerular capillary loops [140]. Moreover, they are responsible for regulation of 
the filtration surface area and therefore are essential for the integrity of the renal 
filter [12,139]. Mesangial cells, podocytes and endothelial cells constitute a functional 
unit and communicate with each other via cytokine cross-talk [141]. Alteration in any 
of these three cell types can have severe impact on the others. For example, mesangial 
cell injury can result in podocyte foot process fusion and proteinuria, whereas 
podocyte injury can induce mesangial cell proliferation [139]. 
Impairment of either of these glomerular components can lead to proteinuria, which 
designates the presence of increased protein levels in the urine (> 300 mg in 24 hours) 
and constitutes a hallmark of glomerular diseases such as diabetic nephropathy [125].  
 
3.3 Selective permeability  
The overall effective size cutoff for molecules and colloids to pass the filtration barriers 
of the renal corpuscle and enter the urinary space is approximately 8 to 10 nm, referring 
to the hydrodynamic diameter [21-23]. Therefore, most of therapeutic colloids are not 
subject to kidney filtration as their size exceeds the size cutoff unless the filtration 
barrier is impaired by disease or particles are degraded into smaller fragments that fall 
below the kidney filtration threshold [12,22]. 
Colloids with a hydrodynamic diameter below 8 to 10 nm can pass the renal filter and 
are excreted into the urine [21-23]. In contrast, larger particles can enter the glomerulus 
from the afferent arteriole through the endothelial fenestrae, however their 
accumulation within the glomerulus is restricted to the mesangium and the 
extracellular matrix. Choi and colleagues [142] have recently investigated glomerular 
deposition of intravenously administered PEGylated gold NPs as a function of size. 
The total deposition of NPs below 100 nm was increased with larger particles size and 
was primarily controlled by NP uptake into mesangial cells, whereas larger particles 
(> 100 nm) were increasingly restricted from entering the mesangium due to the size 
limitation of endothelial fenestrations.  
Charge selectivity is a second crucial parameter that influences the behavior of colloids 
within the glomerulus [125]. Choi and colleagues [142] have shown that anionic 
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PEGylated gold NPs do not deposit in the GMB or podocytes which could be attributed 
to the repulsive electrostatic forces of the negatively charged GBM. In contrast, 
positively charged polymer-based siRNA NPs of the same size (80 nm) were reported 
to accumulate within the GBM and the mesangium [143]. These findings were 
supported by Bennett et al. [144] who demonstrated that cationic ferritin-decorated NPs 
accumulate in the GBM after intravenous injection in rats. However, the concept of 
charge selectivity remains highly controversial. Kodaira and colleagues [145] found 
that negatively charged polyvinylpyrrolidone (PVP) derivatives could accumulate in 
the glomerulus after systemic administration. Paradoxically, a more pronounced 
negative charge of carboxylated PVP colloids resulted in enhanced accumulation in the 
kidney, with renal levels reaching approximately 30% of the administered dose. 
Interestingly, sulfonated PVP NPs could pass the glomerular filtration barrier and were 
rapidly excreted in the urine.  
Another criterion for kidney filtration is particle geometry. Carbon nanotubes with 
high aspect ratios have been shown to paradoxically being filtered by the 
glomerulus [22,146,147] despite their average length of 100 to 500 nm, which exceeds 
the renal filtration threshold by a factor of 10 to 50. Ruggiero et al. [147] concluded that 
the long axis of single-walled carbon nanotubes was coordinated perpendicular to the 
GBM through hydrostatic forces, thereby orienting their short axis into the pores of the 
GBM. These results were further confirmed by Lacerda and colleagues [146] who used 
transmission electron microscopy (TEM) to demonstrate that the orientation of carbon 
nanotubes within the glomerulus corresponded to the predicted model. 
The filtration threshold can be influenced by further particle characteristics including 
tensile strength and young’s modulus which are primarily dictated by the NP 
composition. The role of flexibility on renal clearance was investigated using 
dendrimers possessing different degrees of intramolecular flexibility. Soft and flexible 
dendrimers with a hydrodynamic size of 18 nm showed renal excretion, whereas 
dendrimers with a rather rigid core but smaller size could not pass the glomerular 
filtration barrier [148-150].  
In summary, particle size, surface charge, shape, and flexibility are all major 
determinants of NP deposition within the glomerulus. However, permeability 
restrictions only apply for healthy tissues and can be greatly altered in a diseased state.  
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3.4 Pathophysiological changes in diabetic nephropathy and targeting 
opportunities 
DN constitutes a life-threatening complication and affects one-third of all patients 
suffering from diabetes [119]. Pathophysiological changes in DN progress rapidly and 
severely affect components of the glomerular filtration barrier [119]. For example, the 
thickness of the GBM increases by about 30% [151] and further worsens during disease 
progression. The number of podocytes is drastically reduced and podocytes start to 
detach from the GBM, leading to a loss of foot process and fusion [152]. Mesangial cells 
start to change their gene expression [153] and are also subject to cell proliferation and 
hypertrophy [140].  The relative increase in volume of the mesangium drastically 
impairs other structures within the glomerulus, resulting in reduction of the 
glomerular filtration area and segmental occlusion of glomerular capillaries [125]. 
Because pathological changes in the mesangium are among the earliest and most 
critical events found in DN [140], it would be highly beneficial to consider mesangial 
cells as therapeutic target for the treatment of renal diseases [154]. 
Due to the fact that mesangial cells are separated from the systemic blood stream only 
by fenestrated endothelial cells, they are accessible for colloids that fall below the 
endothelial pore size of 50 to 100 nm [129]. As aforementioned, recent studies have 
demonstrated that colloids can enter the mesangium via size-selective passive targeting 
which is similar to the EPR effect. For example, Choi and colleagues [142] found that 
PEGylated gold NPs with a size of 50 to 100 nm accumulated in the mesangium and 
were partly internalized by mesangial cells within 24 hours after intravenous injection, 
whereas larger particles (> 100 nm) were not able to access the mesangium due to steric 
restrictions at the endothelial fenestrations. In a different study by Pollinger and 
coworkers [155], it was demonstrated that PEGylated quantum dots (Qdots) with a 
hydrodynamic diameter of approximately 20 nm and distinct negative charge (-14.5 to 
-15.6 mV) displayed pronounced enrichment in the mesangium of healthy mice one 
hour after systemic administration. Although these studies provide important 
information about glomerular deposition of colloids as a function of their attributes 
(i.e. size), these inorganic nanomaterials are not suited as drug delivery system as their 
solid cores cannot be loaded with therapeutic drugs. Recently, Li and coworkers [156] 
combined the advantages of polymeric NPs and the size selectivity of renal glomerulus. 
To this end, they prepared dexamethasone acetate-loaded polymeric NPs which were 
injected into healthy rats. They found that drug-loaded polymeric NPs with a 
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hydrodynamic size of 90 nm accumulated in the kidney to a greater extent than free 
DiD solution. Thereby, drug-loaded NPs were primarily deposited within the 
glomerular mesangium. 
These studies emphasize the feasibility of nanomedicines to target the mesangium, 
however, they exclusively rely on passive targeting strategies. Multivalent targeting 
would be the perfect strategy to enhance target selectivity and, in addition, trigger 
uptake into renal cells by receptor-mediated endocytosis. Scindia and colleagues [157] 
have used anti-α8-integrin ligands to enhance glomerular deposition of liposomal 
nanocarriers with a size of 70 to 130 nm in lupus glomerulonephritis susceptible mice. 
In contrast to control immunoglobulin-decorated liposomes, targeted colloids were 
capable of specific accumulation in the mesangium of diseased mice. 
Furthermore, receptor expression of glomerular cells can be altered in a diseased state 
providing a promising opportunity for selective targeting. For example, ανβ3 integrin 
receptors are increasingly expressed on mesangial cells during the progression of 
diabetic nephropathy [158,159], whereas E-selectin expression in endothelial cells is 
upregulated at the onset of glomerulonephritis [160].
Biodegradable polymeric NPs constitute the ideal system for multivalent targeting of 
mesangial cells because they possess highly tunable physicochemical properties, which 
allows for exact tailoring of NP size, they can be modified with multiple targeting 
ligands of defined density, and provide the capacity to accommodate high amounts of 
hydrophobic drugs inside their colloidal core [10,11]. 
 
4 Conclusion 
Multivalent NPs have shown tremendous potential for selective targeting because they 
can accumulate at target sites while sparing healthy off-target tissues. Although the 
kidney is severely affected in various diseases, such as diabetes mellitus, it has largely 
been overlooked as target for NP-mediated therapeutic intervention. In the diseased 
state, the renal filter integrity is severely impaired, allowing colloids to enter or even 
transit the glomerular filtration barrier. Precise tailoring of NP characteristics in terms 
of kidney retention and binding to distinct cell populations which are affected during 
disease progression (i.e. mesangial cells) can be exploited to develop novel therapeutic 
approaches for the treatment of renal diseases.  
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Maximizing drug concentration at the site of disease while minimizing systemic drug 
effects is regarded the ideal conception for pharmacotherapy. This is of particular 
importance when the therapeutic target is confined to a defined tissue which is the case 
for various cancers, vitreoretinal diseases or diabetic nephropathy. Targeted drug 
delivery is widely regarded the most potent tool to make this vision come true. In 
particular, polymeric nanoparticles (NPs) have tremendous potential for targeted 
delivery as they are biocompatible, degradable, possess unique and highly tunable 
physicochemical properties and can be loaded with high amounts of cargo.  
As they provide extremely high flexibility in their design, polymeric NPs can be 
precisely engineered to suit a wide range of therapeutic applications. Although 
polymeric NPs possess tremendous potential, their bench to bedside transition 
proceeds slowly. This is attributed to several limiting factors such as: (1) lack of 
manufacturing platforms that allow for a controlled and scalable synthesis of NPs with 
high batch-to-batch consistency, (2) inadequate knowledge of events at the nano-bio 
interface both in vitro and in vivo, (3) the limited understanding of their fate in the body, 
organs and at cellular levels due to their poor detectability in tissues and biological 
media, (4) incomplete knowledge of critical particle attributes with regards to 
targeting, and (5) insufficient selectivity and efficiency of targeted NPs in vivo. 
The aim of this work was to design and characterize core/shell structured multivalent 
polymeric NPs intended for selective targeting of mesangial cells with special focus on 
addressing the abovementioned challenges. 
Development of therapeutic colloids intended for selective targeting requires the 
precise control of NP attributes. Particle size is widely considered a key factor since it 
determines the interfacial contact area and therefore, has a major impact on multivalent 
binding to target cells. Moreover, with respect to targeting of kidney cells, size also 
constitutes a restricting parameter in terms of glomerular entrance. In Chapter 3, 
microfluidic synthesis of multicomponent polymeric colloids was evaluated and 
compared to bulk nanoprecipitation, which is considered the gold standard in the field. 
Three NP formulations with varying core to shell ratios were optimized by adjusting 
critical process and formulation parameters and the influence on particle size and size 
distribution was investigated and analyzed by dynamic light scattering and 
transmission electron microscopy. 
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A profound understanding of NP behavior at the nano-bio interface is essential for the 
design of therapeutic systems. Adsorption of serum proteins onto the colloidal surface 
can substantially enhance recognition and clearance of NPs by the reticuloendothelial 
system. Moreover, formation of a protein corona can severely impair colloidal stability 
and therefore, has a major impact on the in vivo performance of colloidal drug delivery 
systems. To gain a better understanding of the nano-bio interface, the interaction of 
functionalized NPs with serum proteins was systematically studied as a function of 
surface charge and hydrophobicity. Moreover, the impact of protein corona formation 
on NP integrity was assessed (Chapter 4).  
Surface functionalization with high-affinity ligands is commonly considered the major 
determinant for controlling the uptake efficiency in vitro and in vivo. However, it is 
often not sufficiently taken into consideration that cellular uptake of targeted colloids 
is governed by a delicate interplay between different particle features. In Chapter 5, 
the combinational influence of cRGD ligand density and poly(ethylene glycol) (PEG) 
linker length on NP uptake into αvβ3 integrin overexpressing U87MG glioblastoma 
cells was investigated by flow cytometry and fluorescence microscopy. 
The therapeutic concept of targeted drug delivery systems relies on the specific 
interaction of targeting ligands presented on the colloidal surface with cognate 
receptors of the target cell. However, cell surface receptors are not exclusively located 
on target cells but can also be expressed by healthy off-target tissues. To overcome 
premature NP uptake into off-target cells and minimize systemic toxicity, new 
targeting strategies with enhance selectivity towards target cells are needed. Inspired 
by viruses, which are capable of sequential recognition and entry of their host cells, 
heteromultivalent binding NPs were designed. The advanced specificity of virus 
mimicking dual-targeted NPs towards rat mesangial cells, which are affected in a 
number of severe renal diseases, was assessed by flow cytometry and fluorescence 
microscopy (Chapter 6).   
Polymeric NPs suffer from poor visibility in biological environments. Reliable and 
simultaneous qualitative and quantitative detectability in cells and tissues is a largely 
unmet need. Because profound knowledge of pharmacokinetics and biodistribution 
are key to the successful development of nanomedicines, additional labels are required 
to evaluate their in vivo performance and track their journey from the point of 
administration to the target site. To overcome this limitation, small gold tags were 
introduced as a contrast agent at the core/shell interface of polymeric NPs and 
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polymer/gold hybrid NPs were characterized for their physicochemical characteristics 
and their toxicity in vitro. Moreover, the enhanced detectability in cells was evaluated 
by fluorescence and transmission electron microscopy (Chapter 7).  
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Abstract 
A key challenge in manufacturing of multicomponent polymeric colloids is obtaining 
monodisperse nanoparticles (NPs) with reproducible characteristics. Herein, NP 
formulations with varying core to shell ratios consisting of different poly(lactic 
acid)-poly(ethylene glycol) (PLA-PEG) copolymers (10k-b-5k, 15k-b-5k, 20k-b-5k) and 
poly(lactic-co-glycolic acid) (PLGA) at varying copolymer mass ratios (70/30, 65/35 or 
60/40) were either prepared by bulk nanoprecipitation or microfluidic synthesis and 
evaluated regarding their size and polydispersity. Microfluidic process parameters, 
such as the total flow rate (TFR) and the flow rate ratio (FRR) of the aqueous phase and 
the organic polymer solution, were varied to tune particle size and further improve 
size distribution. Z-average hydrodynamic diameter and polydispersity index (PDI) 
were analyzed by dynamic light scattering (DLS) and selected formulations were 
further examined by transmission electron microscopy (TEM). In general, bulk 
nanoprecipitation resulted in formation of larger particles (52 - 65 nm) with a wide size 
distribution, whereas particles were significantly smaller in size (24 - 43 nm) and 
displayed a rather monodisperse size distribution when they were manufactured with 
a microfluidic system. The FRR was identified to be the key factor for improving the 
size distribution of NPs with a high ratio of PLA-PEG to PLGA, whereas it had only 
minor impact on particle characteristics of formulations with a lower copolymer ratio. 
Polydispersity of different NP formulations was successfully improved by microfluidic 
manufacturing, demonstrating that this technology is a valuable tool that allows for 
reproducible and scalable manufacturing of multicomponent NPs with precisely 
tunable quality attributes.
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1    Introduction 
The use of core/shell structured nanoparticles (NPs) as drug delivery system holds 
tremendous promise for improving the treatment of several diseases in terms of 
therapeutic efficacy and reduced side effects [161]. Especially, biocompatible and 
biodegradable NPs composed of poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) 
and poly(lactic-co-glycolic acid) (PLGA) have gained enormous attention since they 
provide the possibility to combine various useful features such as hosting high 
amounts of hardly soluble drugs, controlled drug release with tunable release profiles 
and specific receptor targeting [162-164]. Different block copolymers are often 
combined to optimize NP composition and engineer their characteristics, such as 
particle size, charge, surface functionalization or the core to shell ratio [60,61]. A fast 
and simple technology to prepare PLGA-blended PLA-PEG nanoparticles is bulk 
nanoprecipitation by solvent exchange [165], which involves dropwise addition of a 
water-miscible organic polymer solution to a larger quantity of an aqueous non-solvent 
under stirring. As a consequence of diffusion, the solvent is exchanged leading to 
interfacial deposition of hydrophobic or amphiphilic polymers and self-assembling 
into core/shell structured NPs in order to reduce the free energy of the system [11,166]. 
However, in a bulk nanoprecipitation approach, phase mixing proceeds slowly and 
uncontrolled, which favors formation of hetero-sized nanocolloids due to the unequal 
distribution of polymer blocks and consequently, results in an insufficient 
batch-to-batch consistency. Hence, precise engineering, optimization and testing of 
core-blended NPs is severely impaired. As the in vivo performance of NPs strongly 
depends on their physicochemical characteristics it is crucial to enhance the 
reproducibility and controllability of NP synthesis [11,167,168]. Microfluidics has 
recently emerged as a new technology that offers precisely controlled reaction 
environments and has been harnessed to manufacture polymeric NPs with defined 
properties and excellent batch-to-batch consistency [61,168]. Furthermore, 
microfluidics can tackle the limited options provided by bulk nanoprecipitation for 
down- and up-scaling which makes this technology highly valuable for 
high-throughput screenings during the development of new nanomedicines as well as 
for clinical applications, where sufficient quantities of NPs with consistent properties 
are needed [61,169]. For these reasons, microfluidics was considered as an ideal 
platform to optimize size distribution of multicomponent polymeric NPs with distinct 
core to shell ratios. In this study, three NP formulations composed of PLA-PEG 
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copolymers with increasing molecular weights of the PLA block (10k-b-5k, 15k-b-5k, 
20k-b-5k) and varying PLA-PEG to PLGA copolymer mass ratios (70/30, 65/35 or 60/40) 
were prepared by bulk nanoprecipitation and microfluidic synthesis. Blends of PLGA 
and PLA-PEG copolymers were used to control the ratio between the hydrophilic PEG 
shell and the hydrophobic PLA/PLGA core of polymeric NPs. Optimization of these 
NP formulations was proceeded by adjusting process and formulation parameters and 
the influence of copolymer concentration, total flow rate (TFR) and the flow rate ratio 
(FRR) of aqueous to organic phase on particle size and size distribution was 
investigated and analyzed by dynamic light scattering (DLS) and transmission electron 
microscopy (TEM).
 
2 Materials and methods 
2.1 Materials 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) solution, 3,6-Dimethyl-1,4-dioxane-
2,5-dione (Lactide), 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TMSP), 
anhydrous dichloromethane (DCM), anhydrous ethyl acetate, deuterated chloroform 
(CDCl3), deuterium oxide (D2O), methoxy poly(ethylene glycol) with a molecular mass 
of 5000 g mol-1 (MeO-PEG5k-OH), Resomer® RG 502 (PLGA) and Tetramethylsilane 
(TMS) were received from Sigma-Aldrich (Taufkirchen, Germany). All other materials 
were reagent grade and obtained from Merck KGaA (Darmstadt, Germany). Ultrapure 
water was obtained by using a Milli-Q water purification system (Millipore, 
Schwalbach, Germany). 
 
2.2 Synthesis of functionalized PLA-PEG block copolymers 
Poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers with different 
polymerization degrees of the PLA block (10k-b-5k, 15k-b-5k, 20k-b-5k) were 
synthesized by ring-opening polymerization as previously described by 
Qian et al. [170] with slight modifications. Prior to use, racemic 3,6-dimethyl-1,4-
dioxane-2,5-dione (D,L-lactide) was purified by recrystallization from anhydrous ethyl 
acetate and dried under vacuum for at least 12 h. Linear methoxy poly(ethylene glycol) 
with a molecular mass of 5000 g mol-1 was used as macroinitiator for the ring-opening 
polymerization of lactide using DBU as catalyst. After quenching the polymerization 
reaction with benzoic acid, block copolymers were subsequently precipitated in diethyl 
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ether and dried under vacuum at 45 °C overnight. 1H-NMR spectra were recorded in 
CDCl3 at 295 K using a Bruker Avance 300 spectrometer (Bruker BioSpin GmbH, 
Rheinstetten, Germany). The number-average molecular weight of PLA-PEG block 
copolymers was determined by integration of the methylene signal of PEG residues 
based on molecular weight (provided by the manufacturer) and calculation of the 
methine and methylene proton signals of PLA. 
 
2.3 Bulk nanoprecipitation of nanoparticles 
Polymeric NPs were prepared by bulk nanoprecipitation as previously described [165]. 
In general, PLA-PEG and PLGA were diluted with acetonitrile to a final polymer 
concentration of 5, 10 or 20 mg mL-1. The polymerization degree of the PLA-PEG 
copolymer (10k-b-5k, 15k-b-5k, 20-b-5k) as well as the mass ratio of PLA-PEG to PLGA 
(70:30, 65:35 or 60:40) was varied depending on the NP formulation. A detailed 
description of the respective NP compositions with either high (NP510m), medium 
(NP515m) or low PEG content (NP520m) is given in Figure 1. The polymer solution 
was added dropwise into 10 volumes of stirred ultrapure water and NP dispersions 
were stirred for 3 hours to evaporate the organic solvent. NPs were filtered through a 
0.45 µM Rotilabo® PES syringe filters (Carl Roth, Karlsruhe Germany) and 
concentrated by ultrafiltration using Pall Macrosep® Advance Centrifugal Devices 
(Pall GmbH, Dreieich, Germany) with 100 kDa MWCO.  
 
2.4 Microfluidic synthesis of nanoparticles 
Polymeric NPs were also prepared via microfluidics using a benchtop 
NanoAssemblr™ instrument (NanoAssemblr™, Pecision NanoSystems Inc., 
Vancouver, Canada) and process parameters were controlled using the corresponding 
NanoAssemblr™ Controller software (v1.0.5). Ultrapure water was injected into the 
first inlet and the organic polymer solution in the second inlet of the microfluidic mixer. 
The TFR was varied from 2 to 17 mL min-1 and the FRR of the aqueous phase and the 
organic polymer solution was either 10:1 or 5:1. NP formulations were collected at the 
outlet channel and stirred for 1 h to remove the organic solvent. Afterwards, NP 
dispersions were filtered through 0.45 µM Rotilabo® PES syringe filters (Carl Roth, 
Karlsruhe Germany). 
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2.5 PEG quantification 
The PEG content was determined by 1H-NMR spectroscopy according to a method 
described by Bertrand et al. [171] with slight modifications. To determine the total PEG 
content in NP formulations, NP510m, NP515m and NP520m were prepared in 
ultrapure water and 600 µL of the concentrated solutions (approx. 4 to 5 mg mL-1) were 
lyophilized for 48 h. The exact NP mass of each sample was determined gravimetrically 
(n=3) and samples were subsequently dissolved in 600 µL of CDCl3 containing 0.05% 
(v/v) TMS as an internal standard. Solutions of MeO-PEG5k-OH at defined 
concentrations (0.1-5.0 mg mL-1) in CDCl3 containing 0.05% (v/v) TMS were used for 
calibration. Methylene protons of PEG (3.65 ppm) were normalized to the proton signal 
of the internal standard (TMS) and used for calculation of the PEG concentration in 
respective samples. To determine the concentration of hydrated PEG in the NP shell, 
NP510m, NP515m and NP520m were prepared in ultrapure water and the solvent was 
exchanged with D2O supplemented with 0.05% (m/v) TMSP as an internal standard 
using Microsep® Advance Centrifugal Devices (Pall GmbH, Dreieich, Germany) with 
100 kDa MWCO. The exact polymer concentration of samples in D2O was determined 
gravimetrically after lyophilization (n=3). The ratio of the methylene protons of PEG 
(3.72 ppm) to the integral of the methyl protons of the internal standard (TMSP) was 
then compared with the calibration curve of MeO-PEG5k-OH (0.1 - 5.0 mg mL-1) in D2O 
to calculate the PEG content in the NP shell. All measurements were conducted on a 
Bruker Avance 300 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) at 
295 K.
 
2.6 Dynamic Light Scattering 
Z-average hydrodynamic size and polydispersity index (PDI) of NP formulations were 
determined on a Zetasizer Nano ZS device (Malvern, Herrenberg, Germany). DLS 
measurements were performed in ultrapure water at a constant temperature of 25 °C 
using semi-micro PMMA disposable cuvettes (Brand, Wertheim, Germany). The 
position from the cuvette wall was set to 4.65 mm and the attenuator was optimized by 
the device. Data were collected and analyzed using the Malvern Zetasizer software 
version 7.11 (Malvern Instruments, Worcestershire, United Kingdom). 
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2.7 Transmission Electron Microscopy 
The particle size, size distribution and morphology of selected NP formulations was 
evaluated on a Zeiss 902 (80 kV) transmission electron microscope (Zeiss, Oberkochen, 
Germany). NP samples were applied onto carbon-coated copper grids (300 mesh; 
Plano, Wetzlar, Germany), incubated for 5 minutes and negatively stained with a 1% 
uranyl acetate solution. Excess sample solution was removed with a filter paper and 
sample grids were dried and stored in a desiccator before use. 
 
2.8 Statistical analysis 
All results are presented as mean ± standard deviation, based on the data obtained 
from at least n = 3 samples unless stated otherwise. Statistical significance was 
determined by means of one-way ANOVA, followed by Tukey’s post-hoc test using 
GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Statistical 
significances were set as indicated.   
 
3 Results and discussion 
3.1 PEG content quantification  
Blending the NP core of polymeric PLA-PEG micelles with additional PLGA does not 
only stabilize the NP core by enhancing the hydrophobic interactions [172,173], but also 
allows for precise tuning of the core to shell ratio [171,174]. However, size and size 
distribution of a NP formulation are strongly affected by the formulation composition 
and the manufacturing process.  
 
 
 
Figure 1. Composition of NP formulations that were used for this study. The core to shell ratio was varied 
by mixing PLA-PEG with increasing PLA block lengths (10k, 15k, 20k) and PLGA at different copolymer 
mass ratios (70/30, 65/35, 60/40).  
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In this study, three NP formulations with different core to shell ratios were prepared 
by bulk nanoprecipitation and microfluidic manufacturing and evaluated for their 
critical quality attributes, such as particle size, size distribution and morphology. To 
this end, PLA-PEG copolymers with constant PEG block lengths and increasing 
polymerization degrees of the PLA block (10k-b-5k, 15k-b-5k, 20k-b-5k) were blended 
with PLGA at different mass ratios of PLA-PEG to PLGA (70/30, 65/35, 60/40) to 
generate particles with high (23.8%), medium (16.7%) and low (12.1%) PEG content, 
referring to as NP510m, NP515m and NP520m, respectively (Figure 1). 
1H-NMR spectroscopy was used to quantify the PEG content in each NP formulation 
and determine the fraction of PEG that was hydrated in the PEG shell (Figure 2). NPs 
were either dissolved in CDCl3, to determine the total amount of PEG, or, dispersed in 
D2O, to quantify the PEG fraction that was hydrated in the shell and therefore, 
accessible for D2O molecules. As shown in Figure 2A, the integral of methylene protons 
as determined by 1H-NMR directly correlated with the PEG concentration of the 
calibration standard prepared in either D2O or CDCl3 with R² of the linear regression 
being 1.0000 and 0.9997, respectively.  
 
 
 
Figure 2. PEG content quantification by 1H-NMR. (A) Solutions of MeO-PEG5k-OH were used to 
determine the correlation of PEG concentration and the integral of the methylene protons in either D2O or 
CDCl3. (B) The absolute PEG content (CDCl3) as well as the amount of hydrated PEG in the shell (D2O) 
were calculated and compared to the PEG contents determined by calculation based on the NP 
composition and the molecular weights of the block copolymers. Levels of significance are indicated as: 
(**) p < 0.01 and (*) p < 0.05, compared to the theoretical PEG content. 
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PEG contents of all NP formulations assessed by 1H-NMR were significantly (p < 0.01 
or p < 0.05 as indicated) decreased compared to calculated values, indicating that the 
fraction of PLA-PEG that is not firmly anchored in PLGA blended NPs is removed 
during the purification process. As PEG contents of NP samples dispersed in D2O and 
dissolved in CDCl3 were comparable and did not show any significant differences, it 
can be concluded that the complete fraction of PEG is solvated in the outside shell of 
the NPs (Figure 2B). These results demonstrate, that composition and core to shell ratio 
can be controlled by the copolymer mass ratio and the PLA polymerization degree. 
 
3.2 Correlation of process parameters and particle characteristics  
To date, polymeric NPs consisting of amphiphilic copolymers are commonly prepared 
by addition of the respective polymers dissolved in a water miscible organic solvent 
into an aqueous non-solvent, leading to gradual solvent displacement and subsequent 
solidification of interfacial deposited polymers. However, when different copolymers, 
such as amphiphilic PLA-PEG and hydrophobic PLGA, are combined to modify the 
NP composition, manufacturing by bulk nanoprecipitation does not offer the 
possibility to precisely control the mixing processes, consequently resulting in 
insufficient batch-to-batch consistency and moreover, a high polydispersity of 
PLGA/PLA-PEG colloids due to an unequal distribution of hydrophobic PLGA. In 
contrast, microfluidic manufacturing provides a promising tool for the controlled 
synthesis of multicomponent polymeric NPs as it enables a rapid and tunable mixing 
of both fluids in a microfluidic channel.  
In this study, NPs were prepared with a benchtop NanoAssemblr™ instrument 
(NanoAssemblr™, Precision Nanosystems Inc, Vancouver, Canada) using 
commercially available micromixer chips that were featured with additional 
herringbone structures (Figure 3). These staggered herringbone structures located in 
the microfluidic mixing channel are known to induce chaotic advection of the fluid 
streams even at lower Reynold numbers (Re < 100), resulting in a decreased average 
diffusion distance necessary to homogenize unmixed volumes [175,176]. Ultrapure 
water was injected into the first inlet and the organic polymer solution in the second 
inlet of the microfluidic mixer and NP formulations were prepared by changing the 
critical process and formulation parameters as depicted in Figure 3.  
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Figure 3. Schematic depiction of the microfluidic process. Polymers dissolved in an organic solvent (ACN) 
and an aqueous buffer are injected into separate inlet channels. The two fluid streams are thoroughly 
mixed in the mixing channel which possesses multiple herringbone structures to enhance chaotic 
advection between both streams and initiate nanoprecipitation. Process and formulation parameters were 
continuously varied and the resulting NP formulations were evaluated for their critical quality attributes.  
 
 
In a first experiment, NP510m were prepared by either bulk nanoprecipitation or 
microfluidic synthesis and critical parameters, such as the copolymer concentration 
(5 - 20 mg mL-1), TFR (2 - 17 mL min-1) and FRR of the aqueous to the organic phase 
(10:1, 5:1) were varied in order to evaluate their influence on particle size and size 
distribution of the obtained NP formulations.  
 
 
 
Figure 4. Size and size distribution of NP510m as a function of polymer concentration and total flow rate 
at a constant FRR of 10 to 1 of the aqueous to the organic phase. NPs were additionally prepared by bulk 
nanoprecipitation at an aqueous to organic phase ratio of 10 to 1. 
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By using higher overall polymer concentrations, the volume of NPs prepared by bulk 
nanoprecipitation increased by a factor of 1.5 (10 mg mL-1) and 1.9 (20 mg mL-1) 
compared to NPs prepared from a 5 mg mL-1 polymer solution, which is much less than 
the concentration difference by a factor of 2 and 4, respectively (Figure 4). In contrast, 
when NPs were manufactured with the microfluidic system, differences between high 
and low concentrations vanished or even displayed reversed correlations at higher 
flow rates (7 - 17 mL min -1).  
Compared to NP bulk formulations (52.2 - 65.1 nm), NPs prepared by microfluidic 
synthesis at an equal aqueous to organic phase ratio (FRR of 10:1) displayed smaller 
z-average hydrodynamic sizes (23.6 - 42.8 nm) and the PDI was slightly decreased at a 
flow rate of 2 mL min-1 and was further improved at flow rates of 7 to 17 mL min-1 
(0.064 - 0.129). Z-average hydrodynamic sizes continuously decreased with higher 
flow rates, since higher flow rates result in enhanced chaotic advection and thus 
optimized mixing conditions that lead to higher nucleation rates and formation of 
smaller NPs. In contrast, NPs prepared by microfluidics at a FRR of 5:1 displayed an 
increase in PDI (Figure 5A) compared to NPs manufactured by microfluidics at a FRR 
of 10:1. These results were supported by TEM analysis, revealing that NPs were bound 
together by interparticular bridges (Figure 5B).  
 
 
 
Figure 5. (A) Size and size distribution of NP510m as a function of polymer concentration and total flow 
rate at a constant FRR of 5:1. (B) TEM images of a selected NP formulation showing particle aggregation 
and coalescence. Scale bar indicates 100 nm.  
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The process of nanoprecipitation occurs in three stages:  First, small aggregates of 
macromolecules are formed due to nucleation, following nuclei growth and finally, 
aggregation until the colloidal stability is reached [177]. Self-assembly of amphiphilic 
copolymers can reach an equilibrium through two mechanisms [178]: If the mixing 
time is smaller than the time for aggregation, the NP size remains constant after the 
growing step and particle self-assembly occurs primarily when the solvent exchange is 
completed. In case that the mixing time is longer than the aggregation time, particles 
keep growing because macromolecules are continuously being delivered during the 
mixing process (Figure 6). 
 
 
 
Figure 6. Schematic depiction of NP formation through nanoprecipitation. Small aggregates of copolymers 
are formed due to nucleation (stage I), following nuclei growth (stage II) and finally, aggregation (stage 
III). (Figure adapted from [178]) 
 
 
Thereby, supersaturation (S) of the polymer solution is considered as key factor for 
determination of the nucleation rate and can be expressed using equation 1 [179]: 
 
S = c
c∞
      (1) 
 
With c being the polymer concentration in the initial organic solvent and c∞ being the 
bulk solubility in the final solvent mixture. By using a higher ratio of solvent to 
nonsolvent, the solubility of the polymer in the solvent mixture is increased which 
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results in lower supersaturation. As a consequence, solvent diffusion and thus 
nucleation rate is slowed down, which can promote Ostwald ripening leading to an 
increase in particle size [180]. Furthermore, a low supersaturation leads to secondary 
nucleation, meaning that both nucleation and particle growth concomitantly occur, 
leading to a wider size distribution. 
Next, the impact of NP composition on critical particle characteristics was assessed. NP 
formulations (NP510m, NP515m and NP520m) with different core to shell ratios were 
prepared by microfluidics at a constant polymer concentration of 10 mg mL-1. The 
copolymer mass ratio of PLA-PEG to PLGA and the copolymer block length was 
adjusted as described in Figure 1 and NPs were prepared at a FRR of 10:1 or 5:1 and a 
TFR of 2 to 17 mL min-1. As shown in Figure 7, the z-average hydrodynamic particle 
size of NP510m, NP515m and NP520m was significantly smaller when NPs were 
prepared by microfluidics compared to bulk nanoprecipitation. Interestingly, changes 
in TFR and FRR had the highest effect on particle size and PDI of NP510m, and only 
minor impact on size and PDI of NP515m and NP520m. In general, neither size nor 
PDI of NP515m and NP520m were significantly altered except for NP515m prepared 
at a FRR of 5:1 and a TFR of 12 or 17 mL min-1, both displaying a higher PDI compared 
to NP515m prepared at equal TFR but a FRR of 10:1. As NP515m and NP520m are 
composed of increasing fractions of hydrophobic PLA and PLGA as compared to 
NP510m, the solubility of the copolymer mixture in the final aqueous solvent mixture 
is vastly decreased, whereas the solubility in acetonitrile is only slightly changed, 
leading to higher supersaturation according to equation 1. In addition, the increase in 
supersaturation attributed to changes in the polymer composition seemed to 
overcompensate the decrease in supersaturation caused by the increased solubility in 
the final solvent mixture due to a change in solvent ratios. 
These data suggest, that the composition of multicomponent polymeric NPs has a 
major impact on the critical quality attributes during manufacturing since it is an 
important determinant for the solubility of copolymers in the organic phase and final 
aqueous solvent, and thus has a major impact on supersaturation. Furthermore, as 
PLA-PEG is an amphiphilic block copolymer composed of one hydrophilic and one 
hydrophobic block, it can reduce the interfacial surface tension, and therefore leads to 
formation of smaller polymer nuclei in the mixing channel. This was also reflected by 
smaller sizes of NP510m (24.7 ± 0.4 nm), which are composed of a higher fraction of 
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PLA-PEG compared to NP515m (29.2 ± 0.4 nm) and NP520m (33.5 ± 0.4 nm), when NPs 
were prepared by microfluidics at a FRR of 10:1 and TFR of 12 mL min-1. 
 
 
 
Figure 7. Impact of the total flow rate (TFR) and the flow rate ratio (FRR) on the size and size distribution 
of (A) NP510m, (B) NP515m and (C) NP520m prepared from a 10 mg mL-1 polymer solution and ultrapure 
water. All three NP formulations were additionally prepared via bulk nanoprecipitation at an aqueous to 
organic phase ratio of 10:1. 
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3.3 Characterization of the critical quality attributes 
Particle size, size distribution and morphology of selected NP formulations were 
additionally evaluated and compared to respective intensity-weighed size 
distributions as determined by DLS. NP510m and NP520m both were prepared at a 
FRR of 1:10 and a TFR of 12 mL min-1, whereas NP515m was manufactured at a FRR of 
1:10 and a TFR of 17 mL min-1. These NP formulations were selected since they 
displayed an improved size distribution (DLS) with PDIs of 0.084 (NP510m), 0.081 
(NP515m) and 0.092 (NP520m). Respective NP formulations prepared by bulk 
nanoprecipitation were used for comparison (Figure 8).  
 
 
 
Figure 8. (A) Transmission electron microscopy images (scale bar = 200 nm) and (B) intensity-weighted 
size distribution (DLS) of NP510m, NP515m and NP520m prepared by bulk nanoprecipitation and 
microfluidic synthesis.
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As shown in Figure 8, size distributions of NPs prepared by microfluidic synthesis 
were narrower compared to formulations prepared by bulk nanoprecipitation. 
Comparing TEM images of NP510m, bulk nanoprecipitation resulted in high fraction 
in very small polymeric NPs insufficiently stabilized with additional PLGA, whereas 
for NP515m and NP520m, only few single micelles were detected by TEM since these 
two formulations possess a lower fraction of amphiphilic PLA-PEG. In contrast, DLS 
results indicated that the mean particle size decreased when NP510m were prepared 
with the microfluidic system. This is explained by the fact that z-average size analyzed 
by DLS is calculated as intensity-weighed mean diameter derived from the cumulants 
analysis. Herein, the scattering signal strongly dependents on the particle diameter (d), 
with a d6 correlation [181]. Therefore, larger particles are overestimated in this 
calculation, because the contribution of light scattering deriving from smaller NPs is 
vastly decreased, which is also reflected by the intensity-weighed size distribution 
shown in Figure 8B, where bulk formulations display a right-shift of the distribution 
curves towards larger particle sizes compared to microfluidic formulations. For 
NP515m and NP520m formulations, particle size and size distribution determined by 
TEM were in good agreement with corresponding DLS results. 
In summary, these results clearly demonstrate that microfluidic synthesis significantly 
improved polydispersity of PLGA-blended PLA-PEG NPs composed of different 
copolymer compositions.  
 
4 Conclusion 
Bulk nanoprecipitation of multicomponent polymer particles does not offer the 
possibility to precisely control the mixing processes, consequently resulting in 
insufficient batch-to-batch consistency and moreover, a high polydispersity of 
core-stabilized PLGA/PLA-PEG colloids due to an unequal distribution of 
hydrophobic PLGA in the hydrophobic particle core. 
In this study, three NP formulations with different core to shell ratios were prepared 
by bulk nanoprecipitation and microfluidic manufacturing. Dynamic light scattering 
and transmission electron microscopy were used to analyze the respective particle 
characteristics, such as size, size distribution and morphology. In general, both particle 
size and polydispersity index were decreased when NPs were manufactured with 
microfluidics. For NPs with a high copolymer mass ratio of PLA-PEG to PLGA, the 
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flow rate ratio of the aqueous outer to the organic inner phase was identified to be the 
key determinant for tuning the size distribution, whereas particle size was mainly 
controlled by the total flow rate. Polydispersity of core-stabilized PLGA/PLA-PEG NPs 
was significantly improved by microfluidic manufacturing - even at high flow rates 
and high polymer concentrations, demonstrating that microfluidics is a valuable 
technology that allows for reproducible and scalable manufacturing of 
multicomponent NPs with precisely tunable particle characteristics. 
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Abstract 
The majority of efforts in the area of polymeric nanocarriers is aimed at providing 
controlled drug delivery in vivo. Therefore, it is essential to understand the delicate 
interplay of polymeric NPs with serum proteins in order to forecast their performance 
in a biological system. In this study, the interaction of serum proteins with 
functionalized polymeric colloids as a function of particle charge and hydrophobicity 
was investigated. Moreover, impact on NP stability and cargo leaching was assessed. 
The hard protein corona of polymeric NPs with either uncharged methoxy groups 
(NP510m), positively charged amine groups (NP510N), negatively charged carboxylic 
acid groups (NP510C) or zwitterionic NPs decorated with amine and carboxylic acid 
groups (NP510CN) was quantitatively and qualitatively analyzed and correlated with 
the respective colloidal stability using fluorescence resonance energy transfer (FRET). 
Positively charged NP510N displayed an enhanced interaction with serum proteins via 
electrostatic interactions resulting in a hard corona consisting of diverse protein 
components. As revealed by FRET and agarose gel electrophoresis, the enhanced 
adsorption of proteins onto the colloidal surface significantly altered the NP identity 
and severely impaired the colloidal integrity as the lipophilic cargo was continuously 
leached out of the hydrophobic NP core. 
These results highlight the importance of generating a profound knowledge of the 
bio-nano interface because adherence of biomolecules can severely compromise the 
performance of a colloidal drug delivery system in vivo by changing its identity and 
integrity. 
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1    Introduction 
Upon administration of nanoparticles (NPs) into the blood stream, serum proteins 
spontaneously bind to the colloidal surface, forming a biomolecular adsorption layer 
which is commonly referred to as protein corona (PC). The PC is a highly complex 
structure that consists of hard and soft layers that form around the NP 
surface [29,182,183]. The different types of layers are defined depending on how tightly 
biomolecules are associated with the colloids. The hard corona (HC) is composed of 
proteins that initially bind to the NP surface with high affinity, whereas biomolecules 
that are part of the soft corona (SC) secondarily interact with components of the HC 
rather than with the bare NP surface [184]. Furthermore, the SC is deemed to be more 
dynamic, consisting of rapidly exchanging biomolecules [185]. The adsorption of 
biomolecules onto nanomaterials is generally driven by the high surface energy of 
nanoscaled colloids. Thereby, interactions between proteins and NPs are governed by 
Coulomb forces, London dispersion, hydrogen-bonds, hydrophobic interactions, and 
π-π stacking [186]. Diverse particle characteristics, such as particle charge [30,187], size 
and surface curvature [30,33,34], surface topography [32] and hydrophobicity [31] have 
been identified to determine the degree, identity and kinetics of PC formation. 
Adherence of biomolecules to NPs can severely alter particle attributes, which has a 
major impact on their key performance indicators, such as targeting capability, toxicity, 
aggregation behavior and their circulation time in vivo [171,188-190]. In addition, after 
being exposed to biomolecules, NPs can completely lose their integrity through 
disassembly, which is considered the dominant reason for premature cargo release 
from polymeric drug delivery systems [191]. Because protein-coating severely 
compromises the performance of a drug delivery system in vivo, it is crucial to 
understand and establish the relationship between physicochemical properties of 
polymeric colloids and interactions with serum proteins and, moreover, evaluate 
consequences of PC formation on NP stability and cargo release. Many efforts have 
been made to characterize the bio-nano interface of different kinds of NPs, however, as 
the interaction between serum proteins and colloids highly depends on the NP 
material, results often cannot be translated. NPs composed of poly(lactic-co-glycolic 
acid) and poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) have recently received 
growing attention as drug delivery vehicles as they are biodegradable, biocompatible 
and offer the possibility to accommodate high amounts of hydrophobic drugs inside 
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the colloidal core [10,162,164]. However, there are only limited studies available 
focusing on the interaction of core/shell structured polymeric colloids with 
biomolecules, and even less is known about their corona identity or cargo release 
mechanisms which makes their performance in a biological environment 
unpredictable. 
Herein, core/shell structured NPs with differently charged surface end-groups were 
prepared through nanoprecipitation and the influence of surface functionalization on 
protein corona formation was investigated. To this end, PLA-PEG copolymers with 
different end-groups were synthesized and blended with PLGA to prepare NPs with 
either uncharged methoxy groups (NP510m), positively charged amine groups 
(NP510N), negatively charged carboxylic acid groups (NP510C) or zwitterionic NPs 
containing a mixture of amine and carboxylic acid groups (NP510CN). In the first part 
of this study, the four different NP formulations were evaluated for their interaction 
with serum proteins as a function of surface functionalization. The hard protein corona 
that was formed around the colloidal surface upon incubation with fetal calf serum 
(FCS) was quantified and its composition was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Furthermore, the colloidal stability in 
presence of serum proteins was investigated by fluorescence resonance energy transfer 
(FRET). In the second part, the impact of albumin adsorption on NP integrity was 
assessed as a function of incubation time and protein concentration using a 
combination of dynamic light scattering (DLS) and FRET. Protein corona induced cargo 
leaching of amine modified NPs was quantified by agarose gel electrophoresis. 
 
2 Materials and methods 
2.1 Materials 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) solution, 2-Mercaptoethanol (BME), 
3,6-Dimethyl-1,4-dioxane-2,5-dione (Lactide), ammonium persulfate (APS), anhydrous 
dichloromethane (DCM), anhydrous ethyl acetate, bovine serum albumin (BSA), 
deuterated chloroform (CDCl3), fetal calf serum (FCS), formaldehyde solution 
(37 wt%), methoxy poly(ethylene glycol) with a molecular mass of 5000 g mol-1 
(MeO-PEG5k-OH), Resomer® RG 502 (PLGA), sodium thiosulfate pentahydrate, 
trifluoroacetic acid (TFA) and the QuantiPro™ BCA Assay kit were received from 
Sigma-Aldrich (Taufkirchen, Germany). 1,1’-Dioctadecyl-3,3,3’,3’-tetramethylindo-
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carbocyanine perchlorate (DiI), 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO), 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD) and 
Dulbecco’s phosphate buffered saline pH 7.4 (DPBS; consisting of 1.5 mM KH2PO4, 8 
mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl) were obtained from Invitrogen GmbH 
(Karlsruhe, Germany). Barium chloride dihydrate, iodine solution (0.1 N) and 
tetramethylethylendiamin (TEMED) were purchased from Carl Roth GmbH & Co KG 
(Karlsruhe, Germany). Pierce™ unstained protein molecular weight marker was 
obtained from Thermo Fisher Scientific (Schwerte, Germany). Bifunctional hydroxyl 
poly(ethylene glycol) carboxylic acid (COOH-PEG5k-OH) and hydroxyl poly(ethylene 
glycol) Boc-amine (Boc-NH-PEG5k-OH) with a molecular mass of 5000 g mol-1 were 
purchased from JenKem Technology USA Inc. (Allen, TX, USA). 
Acrylamide/bis-acrylamide (37.5:1) solution, bromphenol blue sodium salt and sodium 
dodecylsulfate (SDS) were received from Serva Electrophoresis GmbH (Heidelberg, 
Germany). All other materials were reagent grade and obtained from Merck KGaA 
(Darmstadt, Germany). Ultrapure water was obtained using a Milli-Q water 
purification system (Millipore, Schwalbach, Germany). 
 
2.2 Synthesis of functionalized PLA-PEG block copolymers 
PLA-PEG-OMe (10k-b-5k), PLA-PEG-COOH (10k-b-5k) and PLA-PEG-NH2 (10k-b-5k) 
block copolymers were synthesized by ring-opening polymerization as previously 
described by Qian et al. [170] with slight modifications. Prior to use, racemic 
3,6-dimethyl-1,4-dioxane-2,5-dione (D,L-lactide) was purified by recrystallization from 
anhydrous ethyl acetate and dried under vacuum for at least 12 h. MeO-PEG-OH, 
Boc-NH-PEG-OH or COOH-PEG-OH were used as macroinitiators for a ring-opening 
polymerization of cyclic rac-Lactide using DBU as catalyst. After 1 h, the 
polymerization was quenched with benzoic acid. For cleavage of the Boc protection 
group of Boc-NH-PEG-PLA the respective polymer was dissolved in 50% (v/v) TFA in 
anhydrous DCM. After stirring for 30 min at RT, the solution was diluted with three 
volumes of anhydrous DCM and washed three times with saturated sodium 
bicarbonate solution and subsequently with ultrapure water. The organic phase was 
dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
pressure. For purification, block copolymers were precipitated in diethyl ether and 
dried under vacuum at either 35 °C (PLA-PEG-NH2) or 45 °C (PLA-PEG-OMe, 
PLA-PEG-COOH). 1H-NMR spectra were recorded in CDCl3 at 295 K using a Bruker 
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Avance 300 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany). The 
number-average molecular weight of block copolymers was determined by integration 
of the methylene signal of PEG residues based on molecular weight (provided by the 
manufacturer) and calculation of the methine and methylene proton signals of PLA. 
 
2.3 Preparation and characterization of polymeric nanoparticles 
Polymeric NPs were prepared by bulk nanoprecipitation as previously described [165]. 
In general, functionalized PLA-PEG and PLGA were diluted with acetonitrile to a final 
polymer concentration of 10 mg mL-1. The copolymer mass ratio of PLA-PEG to PLGA 
was kept constant at 70/30. For preparation of FRET NPs, DiO and DiI were added to 
the organic polymer solution (10 nmol per mg polymer). For cargo leaching 
experiments, NP510N were labeled with DiD (2.5 nmol mg-1). NPs used for the 
determination of the hard protein corona (Micro BCA, SDS PAGE) were labeled with 
DiI (1 nmol mg-1). The polymer solution was then added dropwise into 10 volumes of 
vigorously stirred ultrapure water and NP dispersions were stirred for 3 hours to 
remove the organic solvent. NPs were filtered through a 0.45 µM Rotilabo® PES 
syringe filter (Carl Roth, Karlsruhe Germany) and purified via ultrafiltration using 
Macrosep® Advance Centrifugal Devices (Pall GmbH, Dreieich, Germany) with 
100 kDa MWCO. The exact NP concentration was either weighed out after 
lyophilization or determined by an iodine complexation assay [192]. Z-average 
hydrodynamic size, polydispersity index (PDI) and ζ-potential of NPs were 
determined on a Zetasizer Nano ZS device (Malvern, Herrenberg, Germany). DLS 
measurements were performed in ultrapure water at a constant temperature of 25 °C 
using semi-micro PMMA disposable cuvettes (Brand, Wertheim, Germany). The 
position from the cuvette wall was set to 4.65 mm and the attenuator was optimized by 
the device. The ζ-potential was measured in 1 mM NaCl solution at 25 °C using folded 
capillary cells (Malvern, Herrenberg, Germany). Data were collected and analyzed 
with the Malvern Zetasizer software version 7.11 (Malvern Instruments, 
Worcestershire, United Kingdom).  
 
2.4 Nanoparticle quantification  
Three batches of each NP formulation (NP510C, NP510N, NP510CN and NP510m) 
were prepared in ultrapure water, purified and concentrated as described above. A 
colorimetric iodine complexation assay [192] was used to quantify the exact amount of 
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PEG. In brief, NP samples were diluted in ultrapure water to a final PEG concentration 
of approximately 2.5 to 50 µg mL-1. Dilutions of methoxy poly(ethylene glycol) with a 
molecular mass of 5000 g mol-1 were used as calibration standards (0 – 50 µg mL-1). Two 
parts of a solution containing 5% (m/v) barium chloride in 1 N HCl were mixed with 
1 part of a 0.1 N iodine/ potassium iodide solution immediately before use. 140 µL of 
sample and standard dilutions were transferred into a 96-well plate, mixed with 60 µL 
of the iodine reagent and incubated for 15 min at room temperature. Absorbance was 
measured at 535 nm using a FluoStar Omega fluorescence microplate reader (BMG 
Labtech, Ortenberg, Germany). The exact polymer concentration was determined 
gravimetrically after lyophilization of the concentrated NP samples and plotted against 
the PEG content determined by the iodine assay. As the PEG content of each NP 
formulation was considered to be constant, from this point on, the PEG content of 
freshly prepared samples was determined against the mPEG5k standard and used to 
calculate the polymer concentration (Figure S1). 
 
2.5 Characterization of the hard protein corona 
Equal amounts of DiI labeled functionalized NPs were incubated with 50% (v/v) FCS 
for 1 hour at 37 °C. Afterwards, NPs were isolated by centrifugation at 20,000 g, for 2 h 
at 4 °C and resulting NP pellets were washed two times with ultrapure water to remove 
any unbound protein. To ensure that NP pellets only consisted of 
nanoparticle-associated proteins, FCS in DPBS was treated equally and used as control. 
NPs were dispersed in ultrapure water and stored at 4 °C. Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyze the composition 
of the hard protein corona of the four different NP formulations. NP samples (650 µg 
mL-1), the FCS placebo control (undiluted) and a 0.5 % (m/v) FCS solution were diluted 
with Laemmli sample buffer (4x) supplemented with 2-mercaptoethanol and boiled for 
5 minutes at 95 °C to elute and denaturate proteins adsorbed to the colloidal surface. 
An unstained protein molecular weight marker with a molecular range from 14.4 to 
116 kDa was used as molecular weight standard. Proteins were separated by 
SDS-PAGE using a 4.5% stacking/ 12% separating gel. The electrophoresis was run for 
1 h at a constant voltage of 120 V and a decreasing current starting at 68 mA using a 
Pharmacia Amersham EPS 600 gel electrophoresis device (Bio-Rad Laboratories, 
Munich, Germany). Protein bands were visualized by silver staining [193]. Gels were 
imaged with a ChemiDoc™ MP gel imaging system (BioRad, Munich, Germany) and 
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evaluated with the software Image Lab 6.0 (BioRad, Munich, Germany). For 
quantification of the hard protein corona, NPs were diluted to a polymer concentration 
of 500 µg mL-1, the FCS placebo control was analyzed undiluted. The amount of 
proteins bound to each NP formulation was quantified using a Micro BCA™ Protein 
Assay Kit (Thermo Fisher Scientific, Dreieich, Germany) according to the 
manufacturer’s instruction and normalized to the colloidal surface area. All NP and 
control samples were analyzed in quadruplicates. 
 
2.6 Fluorescence Resonance Energy Transfer (FRET) 
A FRET experiment was used to assess the colloidal stability of functionalized NPs. 
DiO/DiI co-labeled NPs were diluted at a volume ratio of 1 to 10 in either DPBS (pH 7.4) 
or FCS and incubated at 37 °C. Fluorescence spectra were recorded during an 
incubation period of 24 h on an LS-55 fluorescence spectrophotometer (PerkinElmer, 
Rodgau, Germany). FRET fluorescence was excited at 460 nm (DiO) and emission 
spectra (DiI) were recorded between 485 and 710 nm. FRET ratios of different NP 
formulations were calculated using equation 1 [194]: 
 
FRET=
IDiI(corr.)
IDiO(corr.)+ IDiI(corr.)
     (1) 
 
Where IDiI(corr.) and IDiO(corr.) are the blank-corrected fluorescence intensities at the 
emission maxima of DiI and DiO, respectively. Calculated FRET ratios were 
normalized to t = 0. 
 
2.7 Adsorption of bovine serum albumin to nanoparticles 
The adsorption of BSA onto the colloidal surface was investigated by DLS. 
Functionalized NPs (0.1 mg mL-1) were incubated in either DPBS pH 7.4 or in DPBS 
supplemented with 45 mg mL-1 BSA for 1 h at 37 °C and subsequently cooled down to 
ambient temperature. Changes in particle size were analyzed by DLS as described 
above.  
 
2.8 Serum stability of amine-modified NPs (NP510N)  
For cargo leaching experiments, NP510N were labeled with DiD (2.5 nmol mg-1) that 
was physically entrapped in the hydrophobic core. NP510N (1.0 mg mL-1) were 
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incubated with 0, 15, 45 or 90 mg mL-1 BSA or 90 % FCS for 1 hour at 37 °C and DiD 
leaching was determined by agarose gel electrophoresis at 60 V for 1 h using a 0.75% 
agarose gel. A solution of BSA (90 mg mL-1) spiked with 12.5 µM DiD served as control. 
Gel images were acquired on a ChemiDoc™ MP gel imaging system (BioRad, Munich, 
Germany) and analyzed with the corresponding software Image Lab 6.0 (BioRad, 
Munich, Germany) before and after iodine staining (15 min: 2% BaCl, 0.02 N iodine in 
0.4 M HCl). Relative fluorescence intensities of DiD-labeled NPs and released DiD was 
quantified using ImageJ image analysis software (version 1.52, National Institutes of 
Health, Bethesda, Maryland). All cargo leaching samples were analyzed in duplicates. 
For FRET experiments DiO/DiI labeled NP510N were diluted in DPBS supplemented 
with 0, 15, 45 or 90 mg mL-1 BSA or 90% (v/v) FCS to attain a final NP concentration of 
0.1 mg mL-1 and incubated at 37 °C for different periods of time (0, 1, 2, 4, 7, 12, 24 h). 
NP dilutions in acetone were used to achieve complete decomposition of polymeric 
NPs and served as positive control. FRET fluorescence was excited at 460 nm (DiO) and 
emission spectra (DiI) were recorded between 485 and 710 nm using an LS-55 
fluorescence spectrophotometer (PerkinElmer, Rodgau, Germany). Spectra smoothing 
was performed using a Savitzky-Golay polynomial. FRET ratios were calculated as 
described above and normalized to t = 0 h.  
Transmission electron microscopy (TEM) was used to evaluate the size, morphology 
and size distribution of NP510N prior and after incubation with BSA (45 mg mL-1) for 
5 hours at 37 °C. To remove unbound proteins and buffer salts, NPs were subsequently 
dialyzed (100 kDa MWCO) against 4 L of ultrapure water. Freshly prepared NP510N 
served as control. NP samples were diluted to a final polymer concentration of 
approximately 0.1 mg mL-1 and applied onto carbon-coated copper grids (300 mesh; 
Plano, Wetzlar, Germany). After incubation for 5 minutes, excess sample solution was 
removed with a filter paper and samples were negatively stained with 1% uranyl 
acetate solution. Sample grids were dried and stored in a desiccator until they were 
analyzed. TEM images were acquired on a TEM Zeiss 902 (80 kV) electron microscope 
(Zeiss, Oberkochen, Germany). 
 
2.9 Statistical analysis 
All results are presented as mean ± standard deviation, based on the data obtained 
from at least n = 3 samples unless stated otherwise. Statistical significance was 
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determined by means of one-way ANOVA, followed by Tukey’s post-hoc test using 
GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Statistical 
significances were set as indicated.   
  
3 Results and discussion  
3.1 Characteristics of functionalized polymeric nanoparticles 
Core/shell structured NPs consisting of hydrophobic PLGA and amphiphilic PLA-PEG 
were used to evaluate the interaction of serum proteins with functionalized polymeric 
colloids. Herein, PLA-PEG was used to introduce different functional groups, such as 
methoxy groups, amine groups or carboxylic acid groups. Using blends of PLGA and 
functionalized PLA-PEG copolymers, four different NP formulations were generated 
that were functionalized with either uncharged methoxy groups (NP510m), positively 
charged amine groups (NP510N), negatively charged carboxylic acid groups (NP510C) 
or a mixture of amine and carboxylic acid groups (NP510CN).  
Functionalized NPs were characterized for their hydrodynamic z-average size and 
ζ-potential in ultrapure water and 1 mM NaCl solution, respectively. The 
hydrodynamic particle size as determined by DLS was comparable for all four NP 
formulations, ranging from 59.7 to 69.4 nm (Figure 1A). Surface functionalization of the 
four NP formulations was confirmed by ζ-potential measurements (Figure 1B).  
 
 
Figure 1. (A) Hydrodynamic z-average size and (B) ζ-potential of polymeric NPs functionalized with 
either carboxylic acid groups (NP510C), amine groups (NP510N), carboxylic acid and amine groups 
(NP510CN) or methoxy groups (NP510m).  
Results and discussion  
51 
NPs decorated with carboxylic acid groups (NP510C) possessed a strong negative 
charge of -25.5 mV, whereas NPs functionalized with amine groups (NP510N) had a 
positive charge of +20.2 mV. The uncharged NP510m and zwitterionic NP510CN were 
both slightly negatively charged (-4.9 and -9.1 mV) which was expected as PLGA which 
is part of the particle core contains residual free carboxylic acid groups and therefore, 
possesses a negative charge. Bare PLGA and PLA NPs are reported to have ζ-potentials 
ranging from -20 mV to -70 mV [194,195]. 
 
3.2 Characterization of the hard protein corona 
Composition and quantities of biomolecules adsorbed onto the colloidal surface play 
an important role in identifying the unique physiological response to a distinct 
nanomaterial after administration into the blood stream. One dimensional SDS-PAGE 
was used to identify the components involved in the hard protein corona formed upon 
incubation of NPs with fetal calf serum for 1 h at 37 °C. Samples were adjusted to equal 
polymer concentrations to enable a semi quantitative comparison. A placebo buffer 
solution mixed with FCS was treated equally and used as control to make sure that 
only nanoparticle-associated proteins were isolated by centrifugation. As shown in 
Figure 2A, a distinct protein band with a molecular weight of approximately 66-67 kDa 
could be found in the hard corona of all NP samples. This band is most likely attributed 
to albumin (66 kDa) [196], the most abundant protein in plasma. 
Positively charged NP510N displayed the highest number and amount of proteins 
adsorbed onto the colloidal surface which was expected since most of the serum 
proteins possess a negative net charge at physiological pH, which instantly enables the 
adsorption onto the colloidal surface due to strong electrostatic interactions followed 
by the adherence of oppositely charged proteins. 
Interestingly, albumin was also enriched in the corona of negatively charged NP510C. 
Although albumin is negatively charged at physiological pH, it contains 60 positively 
charged lysine groups [197,198], providing cationic patches on the surface that can 
interact with the carboxylate groups on the colloids. Moreover, albumin can also 
interact with positively charged proteins that initially adhere to the NPs, forming a 
second protein layer. Although zwitterionic NP510CN and uncharged NP510m 
displayed comparable ζ-potentials, the protein corona of NP510m was more 
pronounced and also composed of a higher number of different proteins as most serum 
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proteins undergo conformational changes when they come into contact with 
nanocarriers and thereafter, can interact via hydrophobic interactions. BSA has been 
reported to show clear conformational changes with significant reduction in its 
alpha-helical structures upon binding to cationic or hydrophobic colloids, whereas 
BSA adsorbed onto the surface of anionic colloids retains its native structure [197,199].  
 
 
 
Figure 2. (A) Composition of the hard protein corona of NP510C, NP510N, NP510CN and NP510m was 
evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After incubation of 
functionalized NPs with fetal calf serum for 1 h at 37 °C, NPs were purified from unbound proteins by 
centrifugation. To make sure that only nanoparticle-associated proteins were analyzed, FCS in DPBS was 
treated equally and used as placebo control. Diluted FCS (1:200) was used to determine the full range of 
proteins that can potentially interact with functionalized NPs. (B) Quantification of the hard protein 
corona using a Micro BCA™ Protein Assay Kit. The amount of proteins was normalized to the respective 
surface area of functionalized NPs. Levels of significance are indicated as: (**) p < 0.01, compared to all 
other NP formulations. Data are expressed as mean ± standard deviation. 
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The amount of proteins involved in formation of the hard protein corona was further 
quantiﬁed by a commercially available Micro BCA™ Protein Assay Kit and normalized 
to the NP surface area. As depicted in Figure 2B, the hard protein corona of zwitterionic 
NP510CN displayed the lowest amount of proteins (725 µg per m²), as this NP 
formulation provides the fewest regions where hydrophobic or electrostatic 
interactions can occur. The amount of adsorbed serum proteins was 1.3-fold and 
1.6-fold increased for uncharged NP510m (935 µg per m²) and negatively charged 
NP510C (1124 µg per m²) as these NP formulations can interact via hydrophobic and 
electrostatic forces, respectively. Positively charged NP510N showed the highest 
amount of proteins bound to the surface (1713 µg per m²) which was even 2.4-fold 
increased compared to NP510CN. In summary, it can be concluded that NP charge and 
hydrophobicity both are decisive factors for the identity and amount of biomolecules 
involved in the formation of the hard protein corona, which is in accordance with 
literature [200].  
 
3.3 Impact of corona formation on nanoparticle integrity 
Colloidal stability of DiO/DiI loaded functionalized NPs in presence of serum proteins 
was assessed by fluorescence resonance energy transfer (FRET). For this purpose, a 
lipophilic FRET pair (DiO and DiI) was physically entrapped into the hydrophobic 
particle core. Energy transfer from the green fluorescent donor DiO (emission 
maximum: 505 nm) to the red-orange acceptor probe DiI (emission maximum: 575 nm) 
only occurs if the dye molecules are in close proximity to each other.  Release of 
lipophilic fluorescent molecules, e.g. due to NP disassembly or cargo leaching, results 
in enlarged distance between the two dye molecules and consequently, to a reduced 
FRET efficiency [191,201]. The basic principle of FRET is outlined in Figure 3A 
displaying fluorescence spectra of NPs dispersed in DPBS and acetone. FRET-labeled 
NPs in DPBS exhibit a fluorescence maximum at around 575 nm, which corresponds 
to the DiI emitted fluorescence. In contrast, the emission maximum was shifted to 505 
nm (DiO) when particles were decomposed in acetone because the distance of both 
dyes was above the required range and the energy transfer from DiO to DiI was 
maximally suppressed. 
For each NP formulation, FRET ratios were calculated and normalized to t = 0. As 
depicted in Figure 3B, the FRET ratio only marginally decreased by 4.4% (to 7.9%) 
when NPs were incubated in DPBS (pH 7.4) at 37 °C for different periods of time. In 
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contrast, FRET ratios exponentially decreased over time when functionalized NPs 
where incubated with 90% FCS, indicating that the integrity was severely impaired and 
dye molecules were released over time. 
 
 
 
Figure 3. (A) Exemplary fluorescence spectra of NPs dispersed in either DPBS (solid line) or acetone 
(dashed line). FRET-labeled NPs in DPBS exhibit a fluorescence maximum at around 575 nm, whereas the 
emission maximum was shifted to 505 nm when particles were dispersed in acetone which leads to 
complete dissolution of the polymeric NPs. (B) Time-resolved FRET ratios of functionalized NPs incubated 
in either DPBS (pH 7.4) or 90 % (v/v) FCS at 37 °C. Data were normalized to t = 0 and expressed as 
mean ± standard deviation. Levels of significance are indicated as: (**) p < 0.01, compared to all other NP 
formulations and (##) p < 0.01, comparing NP510C and NP510CN. 
 
 
Positively charged NP510N displayed the most pronounced decay in FRET efficiency, 
whereas the FRET ratio of anionic NP510C, zwitterionic NP510CN and uncharged 
NP510m remained significantly higher (p < 0.01) during the 24 h incubation period, 
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indicating enhanced stability of these NP formulations in presence of serum proteins. 
The decay curve of NP510CN was slightly upshifted compared to NP510C and 
NP510m during the first 8 hours of incubation (p < 0.01 compared to NP510C at 2 h and 
6 h). Decay curves of all samples were fitted with a one phase exponential decay to 
determine the half lifes (t1/2) and plateaus that are theoretically reached end points, as 
both parameters are indicator for NP stability (Table 1). 
 
 
Table 1: Stability of different NP formulations in fetal calf serum. FRET efficiency curves were fitted with 
a one phase exponential decay.   
 
NP Formulation Plateau/ % Half Life/ h 
Quality of curve 
fitting (R²) 
NP510C 57.59 ± 1.08 2.167 0.9932 
NP510N 53.32 ± 0.85 1.639 0.9952 
NP510CN 58.55 ± 0.68 2.699 0.9979 
NP510m 58.86 ± 0.63 2.165 0.9976 
 
 
The calculated t1/2, corresponding to the range between the initial FRET ratio at t = 0 and 
the calculated plateaus, was 1.6-fold higher for zwitterionic NP510CN (t1/2 = 2.70 h) 
compared to NP510N (t1/2 = 1.64 h) and 1.2-fold higher compared to uncharged NP510m 
(t1/2 = 2.17 h) and anionic NP510C (t1/2 = 2.17 h). Although the half life of NP510CN was 
significantly higher, the plateau of NP510CN (58.6%) was comparable to plateaus of 
NP510m (58.9%) and NP510C (57.6%). In contrast, the plateau calculated for NP510N 
(53.3%) was significantly lower, implying that the stability of NP510N was most 
impaired in presence of serum compared to its uncharged, zwitterionic charged and 
anionic counterparts. These results clearly demonstrate that NP integrity can be 
directly correlated with the amount of protein bound to the colloidal surface. 
 
3.4 Nanoparticle-albumin interaction 
The degree of protein adsorption onto the colloidal surface was assessed by DLS since 
adsorption of proteins leads to an increase in hydrodynamic size and mass of NPs and 
thus alters their Brownian motion [202]. Albumin was chosen as model protein for this 
investigation as it was present in the protein corona of all NP formulations as described 
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above. Moreover, albumin is the most abundant protein in human plasma with a 
concentration in the range of 35 to 50 mg mL-1 [203] and along with IgG and fibrinogen, 
it is known to be involved in the early stage of corona formation as it rapidly adsorbs 
onto colloidal surfaces in plasma [30,204] and has been reported to have a major impact 
on in vivo biodistribution of NPs [194]. In this experiment, NPs were incubated with 
45 mg mL-1 BSA, corresponding to plasma concentrations in vivo.  
Figure 4 shows the intensity-weighted size distribution of NP510C, NP510N, NP510CN 
and NP510m. Upon incubation with BSA, a right shift of intensity-weighed 
nanoparticle peak positions could be observed, indicating an increase in size resulting 
from the formation of a protein layer around the NP surface.  
 
 
 
Figure 4. Intensity-weighed size distribution of (A) NP510C, (B) NP510N, (C) NP510CN and (D) NP510m 
determined by DLS in either DPBS (solid line) or after incubation for 1 h at 37 °C with 45 mg mL-1 BSA 
(dashed line). Peak intensities were normalized for better comparison. 
 
 
The increase in size, as determined by comparison of the mean values of 
intensity-derived peaks, was only minor for negatively charged NP510C (+7.8%) and 
medium for zwitterionic NP510CN (+10.4%) and uncharged NP510m (+16.2%). 
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Although the ζ-potential of NP510CN and NP510m was slightly negative, 
methoxy-decorated NPs can further interact with BSA via hydrophobic interactions. In 
contrast, albumin adsorption was most pronounced for NP510N due to strong 
electrostatic interaction of positively charged amine groups with albumin that possess 
a negative net charge at physiological conditions, leading to a significant increase in 
colloidal size (+22.5%) which derives from the formation of a distinct BSA corona. For 
NP samples that were incubated with BSA, two distinct DLS populations were 
obtained, referring to unbound BSA with a hydrodynamic diameter of approximately 
9 nm [194] and NPs with a BSA corona. As a result, the PDI of these samples was vastly 
increased, e.g. the PDI of NP510N was 0.13 in DPBS and 0.63 in DPBS supplemented 
with BSA (Figure S2). 
Because the interaction of NP510N with BSA was most pronounced, this NP 
formulation was further used to assess the kinetics of albumin adsorption. To this end, 
NP510N were incubated in either PBS pH 7.4 or DPBS supplemented with 45 mg mL-1 
BSA at 37 °C and size and PDI were measured in 0.5 h intervals over a period of 12 
hours. As depicted in Figure S2, the size of NPs incubated with BSA initially increased 
by approximately 20 nm but thereafter, remained constant over time. This indicates, 
that adsorption of albumin occurs within a few seconds, which is in agreement with 
previous studies [204].  
To investigate the impact of albumin concentration on cargo release kinetics, DiO/DiI 
co-labeled NP510N were incubated with increasing BSA concentrations (0 - 90 mg mL-1) 
and the FRET fluorescence emission was monitored for a period of 24 h. No significant 
changes in FRET signals were observed when NPs were incubated in DPBS (Figure 5A) 
implying that the colloidal integrity was maintained and dye molecules were not 
released into the surrounding aqueous media. In contrast, for samples that were 
incubated with albumin, both, the DiO and the DiI fluorescence intensity increased 
with higher albumin concentration and longer incubation time, as indicated by arrows 
(Figure 5B-D). This was somewhat surprising since previous studies had demonstrated 
that the release of dye molecules from the particle core results in the increase in DiO 
fluorescence, whereas the DiI fluorescence simultaneously decreases [205]. The 
obtained results can be explained by partitioning of the fluorescent dyes. One fraction 
of the molecules is accumulating in a domain, where the distance between the donor 
and the acceptor is reduced, which consequently increases the DiI fluorescence.  
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However, another fraction of the FRET pair is moving away from each other, resulting 
in a larger distance and a decrease in the energy transfer from DiO to DiI, consequently 
leading to an increase of the DiO-associated fluorescence intensity. 
 
 
 
Figure 5 Time-resolved FRET emission fluorescence spectra of DiO/DiI loaded NP510N measured during 
incubation (37 °C) with either (A) 0 mg mL-1, (B) 15 mg mL-1, (C) 45 mg mL-1 or (D) 90 mg mL-1 BSA after 
0, 1, 2, 4, 7, 12 and 24 hours. The maximum at 505 nm derives from the donor dye (DiO), whereas the 
maximum at 570 nm is attributed to the emission of the acceptor dye (DiI). 
 
 
Moreover, partitioning of DiO and DiI was identified to be a two step process, as the 
increase in DiI fluorescence instantly occurred upon incubation with BSA, whereas the 
increase in DiO fluorescence emerged at a later stage (Figure 6). This clearly 
demonstrates, that adsorption of BSA onto the colloidal surface triggers an immediate 
cargo partitioning from the particle core into the protein corona, resulting in a closer 
proximity of the dye molecules and thus, to an enhanced FRET efficiency. As there is a 
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constant exchange of BSA molecules that are adsorbed on the surface with unbound 
BSA in solution, dyes will be constantly leached out until an equilibrium is reached, 
which will be determined by the concentration and localization of lipophilic molecules 
in the hydrophobic particle core. It is assumed that diffusion of dyes within the 
polymeric core is limited and cargo leaching only occurs if proteins and dyes are in 
close proximity to each other. Thus, it is expected that leaching induced cargo escape 
will reach a plateau over time after the outer dye layer at the interface of hydrophobic 
core and hydrophilic shell is depleted. 
 
 
 
Figure 6. FRET fluorescence spectra of DiO/DiI loaded NP510N recorded (A) after 0 and (B) after 24 hours 
of incubation with increasing concentrations of BSA. 
 
 
To determine the incubation time needed to reach an equilibrium where no further 
decrease in energy transfer occurs, FRET ratios of NP510N samples were calculated. 
As shown in Figure 7, NP samples incubated with 15 mg mL-1 BSA displayed no 
significant reduction in FRET efficiency compared to the control (0 mg mL-1) over time, 
whereas the FRET ratio of NP510N incubated with either 45 or 90 mg mL-1 BSA 
gradually decreased during the initial 4 hours of incubation and then stayed constant 
at 85.7% and 77.6%, respectively.  
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Figure 7. Normalized FRET ratios of NP510N incubated with different BSA concentrations at 37 °C. Data 
were normalized to t=0 and expressed as mean ± standard deviation. Levels of significance are indicated 
as: (*) p < 0.01, compared to control NPs incubated in DPBS. 
 
 
The degree of cargo leaching caused by protein adsorption onto the NP surface was 
quantified by agarose gel electrophoresis. NP510N were incubated with increasing 
concentrations of BSA (0, 15, 45 or 90 mg mL-1) or 90% FCS for 4 hours at 37 °C. DiD in 
DPBS supplemented with or without 90 mg mL-1 BSA served as references. Samples 
were separated on a 0.75% agarose gel and DiD associated fluorescence was used to 
assess the amount of dye either physically entrapped inside the particle core or leached 
out and bound to serum proteins. Gels were additionally analyzed after staining with 
iodine solution, as iodine incorporates into PEG polymers and forms a brownish 
precipitate. This treatment was expected to mask fluorescence associated with NPs 
because the formation of a precipitate in the PEG shell was considered as an embargo 
for fluorescence emission originating from the particle core. By this experimental 
design, even low amounts of protein-bound DiD could be detected after staining. The 
protein/dye control consisting of BSA spiked with DiD was not only considered as 
marker to evaluate the position of protein-bound cargo, but was further used to 
determine a fluorescence ratio of the acquired fluorescence images before and after 
staining, which allows for the quantification of the faint protein-bound dye in relation 
to dye entrapped in NPs. All samples were loaded into pockets located in the vertical 
center of the agarose gel as protein formation was expected to invert the NP charge.  
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Figure 8. Cargo leaching of DiD loaded NP510N was assessed by agarose gel electrophoresis (A) before 
and (B) after iodine staining. DiD in DPBS and DiD in 90 mg mL-1 BSA served as dye controls. NPs were 
either incubated with increasing concentrations of BSA (0 – 90 mg mL-1) or with 90% (v/v) FCS for 4 hours 
at 37 °C. NPs stored at 4 °C served as particle control. (C) Fluorescent band detected in the unstained gel 
were used to assess the amount of negative and positive NP species, the iodine stained gel was used to 
determine the amount of protein-bound cargo. 
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With this setting, NP species that still possess a positive charge migrate upwards to the 
cathode, whereas negatively charged NP species as well as BSA-bound cargo 
approaches the anode. As depicted in Figure 8A, NP510N that were either freshly 
prepared (lane 5 and 6) or incubated in PBS without the addition of BSA (lane 7 and 8) 
almost completely consisted of positively charged NP species. In contrast, samples that 
were incubated with BSA displayed an additional band below the pockets which was 
considered as NP species possessing a negative charge. This charge inversion was 
attributed to the adsorption of high amounts of negatively charged BSA onto the 
surface of NP510N. With increasing concentrations of BSA (lane 5 to 14) the migration 
distance of the positively charged NP species towards the cathode decreased, as 
adsorption of proteins not only resulted in an increase in NP size, but also led to a 
reduction of the positive ζ-potential. After iodine staining, an additional faintly 
fluorescent band was visible that could be attributed to BSA-bound dye (Figure 8B). 
Formation of negatively charged NP species and cargo leaching was most pronounced 
for samples incubated with FCS (lane 15 and 16) as a full hetero-multilayer corona was 
formed. The amount of positively charged NP species, negatively charged NP species 
as well as the fraction of protein-bound dye was further quantified by analyzing the 
intensities of the fluorescent bands before and after iodine staining. 
As shown in Figure 8C, samples incubated with BSA or FCS showed a different species 
pattern compared to freshly prepared NP510N (lane 5 and 6) and NPs incubated in 
DPBS (lane 7 and 8). The fraction of positively charged NP species decreased, whereas 
the fraction of negatively charged NP species significantly increased (p < 0.05) upon 
incubation with higher amounts of BSA. The fraction of protein-bound cargo 
significantly increased with higher protein concentration from 0% (no BSA) to 1.7% 
(90 mg mL-1 BSA), however, differences were not significant. NP510N incubated with 
FCS displayed the highest degree of cargo leaching (3.0%) when multiple different 
biomolecules were involved in the development of the hard and soft protein corona. 
Transmission electron microscopy was used to assess changes in particle core size, size 
distribution and morphology of NP510N upon incubation with BSA. To this end, 
NP510N were incubated in PBS pH 7.4 supplemented with 90 mg mL-1 BSA for 5 hours. 
Buffer salts and unbound BSA were removed by dialysis against ultrapure water using 
a dialysis membrane (100 kDa MWCO). NPs that were freshly prepared in ultrapure 
water and subsequently applied onto a carbon-coated copper grid served as reference. 
Both samples displayed a comparable core size distribution as depicted in Figure 9.  
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The size of NP510N incubated with BSA was slightly shifted towards larger core 
diameters due to the adsorption of albumin onto the colloidal surface.
 
 
 
Figure 9. Size and morphology of NP510N was analyzed by TEM (A) immediately after preparation 
(B) and after incubation with 90 mg mL-1 BSA for 5 hours at 37 °C following dialysis to remove unbound 
proteins and buffer salts. Scale bars indicate 100 nm. Particle size frequency distribution was determined 
from 200 particles.  
 
 
Furthermore, the reduction in counts of small polymeric NPs (< 7.5 nm) may also result 
from the purification procedure, as those NPs possess a similar size as albumin (dH of 
approximately 7 nm) [206] and consequently, can pass through the dialysis 
membrane [207]. As DLS results (cf. Figure S2) did not indicate any significant changes 
in size or polydispersity, disassembly of small polymeric micelles is rather unlikely and 
therefore negligible. The cloudy spots that could be observed in the TEM images of 
NP510N incubated with BSA (Figure 9B) most probably derive from insoluble BSA 
aggregates or from residual phosphate salts that can react with uranyl acetate to 
insoluble uranyl phosphate [208].
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4 Conclusion 
In this study, functionalized polymeric NPs with different surface charge and 
hydrophobicity were evaluated regarding their interaction with serum proteins and its 
impact on their colloidal stability and cargo leaching. From the quantitative and 
qualitative analysis of the hard protein corona it was concluded, that zwitterionic NPs 
were least affected by the development of a protein corona as this NP formulation 
provides only limited opportunities for serum proteins to interact via electrostatic or 
hydrophobic interactions compared to polymeric colloids functionalized with 
uncharged methoxy-groups or negatively charged carboxylate groups. In contrast, 
positively charged NPs displayed an enhanced interaction with serum proteins 
resulting in a diverse range of different proteins that were part of the hard corona. This 
enhanced interaction also significantly impaired the colloidal integrity as the lipophilic 
cargo was continuously leached out of the hydrophobic NP core. Agarose gel 
electrophoresis revealed that cargo leaching directly correlated with the protein 
concentration and that the identity of amine-decorated NPs was significantly altered 
upon incubation with albumin, leading to the formation of negatively charged NP 
species. Cargo leaching was identified to be a two step process as the cargo was first 
redistributed from the particle core to proteins adsorbed onto the colloidal surface, 
followed by the final escape through desorption of the protein carrier from the particle.  
In summary, these findings highlight the importance of generating a profound 
knowledge of the protein corona, as it can bestow a new biological identity to NPs and 
moreover, severely impair NP integrity.
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Ligand density and linker length are critical 
factors for multivalent nanoparticle-receptor 
interactions 
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Abstract 
Although there are a large number of studies available evaluating the therapeutic 
efficacy of targeted polymeric nanoparticles, little is known about the critical attributes 
that can further influence their uptake into target cells. In this study, varying cRGD 
ligand densities (0 - 100% surface functionalization) were combined with different PEG 
spacer lengths (2/3.5/5kDa) and the specific receptor binding of targeted core/shell 
structured PLGA/PLA-PEG nanoparticles was evaluated using αvβ3 integrin 
overexpressing U87MG glioblastoma cells. Nanoparticles with 100% surface 
functionalization and short PEG2k linkers displayed a high propensity to form 
colloidal clusters, allowing for the cooperative binding to integrin receptors on the 
cellular membrane. In contrast, the high flexibility of longer PEG chains enhanced the 
chance of ligand entanglement and shrouding, decreasing the number of 
ligand-receptor binding events. As a result, the combination of short PEG2k linkers 
and a high cRGD surface modification synergistically increased the uptake of 
nanoparticles into target cells. Even though to date, the nanoparticles size and its 
degree of functionalization are considered to be major determinants for controlling the 
uptake efficiency of targeted colloids, these results strongly suggest that the role of the 
linker length should be carefully taken into consideration for the design of targeted 
drug delivery formulations in order to maximize the therapeutic efficacy and minimize 
adverse side effects. 
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1    Introduction 
Over the past decades, tethering of targeting moieties to core/shell structured 
polymeric nanoparticles (NPs) has become a well-established strategy to precisely 
control the interaction between ligand-decorated NPs and target cells. By this rational 
design, colloidal drug delivery systems can be tailored to selectively deliver 
therapeutic cargos to the site of action, maximizing the therapeutic efficacy and 
significantly reducing the incidence of adverse side effects [161]. 
Although NP size [209,210] and surface functionalization with high-affinity 
ligands [11,211] are widely considered to be the most important key factors, it is 
generally accepted that the targeting capability can be further optimized by precisely 
tailoring the properties of ligand-decorated NPs, such as ligand density, size, charge, 
hydrophobicity or shape [59-61,212,213]. For example, a high degree of colloidal 
surface functionalization with ligands or a worm-like shape of ligand-decorated NPs 
generally result in an enhanced recognition of target cells by virtue of multivalent 
receptor binding, given that the receptor density on the cellular membrane is 
sufficiently high. Moreover, recent studies on targeted drug delivery into cells have 
highlighted the importance of particle size. Although NPs in the size range of tens to 
hundreds of nanometers can be internalized by cells via wrapping, the optimal NP size 
range for cell entry was identified to be 50 to 100 nm [64,65]. To optimize the design of 
colloidal drug delivery systems, a profound knowledge of all key attributes affecting 
the ligand’s affinity and thus, the targeting efficiency, is of utmost importance. 
However, the majority of recent studies focusing on the optimization of targeting 
strategies have only evaluated a single key attribute, neglecting the fact that these 
contributing factors mutually influence each other.  
Poly(ethylene glycol) (PEG) is one of the most prominent linkers used for ligand 
tethering as PEG is known to enhance the colloidal stability and reduce serum protein 
adsorption in vivo [15,214]. Moreover, modification of NPs with polymer layers 
increases the particle size as a function of linker length and grafting density. On the 
other hand, polymer linkers reduce the propensity of NPs to aggregate and thus have 
an indirect influence on the actual colloidal size. Although it is known that the length 
of the PEG linker plays a pivotal role in regulating the unspecific NP uptake [215], the 
effect of the linker length is not sufficiently taken into consideration for the 
development of targeted nanocarriers. Furthermore, the delicate mutual influence of 
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ligand density and linker length is not fully understood yet. Therefore, an extensive 
investigation of NP uptake as a combinational dependency of the surface 
functionalization degree and the linker length is needed to better understand the 
interaction of ligand-decorated nanoscaled colloids with the targeting receptors.  
For this purpose, cyclic RGD (cRGD) was selected as ligand because it is already 
well-established as a targeting moiety and has been routinely used in uptake studies 
due to its high affinity towards αvβ3 and αvβ5 integrin receptors [81-83,216]. Moreover, 
binding of cRGD to the integrin receptor triggers endocytosis of the NP-receptor 
complex [217], which is indispensably required if a cargo has to be delivered into the 
cell to achieve a therapeutic effect.  
Polymeric NPs consisting of poly(lactic-co-glycolic acid) (PLGA) and amphiphilic 
poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) were considered ideal for this study 
as they are biodegradable, biocompatible and could also be used as a carrier to deliver 
drugs. Furthermore, the block copolymers can be pre-modified with ligands or 
fluorescent tags and the blending of different polymers allows for a precise tailoring of 
NP composition, which is of particular importance if the ligand density has to be 
controlled during the NP manufacturing process. 
In this study, the contribution of the ligand density and the PEG linker length on the 
integrin binding kinetics and uptake efficiency of cRGD-decorated polymeric colloids 
was evaluated using αvβ3 integrin overexpressing U87MG glioblastoma cells as model 
cell line. To this end, PLA-PEG copolymers consisting of carboxylic acid terminated 
short (2kDa), medium (3.5kDa) or long (5kDa) PEG blocks and a constant PLA part 
(10kDa) were synthesized and the ligand was covalently attached to the carboxylic acid 
function of the PEG chain. In the first part, polymeric NPs with either short, medium 
or long PEG-linkers and different cRGD densities were prepared by nanoprecipitation 
of polymer blends consisting of constant amounts of PLGA and different feed ratios of 
PLA-PEG-COOH (2kDa, 3.5kDa or 5kDa PEG) and corresponding PLA-PEG-cRGD 
copolymers and NPs were evaluated regarding their physicochemical characteristics, 
such as their actual ligand density, ζ-potential, colloidal size and morphology. 
In the second part, the influence of the ligand density and PEG-linker length on the 
integrin receptor binding efficiency was assessed by flow cytometry using αvβ3 integrin 
overexpressing U87MG glioblastoma cells as model cell line. In the last part, the uptake 
kinetics of fully functionalized NPs as a function of PEG linker length was analyzed by 
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flow cytometry and confocal laser scanning microscopy to evaluate the 
time-dependent internalization and cellular distribution of the different targeted NP 
formulations.
 
2 Materials and methods 
2.1 Materials 
1,4-Diazabicyclo[2.2.2]octane hydrochloride (DABCO), 1,8-Diazabicyclo[5.4.0]undec-
7-ene (DBU) solution, 3,6-Dimethyl-1,4-dioxane-2,5-dione (Lactide), 
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), N-hydroxy-succinimide 
(NHS), N,N-Diisopropylethylamine (DIPEA), CF™ 488A amine and CF™  647 amine, 
anhydrous N,N-Dimethylformamide (DMF), anhydrous dichloromethane (DCM), 
methoxy poly(ethylene glycol) with a molecular mass of 5000 g mol-1 (mPEG5k) and 
Resomer® RG 502 (PLGA) were received from Sigma-Aldrich (Taufkirchen, Germany). 
Hydroxyl poly(ethylene glycol) carboxylic acid with a molecular mass of 2000, 3500 
and 5000 g mol-1 (COOH-PEG-OH) was provided by JenKem Technology USA Inc. 
(Allen, TX, USA). Cyclic RGDfK (cRGDfK) was purchased from SynPeptide Co. Ltd 
(Shanghai, China). All other materials were reagent grade and obtained from Merck 
KGaA (Darmstadt, Germany). Ultrapure water was freshly prepared using a Milli-Q 
water purification system (Millipore, Schwalbach, Germany).  
 
2.2 Fluorescent labeling of PLGA (PLGA-CF488/-CF647) 
PLGA was dissolved in anhydrous DMF and the carboxylic acid group was activated 
by the addition of DMTMM for two hours. Afterwards, 0.1 equivalents of an 
amine-functionalized dye (CF™ 488A amine or CF™ 647 amine) were added and 
stirred overnight to yield PLGA-CF488A and PLGA-CF647. To remove any unreacted 
dye, fluorescently labeled PLGA was purified by several precipitation steps in 
methanol (2x) and water (1x), followed by dialysis against water and lyophilization of 
the polymer conjugate. 
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2.3 Synthesis of PLA-PEG-COOH  
PLA-PEG-COOH block copolymers (10k-b-2k, 10k-b-3.5k, 10k-b-5k) were synthesized 
by a ring-opening polymerization as previously described in literature [170]. Linear 
hydroxyl poly(ethylene glycol) carboxylic acid with a molecular mass of 2000, 3500 and 
5000 g mol-1 was used as macroinitiator for the ring-opening polymerization of lactide 
using DBU as catalyst. 1H-NMR (CDCl3, 300 Hz) was used to characterize the precursor 
PLA-PEG-COOH polymers (10k-b-2k, 10k-b-3.5k, 10k-b-5k) and calculate the degree 
of polymerization. 
 
2.4 Synthesis of PLA-PEG-cRGD 
Cyclo(RGDfK) was covalently conjugated to carboxy-modified PLA-PEG block 
copolymers via the lysine residue of the cyclic peptide [60] (Figure 1). First, the 
carboxylic acid function of PLA-PEG-COOH was activated by EDC (25 equiv) and 
NHS (25 equiv) for 2 hours in anhydrous DMF. Then, BME (30 equiv) was added to 
quench the reaction. DIPEA (10 equiv) and cRGDfK (3 equiv) were subsequently added 
and stirred for 24 hours. The ligand-modified copolymer was purified by several 
precipitation steps in diethyl ether/ methanol mixtures, followed by dialysis against 
water for 24 hours to remove excess free ligand and reactants. 
 
2.5 Preparation of polymeric nanoparticles 
For the manufacture of nanoparticles (NPs) consisting of PLA-PEG5k-COOH and PLGA 
(NP-cRGD0-5k), polymers were diluted with acetonitrile to a final polymer 
concentration of 10 mg mL-1. The copolymer ratio of PLA-PEG to PLGA was kept 
constant at 70/30 (m/m). The polymer mixture was then added dropwise into 
10 volumes of DPBS (75 mM, pH 7.4) while stirring. NP dispersions were stirred for 
3 hours to evaporate the organic solvent. NPs were concentrated by centrifugation at 
2500 g for 15 min using Pall Microsep® filters (MWCO 100 kDa). 
For different cRGD ligand densities and varying PEG linker length, PLA-PEG-COOH 
was substituted with different amounts of PLA-PEG-cRGD. The copolymer ratio of 
PLA-PEG to PLGA was continuously adjusted to obtain particles with consistent 
molarities of PLA-PEG and PLGA, resulting in a constant molar ratio of PEG chains 
per fluorescence tags. 
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2.6 Dynamic light scattering and ζ-potential 
The size of all NP formulations was analyzed on a Malvern Zetasizer Nano ZS 
(Malvern, Herrenberg, Germany) equipped with a 633-nm He-Ne laser and operating 
at an angle of 173°. Samples were measured at a constant temperature of 25 °C in either 
75 mM (DLS) or 15 mM (ζ-potential) PBS pH 7.4. Semi-micro PMMA disposable 
cuvettes (Brand, Wertheim, Germany) were used for size measurements and folded 
capillary cells (Malvern, Herrenberg, Germany) were utilized for the ζ-potential 
determination. The position from the cuvette wall was set to 4.65 mm and the 
attenuator was optimized by the device. Data were collected and analyzed using the 
Malvern Zetasizer software version 7.11 (Malvern Instruments, Worcestershire, United 
Kingdom).  
 
2.7 Transmission electron microscopy 
The size and aggregation behavior of functionalized NPs were evaluated on a Zeiss 902 
(80 kV) transmission electron microscope (Zeiss, Oberkochen, Germany). 
NP-cRGD100-2k, NP-cRGD100-3.5k and NP-cRGD100-5k were prepared in DPBS (75 mM, 
pH 7.4), stirred for 3 hours to remove the organic solvent and subsequently dialyzed 
against ultrapure water to remove buffer salts. NP samples (50 µg mL-1) were applied 
onto carbon-coated copper grids (300 mesh; Plano, Wetzlar, Germany), incubated for 
5 minutes and negatively stained with 1% uranyl acetate solution. Excess sample 
solution was removed with a filter paper and sample grids were dried and stored in a 
desiccator before use.   
 
2.8 Nanoparticle quantification by an iodine assay (IA) 
Three batches of nontargeted NPs (NP-cRGD0-5k) consisting of PLA-PEG5k-COOH and 
PLGA were prepared in ultrapure water, purified and concentrated as described 
above. A colorimetric iodine complexation assay [192] was used to quantify the exact 
amount of PEG. In brief, NP samples were diluted in ultrapure water to a final PEG 
concentration of approximately 2.5 to 50 µg mL-1. Dilutions of methoxy poly(ethylene 
glycol) with a molecular mass of 5000 g mol-1 (mPEG5k) were used as calibration 
standards (0 - 50 µg mL-1). Two parts of a solution containing 5% (m/v) barium chloride 
in 1 N HCl were mixed with 1 part of a 0.1 N iodine/ potassium iodide solution 
immediately before use. 140 µL of sample and standard dilutions were transferred into 
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a 96-well plate, mixed with 60 µL of the iodine reagent and incubated for 15 min at 
room temperature. Absorbance was measured at 535 nm using a FluoStar Omega 
fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). The exact 
polymer concentration was determined gravimetrically after lyophilization of the 
concentrated NP samples and plotted against the PEG content determined by the 
iodine assay. As the PEG content of each particular formulation was considered to be 
constant, from this point on, the PEG content of freshly prepared samples was 
determined against the mPEG5k standard and used to calculate the polymer 
concentration (Figure S3).  
For different cRGD ligand densities and varying PEG linker lengths, the PEG content 
was analyzed and diluted to attain equal molarities of PEG in each formulation. 
 
2.9 Phenanthrenequinone Assay (PCA)   
The cRGDfK content of different NP formulations was determined by quantification of 
the arginine content as described previously [83]. In brief, NP samples were diluted in 
ultrapure water to a final polymer concentration of approximately 1 mg mL-1. Dilutions 
of cRGDfK (0 - 40 µg mL-1) were used for calibration. Then, 6 parts of a 
9,10-phenanthrenequinone solution (150 µM in ethanol) were mixed with 1 part of 2 N 
NaOH. 50 µL of sample or standard solutions were mixed with 175 µL of the 
phenanthrenequinone reagent solution and incubated at 60 °C for 3 hours. 125 µL 
aliquots were transferred into a 96-well plate, mixed with 125 µL 1 N HCl and 
incubated at room temperature for 1 hour. Fluorescence was excited at 312 nm and 
emission was recorded at 395 nm using a PerkinElmer LS 55 Fluorescence spectrometer 
(Perkin Elmer, Wiesbaden, Germany). The surface functionalization degree (SFD) for 
each NP formulation was calculated using equation 1. 
 
SFD [%] =
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2.10 Determination of the PEG grafting density and ligand density 
The PEG grafting density and the ligand density were calculated as previously 
described in literature [174,218]. The absolute ligand density (number of 
peptide-conjugated PEG molecules per µm2) was calculated based on the SFD and PEG 
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grafting density (PEG chains per nm2) which was obtained by relating the number of 
PEG molecules (calculated based on Mw(PEG), wt % of PEG in PLA-PEG determined by 
1H-NMR and the theoretical NP composition) to the surface area (S(NP)) and NP volume 
(V(NP)) using a density (ρ(NP)) of 1.2 g cm−3: 
PEG grafting density =  
!" % # $(&') #  )(&') # *+
,!('-.) # /(&')
  (2) 
where S(NP) and V(NP) are calculated using the z-average diameter of the NP 
distribution, Mw(PEG) is the PEG average molecular weight according to the 
specification sheet provided by the manufacturer, and NA is the Avogadro’s number.  
 
2.11 Flow cytometry assessment of cellular uptake 
To quantify the cellular uptake of CF™647-labeled NPs with different PEG spacer 
lengths and different surface functionalization degrees, flow cytometry experiments 
were performed. Particle concentrations were adjusted to equal PEG molarities per 
sample, corresponding to 200 µg mL-1 of NP-cRGD0-5k as reference. U87MG cells were 
seeded into collagen-coated 24-well plates at a density of 80,000 cells per well and 
cultured for 72 h. NP test solutions were prepared in TRIS binding buffer (20 mM TRIS, 
150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1% BSA) supplemented with 
10% FCS and incubated for 15 min at 37 °C to induce the formation of a protein corona 
and cells were subsequently treated with NP solutions for 45 min at 37 °C. To evaluate 
the binding kinetics of cRGD-decorated nanoparticles with different PEG linker lengths 
(NP-cRGD-2k, NP-cRGD-3.5k and NP-cRGD-5k), incubation times were varied from 
15 to 180 minutes. For the control experiment, an excess of cRGDfK (500 µM) was used 
to suppress binding to the αvβ3 receptor. After incubation, cells were washed with 
DPBS, trypsinized and centrifuged at 200 g for 5 min and washed once with DPBS. 
Cells were suspended in 200 µL DPBS and cellular fluorescence was analyzed with a 
FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, USA) using a 633 nm 
laser for excitation and a 670 nm long pass (LP) filter for detection. Resulting data were 
evaluated using the Flowing Software v2.5 (Turku, Finland).  
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2.12 Confocal laser scanning microscopy 
To analyze the NP binding pattern on cells, confocal microscopy was conducted. 
U87-MG cells were seeded into collagen-coated 8-well Chamber Slide ™ systems 
(Lab-Tek®) at a density of 15,000 cells/well and cultivated for 48 h. CF™ 488A-labeled 
sample solutions were prepared in RGD binding buffer (20 mM TRIS, 150 mM NaCl, 
2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1% BSA) supplemented with 10% FCS and 
incubated for 15 min at 37 °C to induce the formation of a protein corona. Cells were 
treated with the pre-warmed NP test solutions for either 15 or 60 min at 37 °C. Then, 
cells were washed, fixed with 2% paraformaldehyde in DPBS for 10 min at room 
temperature and washed extensively with DPBS. Samples were embedded in Mowiol 
aqueous embedding medium supplemented with 2.5% (w/v) DABCO and analyzed 
with a Zeiss Axiovert 200 microscope combined with an LSM 510 laser-scanning device 
at 63-fold magnification. NP fluorescence was excited with an argon laser at 488 nm 
and the emission was recorded using a 530/30 nm bandpass (BP) filter. 
 
2.13 Statistical analysis 
All results are presented as mean ± standard deviation, based on the data obtained 
from at least n = 3 samples. Statistical significance was determined by means of 
one-way ANOVA, followed by Tukey’s post-hoc test using GraphPad Prism 6.0 
(GraphPad Software Inc., La Jolla, CA, USA). Statistical significances were set as 
indicated. 
 
3 Results and discussion 
3.1 Preparation of NPs with different surface functionalization 
To allow for precise tuning of the NP composition, a set of block copolymers with 
distinct molecular weights was first synthesized and conjugated with cRGD ligands. 
Carboxylic acid terminated PLA-PEG block copolymers with constant PLA blocks and 
different PEG lengths (10k-b-2k, 10k-b-3.5k, 10k-b-5k) were prepared by a catalyzed 
ring opening polymerization and the resulting block copolymers were then modified 
with cRGD by EDC/NHS chemistry (Figure 1A). PLGA was labeled with a fluorescent 
dye (CF488A or CF647) to enable tracing of polymeric colloids in in vitro experiments 
(Figure 1B). To investigate the influence of ligand density and PEG-linker length on the 
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cellular uptake into U87MG glioblastoma cells, polymeric NPs with either a short, 
medium or long PEG-linker length and with tunable cRGD densities were 
manufactured (Figure 1C) by changing the set of PLA-PEG block copolymers 
(10k-b-2k, 10k-b-3.5k, 10k-b-5k) and the feed mass ratio of PLA-PEG-cRGD and 
PLA-PEG-COOH (0/100, 25/75, 50/50, 75/25 or 100/0). The corresponding NP samples 
were defined as NP-cRGDx-2k, NP-cRGDx-3.5k or NP-cRGDx-5k to distinguish 
between the linker length and as NP-cRGD0, NP-cRGD25, NP-cRGD50, NP-cRGD75, 
NP-cRGD100 to define the surface functionalization degree. 
 
 
 
Figure 1. Synthesis strategies for the block copolymers and preparation of the NPs. (A) Synthesis of 
PLA-PEG-COOH (10k-b-2k, 10k-b-3.5k, 10k-b-5k) copolymers and conjugation of c(RGDfK) using 
EDC/NHS chemistry. (B) Conjugation of fluorescent dyes (CF647/CF488A) to carboxylic acid terminated 
PLGA using DMTMM. (C) Preparation of NP formulations with different ligand densities and different 
PEG-spacer lengths by blending constant amounts of PLGA with different mass ratios of PLA-PEG-COOH 
(10k-b-2k, 10k-b-3.5k, 10k-b-5k) and corresponding PLA-PEG-cRGD copolymers. 
 
 
3.2 Characterization of nanoparticles 
To confirm the correlation between predicted and actual ligand density, the molar 
amounts of PEG and cRGD were quantified with an iodine complexation assay and a 
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9,10-phenanthrenequinone assay, respectively. The surface functionalization degree of 
each NP formulation was calculated using equation 1. As depicted in Figure 2 the 
predicted cRGD density highly correlated with the experimentally determined ligand 
density (R² = 0.9975, 0.9888 and 0.9980) confirming that the pre-modification of block 
polymers and the manufacturing process allow for a precise tailoring of the surface 
composition of polymeric PLGA blended PLA-PEG NPs. 
 
 
 
Figure 2. Correlation of predicted and measured ligand density. (A) NP-cRGD-2k, (B) NP-cRGD-3.5k, 
(C) NP-cRGD-5k. The amount of peptide was determined by a 9,10-phenanthrenequinone assay and the 
amount of PEG was analyzed using an iodine complexation assay.  
 
 
Furthermore, all NP formulations were analyzed with regard to their size and 
ζ-potential. Modification of the colloidal surface with increasing amounts of cRGD 
ligands generally resulted in a consecutive increase in the hydrodynamic diameter and 
also in the ζ-potential (towards less negative values). While the increase in the 
hydrodynamic diameter was only minor for NPs with long PEG5k-linkers (38.4 to 
54.1 nm), the increase in size was even more pronounced for NPs with medium 
PEG3.5k-linkers (36.0 to 97.3 nm) and short PEG2k-linkers (43.3 to 171.9 nm) when the 
surface functionalization degree was 100% compared to the respective unmodified 
counterparts. In contrast, the ζ-potential became less negative upon conjugation of the 
carboxylic acid groups with cRGD, also indicating that the coupling reaction was 
successful and that less charged groups are available on the surface. TEM images of 
NP-cRGD100-2k (Figure 3G), NP-cRGD100-3.5k (Figure 3H) and NP-cRGD100-5k 
(Figure 3I) revealed that the increase in size measured by DLS was not a result of an 
actual enlargement of the particle size, but of a higher tendency of spherical NPs with 
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short and medium PEG-linkers to form NP clusters upon functionalization of the 
carboxylic acids groups on the colloidal surface with the peptide (Figure S4). The 
clustering tendency was also reflected in the number-weighted size distribution 
patterns obtained by DLS (cf. Figure S5).  
In case of NP aggregation, the specific surface area per cluster volume decreases. Since 
these polymeric NPs generally have a negatively charged particle core due to 
unmodified carboxylic acid groups of the PLGA polymer, an increase in the apparent 
cluster volume also results in a more pronounced negative charge of a cluster 
compared to a single NPs which is opposite to the charge increase (towards a neutral 
charge) on account of surface modification. 
 
 
 
Figure 3. Characterization of different NP formulations. Hydrodynamic diameter and ζ-potential 
polymeric NPs with different surface functionalization degrees (0-100%) and PEG-linker lengths: 
(A,D) NP-cRGD-2k, (B,E) NP-cRGD-3.5k, (C,F) NP-cRGD-5k. TEM images of (G) NP-cRGD100-2k, 
(H) NP-cRGD100-3.5k and (I) NP-cRGD100-5k demonstrating the different clustering tendencies depending 
on the PEG-linker length. Scale bars indicate 50 nm. 
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Hence, the ζ-potential of NP-cRGD100-2k only slightly altered from -22.7 to -14.7 mV 
(Δ= 8.0 mV), whereas NP modified with the medium PEG3.5k-linker and long 
PEG5k-linker displayed a more pronounced change in ζ-potential from -20.1 to -8.5 mV 
(Δ= 11.6 mV) and from -19.0 to -5.6 mV (Δ= 13.4 mV), respectively.  
Interestingly, NP-cRGD100-2k displaying the highest absolute value of the ζ-potential 
(-14.7 mV) compared to NP-cRGD100-3.5k (-8.5 mV) and NP-cRGD100-5k (-5.6 mV) 
possessed the lowest colloidal stability. This was mainly attributed to the fact that the 
ζ-potential was measured in diluted DPBS (15 mM, pH 7.4) because it is only evaluable 
at low salt concentrations. As the ζ-potential highly depends on ionic strength, absolute 
differences in ζ-potential between these formulations are expected to be even smaller 
in TRIS buffer that was used for uptake experiments, and are not considered to 
significantly influence the colloidal stability in terms of electrostatic repulsion. 
Moreover, PEG is known to enhance the colloidal stability by steric repulsion as a 
function of grafting density and linker length [189,219]. In conclusion, the decrease in 
electrostatic repulsion, which was reflected in a lower absolute value of the ζ-potential, 
was overcompensated by the enhanced steric hindrance of longer PEG linkers. 
 
3.3 Cellular uptake and targeting of nanoparticles 
In this study, polymeric NPs with distinct surface functionalization degrees and 
different PEG spacer lengths were prepared via bulk nanoprecipitation and the impact 
of the ligand density and the PEG spacer length on the integrin receptor binding and 
uptake into U87MG cells was evaluated by flow cytometry. As U87 glioblastoma cells 
are known to overexpress the αvβ3 receptor, which can be effectively targeted with the 
cyclic RGD peptide, they were used as model cell line in this study. Polymeric NPs 
were prepared with a constant molar ratio of PEG chains per fluorescence tags to allow 
for the correlation of the cellular associated fluorescence determined by flow cytometry 
and the relative degree of surface functionalization. 
As shown in Figure 4, cellular associated fluorescence levels increased with higher 
cRGD surface densities of NP-cRGD-2k, NP-cRGD-3.5k and NP-cRGD-5k, indicating 
that higher amounts of ligands present on the colloidal surface increased the targeting 
efficiency towards αvβ3 integrin positive cells. The uptake of NP-cRGD-5k and 
NP-cRGD-3.5k into U87MG cells was similar when the relative cRGD modification was 
0, 25 and 50%, but began to increase for NP-cRGD-3.5k above a surface 
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functionalization level of 50%. In contrast, NP formulations with a short PEG2k linker 
displayed an exponential increase in cell-associated fluorescence with higher degrees 
of surface functionalization. Compared to the other two NP formulations, the uptake 
of NP-cRGD-2k was significantly higher (p < 0.01) at surface functionalization levels of 
50, 75 and 100% (Figure 4), e.g. the cell-associated fluorescence of NP-cRGD100-2k 
(365.7 a.u.) was 3.7 and 5.7 times higher compared to NP-cRGD100-3.5k (98.0 a.u.) and 
NP-cRGD100-5k (64.0 a.u.), respectively. 
 
 
 
Figure 4. Integrin receptor mediated uptake of polymeric NPs modified with different degrees 
of surface functionalization (0-100 %) and PEG-linker lengths (2kDa, 3.5kDa, 5kDa) determined 
by flow cytometry. Data were fitted with a second order polynomial. Levels of significance are 
indicated as: (*) p < 0.01, comparing polymeric NPs with an equal surface functionalization 
degree. 
 
 
Interestingly, the relation of ligand density and uptake efficiency of NP-cRGD-2k and 
NP-cRGD-3.5k could be described using a second order polynomial function, with the 
coefficients of determination being 0.9966 and 0.9948, respectively. In contrast, the 
surface functionalization dependent uptake of NPs decorated with long PEG5k linkers 
(NP-cRGD-5k) could not only be fitted with a second (R² = 0.9988), but also with a first 
order polynomial (R² = 0.9968). In the case of NP-cRGD-2k and NP-cRGD-3.5k the 
relation between NP uptake and the degree of surface functionalization did not follow 
a first order polynomial equation (Table 1), indicating that for NP-cRGD-2k and 
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NP-cRGD-3.5k there is more than one contributing key factor influencing the receptor 
binding efficiency. 
 
 
Table 1: Surface functionalization degrees of different NP formulations were correlated with 
corresponding cell-associated fluorescence levels. Data were fitted with a first and second order 
polynomials.  
 
Formulation First order polynomial R² Second order polynomial R² 
NP-cRGD-2k y = -42.9 + 3.69x 0.9205 y = 1.89 + 0.103x + 0.0359x² 0.9966 
NP-cRGD-3.5k y = -7.90 + 0.992x 0.9565 y = 0.489 + 0.321x + 0.0671x² 0.9948 
NP-cRGD-5k y = -0.0840 + 0.633x 0.9968 y = 1.12 + 0.537x + 0.000959x² 0.9988 
 
 
As demonstrated earlier, NPs with short and medium PEG spacer length exhibited a 
higher tendency to form colloidal clusters, resulting in a higher apparent particle size. 
Based on the z-average size of NPs and clusters as determined by DLS, the absolute 
ligand density per µm2 was calculated for each NP formulation (Figure S6) and the 
cellular associated fluorescence was plotted against the calculated ligand density 
per µm-2. As shown in Figure 5, the mean fluorescence directly correlated with the 
absolute ligand density for all three NP formulations (Table S1), which implies that the 
integrin-mediated cellular uptake highly depends on the absolute ligand density 
expressed as ligands per µm2. 
 
 
 
Figure 5. NP binding to U87MG cells as a function of absolute ligand densities (number of 
peptide-conjugated PEG molecules per µm2) in different NP formulations. (A) NP-cRGD-2k, 
(B) NP-cRGD-3.5k and (C) NP-cRGD-5k. 
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For NP-cRGD-2k, the slope of the fitted straight line was higher (0.0003116) than for 
NP-cRGD-3.5k (0.0001645) and NP-cRGD-5k (0.0001995), indicating that in the case of 
medium and long PEG linkers, not all of the tethered cRGD ligands are available on 
the NP surface. It has already been reported in the literature that molecules conjugated 
to PEG linkers can be entangled by the polymer and may not be available for 
ligand-receptor interactions [54]. As a result, the affinity of the ligand towards the 
receptor is severely impaired. This ligand shrouding effect is highly depending on the 
molecular weight of the linker as the flexibility of PEG chains increases with higher 
polymerization degrees [220]. Interestingly, the change in ζ-potential deriving from the 
progressing surface modification had no effect on binding efficiency at all. This 
observation was further confirmed by a control experiment in which unmodified 
control NPs with different ratios of methoxy- and carboxylic acid terminated PLA-PEG 
copolymers were used to imitate the conversion of the charged groups on the surface 
to neutral conjugates (cf. Figure S7).  
Furthermore, the relation of fluorescence levels and ideal ligand densities, meaning 
that the ligand density of cRGD-decorated NPs corresponding to the PEG grafting 
density multiplied with the surface functionalization degree, could not be described 
with a first order polynomial (with the exception for NP-cRGD-5k, showing no 
significant cluster formation) but instead, followed a second order polynomial. This 
finding indicates, that the effective ligand density of NP clusters is affected by 
rearrangement of PEG linkers upon cluster formation, which results in a higher ligand 
density on the surface of clustered NPs that are available for binding to αvβ3 integrin 
receptors (Figure S8). 
In summary, the clustering tendency and ligand density both have a major impact on 
integrin mediated uptake of NPs. However, both of these determinants are highly 
influenced by PEG linker length, even if the functionalization degree is controlled by 
the relative amount of ligand-conjugated PLA-PEG copolymer used for preparation of 
polymeric NPs. 
 
3.4 Uptake kinetics of nanoparticles with different linker lengths 
In the previous section it was shown that both factors, the ligand density and the linker 
length, are critical attributes that have a major influence on the multivalent 
nanoparticle-receptor interaction. As fully modified NP-cRGD100-2k, NP-cRGD100-3.5k 
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and NP-cRGD100-5k showed significant differences in their clustering tendency and 
thus, in integrin binding efficiency, these three particular formulations were used to 
further investigate the integrin binding kinetics. To this end, U87MG cells were 
incubated with NP-cRGD100-2k, NP-cRGD100-3.5k and NP-cRGD100-5k for different time 
periods, ranging from 15 to 180 minutes. Unmodified NP-cRGD0-5k served as control 
because this formulation is not expected to be internalized via the specific 
receptor-mediated endocytosis pathway.  
 
 
 
Figure 6. Binding kinetics of (A) NP-cRGD0-5k (B) NP-cRGD100-5k, (C) NP-cRGD100-3.5k and 
(D) NP-cRGD100-2k. U87MG cells were incubated with different NP formulations for either 15, 60, 120 or 
180 minutes. Cell associated fluorescence was assessed by flow cytometry. 
 
 
As demonstrated in Figure 6, all three cRGD-decorated NP formulation exhibited a 
linear increase in cellular associated fluorescence between 15 and 120 minutes, 
followed by a slightly plateaued increase between 120 and 180 minutes. Because the 
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growth medium is substituted with nutrient free TRIS binding buffer during the 
sample incubation, the receptor mediated internalization kinetics might be altered as a 
result of a change in the physiology of U87MG cells. Furthermore, the change in slope 
may also result from a saturation of receptors on the surface or a decelerated recycling 
process of the integrin receptors, usually undergoing a constant endo/exocytic 
shuttling from the endosome back to the plasma membrane [221,222]. Comparing the 
correlation between fluorescence and incubation time (15 - 120 minutes), the slope of 
the fitted straight line (Table S2) of NP-cRGD100-2k was much higher (4.745 units min-1) 
compared to NP-cRGD100-3.5k (1.195 units min-1) and NP-cRGD100-5k 
(0.972 units min-1). 
Unmodified NP-cRGD0-5k did not show a relevant binding to U87MG cells during the 
whole incubation timeline up to 180 minutes. As the slope is an indicator for uptake 
kinetics, these results clearly indicate that NPs modified with shorter PEG chains are 
more rapidly internalized by the cells than NP decorated with longer PEG chains. This 
can be explained by a thermodynamic approach: When the NP interacts with the cell 
membrane, there are four major determinants that contribute to the free energy of the 
system 
 
Fsum = Fmembrane + Fcytoskeleton + Fligand + Fpolymer    (3) 
 
In this equation Fmembrane is the bending energy of the cellular membrane which is 
related to a change in membrane curvature during endocytosis of the NPs. Fcytoskeleton 
describes the change in deformation energy of the cytoskeleton or, more precisely, actin 
filaments. Fligand represents the specific ligand-receptor interaction and Fpolymer is the free 
energy of the grafted polymer chains resulting from steric repulsion between the 
grafted PEG chains and the cellular membrane [223]. Upon NP binding to the receptor 
Fligand is reduced. Due to changes in curvature of the cellular membrane and the 
deformation of the cytoskeleton during internalization of the receptor-NP complex, 
Fmembrane and Fcytoskeleton increase, respectively. When NP-grafted PEG chains are absorbed 
and covered by the cellular membrane they forfeit conformational degrees of freedom, 
resulting in an increase in Fpolymer. According to equation 3, endocytosis of NPs is 
triggered if the increment in Fmembrane, Fcytoskeleton and Fpolymer is overcompensated by the 
decrease in Fligand. 
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Provided that the receptor density on the cellular membrane is sufficiently high, an 
increase in ligand density generally leads to a higher number of simultaneously 
occurring ligand-receptor binding events consequently resulting in a decrease in Fligand. 
During the initial phase of endocytosis, the repulsive part of the particle-cell interaction 
is mainly governed by deformation of the cytoskeleton and membrane 
bending [224,225]. NP clustering can enhance the reduction of Fligand by cooperative 
binding of ligands on NP clusters via multivalent ligand-receptor interactions [226] 
which then can trigger receptor clustering and further reduce Fligand. Moreover, 
cooperative wrapping of NPs also lowers the free energy threshold necessary for 
bending the membrane (Fmembrane) as the relative surface area of a particle cluster which 
has to be covered is significantly smaller compared to the sum of surface areas of 
independently wrapped particles [227].  
In contrast to their shorter and more rigid counterparts, PEG chains with an increasing 
chain length possess higher flexibility. Therefore, entropic penalty paid for binding to 
αvβ3 integrins on the cellular membrane is significantly higher for longer PEG linker, 
leading to a more substantial increase in Fpolymer of longer linkers compared to PEG2k 
chains [223]. In addition, PEG chains with higher flexibility also have an enhanced 
chance of entangling and cloaking the ligand inside the PEG shell due to partly folding 
on the distal end of the PEG linker [228]. As a consequence, the orientation and thus 
ligand presentation [229] is partially impaired, attenuating the decrease in Fligand as 
there are less ligand-receptor binding events per area. Even though the major 
contribution derives from conformational entropy losses upon binding to the receptors, 
ligand entanglement and shrouding still constitutes a contributing factor as it hinders 
the association of peptides with their target receptors. 
Moreover, membrane bending and deformation near a bound NP can promote further 
NP clustering on the membrane during endocytosis. As the membrane in the adjacent 
location to a bound NP is already partly deformed, it allows neighboring particles to 
gain more contact area. As a result, the energetic threshold of Fmembrane and Fcytoskeleton is 
reduced, which makes adjacent binding energetically favorable. This effect has been 
recently described for norovirus-like particles after binding to glycosphingolipids on a 
supported lipid bilayer [230].  
To ensure that the enhanced uptake of NP clusters derived from specific NP-receptor 
interactions and was not solely attributed to the increase in particle size, an additional 
control experiment was performed. U87MG cells were either treated with 
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cRGD-decorated NPs or simultaneously incubated with NPs and excess of the free 
ligand for 15 or 60 minutes. When cells were co-incubated with targeted NPs and 
cRGD, the specific NP-receptor interaction was completely suppressed to fluorescence 
levels comparable with non-targeted control NPs (Figure 7). These results provide clear 
evidence that the internalization of ligand-decorated NPs was not a result of an 
increased unspecific uptake due to a larger effective particle size of clusters but instead, 
was exclusively mediated by specific ligand-receptor interactions. 
 
 
 
 
Figure 7: Cellular uptake of NP-cRGD0-5k (non-targeted NPs), NP-cRGD100-2k, NP-cRGD100-3.5k and 
NP-cRGD100-5k after 15 and 60 minutes. To suppress specific NP-receptor interactions, cells were simultaneously 
incubated with NPs and excess free ligand (500 µM cRGDfK). Levels of significance are indicated as: 
(***) p < 0.001. 
 
 
In summary, NPs decorated with cRGD tethered to short PEG2k linkers displayed a 
high propensity to form colloidal clusters which allow for cooperative binding to 
integrin receptors. Multivalent receptor binding of NP clusters decreases Fligand and, in 
addition, lowers the energetic threshold of Fmembrane and Fcytoskeleton. In contrast, NPs 
decorated with medium PEG linkers only formed smaller clusters and NP-cRGD100-5k 
did not form clusters at all. Furthermore, NP-cRGD100-3.5k and NP-cRGD100-5k suffered 
from ligand entanglement which led to impairment of ligand interactions with αvβ3 
receptors located on the cell membrane and consequently to a less pronounced 
decrease in Fligand. Moreover, the overall entropic loss upon binding to the receptor was 
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reduced if the ligand was conjugated to shorter PEG chains compared to medium and 
long PEG linkers. As a thermodynamic result, the uptake efficiency of NP-cRGD100-5k 
was low and the uptake of NP with medium PEG3.5k spacers (NP-cRGD100-3.5k) was 
moderate compared to NP-cRGD100-2k which displayed the most efficient integrin 
receptor-mediated uptake (Figure 8). 
 
 
 
Figure 8. Schematic illustration of the αvβ3 receptors binding and cellular uptake of (A) NP-cRGD100-2k, 
(B) NP-cRGD100-3.5k, (C) NP-cRGD100-5k. In general, the number of successful ligand-receptor interactions 
is increased through cooperative binding clustering of NPs and decreased by entanglement and shrouding 
of ligands. 
 
 
3.5 Time-dependent cellular distribution of nanoparticles with different 
linker lengths 
In the last part of this study, the receptor binding and cellular uptake of NPs as a 
function of time was assessed by confocal laser scanning microscopy (Figure 9). The 
objective of this experiment was to confirm, that the increase in cell-associated 
fluorescence determined by flow cytometry was attributed to the specific integrin 
receptor-mediated uptake and did not derive from non-specific adhesion to the cellular 
membrane. For this purpose, U87MG cells were incubated for either 15 or 60 minutes 
with NP-cRGD100-2k, NP-cRGD100-3.5k or NP-cRGD100-5k and subsequently fixed with 
PFA. As flow cytometry results had already revealed that incubation of cells with the 
NP formulations resulted in different intensities of cell-associated fluorescence, 
microscope settings were adjusted to attain images with comparable fluorescence 
levels. After 15 minutes of incubation, NPs mainly accumulated on the cellular 
membrane and only a low amount of NPs was internalized by the cells. However, after 
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60 minutes of incubation, NPs were homogeneously distributed within the cytoplasm 
of the cells and mainly accumulated in endosomes. 
 
 
 
Figure 9. Evaluation of the NP localization and distribution by CLSM. Confocal images of U87MG cells 
treated with either NP-cRGD100-2k, NP-cRGD100-3.5k or NP-cRGD100-5k for 15 or 60 minutes. To allow for 
comparison of all samples, microscope settings were adjusted to attain images with comparable 
fluorescence levels. Scale bars indicate 20 µm. 
 
 
These results are in accordance with previous studies by Sancey et al. who 
demonstrated that multivalent binding of tetrameric RGD to αvβ3 integrin receptors 
resulted in internalization of the ligand-receptor complex via clathrin-mediated 
endocytosis [231]. The ratio of membrane-bound to endocytosed NPs after 15 and 60 
minutes of incubation was similar for all three NP formulations, although NP-cRGD-2k 
samples displayed a much higher fluorescence level. These results clearly demonstrate, 
that regardless of the PEG spacer length, cRGD-modified polymeric NPs were 
internalized by the cells. Moreover, the increase in cell-associated fluorescence of NPs 
with a higher clustering tendency results from enhanced receptor-mediated uptake 
and is not assigned to non-specific binding of NP aggregates to the membrane. 
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Furthermore, these observations support, that U87MG cells are capable of internalizing 
whole clusters of ligand-decorated NPs upon multivalent binding to αvβ3 receptors. 
Nevertheless, it should be noted that the in vitro results cannot ultimately be translated 
into an in vivo performance of targeted nanoscaled colloids as there are numerous 
factors influencing the targeting ability, such as the formation of a protein corona 
influencing the phagocytosis of NPs, physiological barriers on the route to the target 
tissue or enzymes that might have an impact on degradation [10,171,232].
 
4 Conclusion 
In this study, the contribution of the ligand density and the PEG linker length on 
integrin binding kinetics and uptake efficiency of cRGD-decorated polymeric colloids 
was evaluated. Although a sufficiently high cRGD density was considered as a 
prerequisite for the integrin receptor-mediated endocytosis, uptake efficiency of NPs 
possessing a high functionalization degree was mainly dominated by the PEG linker 
length. Ligand-decorated NPs with short PEG2k linkers displayed a high propensity 
to form colloidal clusters allowing for cooperative binding to integrin receptors. 
Furthermore, the higher flexibility of longer PEG chains increased the chance of 
entangling and cloaking the ligand, thereby decreasing the number of ligand-receptor 
binding events on the cell membrane. Moreover, the overall entropic loss upon binding 
to receptor was reduced if ligands were conjugated to shorter PEG chains compared to 
medium and longer PEG linkers. All of these factors affected different thermodynamic 
driving forces which ultimately determine the receptor-mediated internalization 
kinetics into U87MG cells. As a result, it was shown that targeted colloids with short 
PEG2k chains were most efficient in targeting αvβ3 receptors in vitro, whereas NPs with 
medium PEG3.5k and long PEG5k linkers only displayed a moderate and low 
endocytosis rate, respectively. 
On the basis of these results, it should be noted, that the precise control of the ligand 
density might not always be sufficient for optimization of targeted drug delivery 
systems and that the role of the linker length should be taken into serious consideration 
for the design of colloidal drug delivery formulations in order to maximize therapeutic 
efficacy and minimize undesired side effects. 
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Abstract 
Viruses provide pioneering concepts of selective receptor targeting as they recognize 
and enter their host cells by sequential binding to different adhesion and entry 
receptors, which allows them to unequivocally identify their targets. Following this 
strategy, polymeric core/shell structured nanocarriers were designed that were surface 
decorated with two mesangial cell-specific targeting ligands, an aνβ3 integrin-specific 
peptide and an angiotensin II receptor (AT1R) antagonist. Mesangial cells were chosen 
as model targets as they play a central role in the progressive loss of kidney function 
in diabetic nephropathy. The two targeting ligands were tethered to PEG linkers with 
different lengths to allow for sequential ligand presentation. The primary ligand (AT1R 
blocker) was used for the first recognition of the target cell via binding to the AT1R, 
whereas the secondary ligand (cRGD) was initially “invisible” for the cell and 
interacted with the secondary receptor (avβ3 integrin) in a time-shifted manner, 
followed by endocytosis of the colloid. Laser scanning confocal microscopy and flow 
cytometry experiments confirmed that dual-targeted nanoparticles displayed 
synergistic targeting effects with enhanced selectivity towards mesangial cells as 
compared to nanoparticles decorated with a single type of targeting ligand. Thus, 
virus-inspired heteromultivalent nanoparticles offer a versatile platform for delivering 
therapeutic cargos to a target site with significantly improved specificity and targeting 
efficiency. 
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1    Introduction 
Effective and specific targeting of nanoscaled drug delivery systems to the target site 
is of paramount importance for the development of new nanomedicines. One of the 
leading concepts to enhance selectivity towards the target tissue is surface decoration 
of NPs with distinct targeting-moieties. This conventional targeting strategy aims at 
improved multivalent binding to cells that overexpresses a certain kind of target 
receptor in a diseased state. This allows the immobilized receptor ligands on the 
colloidal surface to bind to several cognate target receptor molecules on the cell surface 
simultaneously. Multivalent binding to target cells has been well documented for a 
plethora of nanomaterials [58,233-235] and various receptors such as G protein-coupled 
receptors (GPCR) [236-238] or integrins[81,239]. 
However, it is often overlooked that there is not one receptor that is exclusively 
expressed on a single cell-type which limits the potential of single-targeted drug 
delivery systems due to binding to off-target tissues. Even though these off-target cells 
express lower levels of the molecular target, they might be earlier accessible for the 
colloid during its route through the organism. Recent approaches have tried to 
overcome these limitations and increase target cell selectivity through simultaneous 
presentation of two different types of ligand. This heteromultivalent strategy has been 
proven to significantly enhance specificity and targeting efficiency in vitro [93-97,240]. 
Nevertheless, this concept has not taken sufficiently into account that by involving 
multiple types of receptor ligands also the number of off-target sites in vivo is increased, 
since the circulating colloids will encounter more types of cell that express either of the 
receptors compared to the single-target approach. 
Viruses are widely considered the pioneers of selective receptor targeting as they have 
evolved unique strategies of recognizing and invading their host cells [100-102]. Virus 
binding to the cell surface and cell entry is a complex multi-stage procedure that 
involves the consecutive binding of different receptor types. The initial recognition of 
the primary adhesion receptor is used to identify their targets and allows the virus to 
attach to the cell membrane, yet it does not trigger virus entry. Nonetheless the close 
vicinity to the cell surface enhances heteromultivalent binding events to entry receptors 
which then initiate cellular uptake of the virus by endocytosis or membrane 
fusion [103-105].  
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Inspired by the sequential binding of viruses to two distinct types of target receptors, 
virus-mimetic heteromultivalent NPs were engineered carrying two different kinds of 
targeting ligands. Thereby, the primary ligand was intended for the initial target cell 
recognition, whereas the secondary ligand was used to confirm cell identity and 
affiliates receptor-mediated endocytosis. Playing a key role in maintaining the 
glomerular function [139,241] and being critically involved in progression of renal 
diseases, such as diabetic nephropathy (DN) [154], mesangial cells were used as model 
target cell line. Pathological changes of mesangial cells are among the earliest and most 
critical events found in DN which makes them a valuable therapeutic target [151]. 
In this study, polymeric core/shell structured nanoparticles (NPs) consisting of 
poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) that were further core-stabilized 
with additional poly(lactic-co-glycolic acid) (PLGA) were used as targeting system. 
Thereby, amphiphilic PLA-PEG block copolymers were utilized to introduce different 
targeting moieties. The primary and secondary ligand were conjugated to PEG linkers 
with different lengths aiming at a time-shifted consecutive binding of two receptor 
types (AT1 and avβ3 receptor) expressed on mesangial cells. 
The schematic illustration of the concept of sequential mesangial cell recognition and 
cell entry by dual-targeted heteromultivalent NPs is depicted in Figure 1.  
 
 
 
Figure 1. Schematic illustration of the concept of heteromultivalent target cell recognition by dual-targeted 
nanoparticles. 
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The primary ligand, an angiotensin receptor blocker (ARB; e.g. Exp3174) is used for the 
first recognition of the target cell via binding to the AT1 receptor, but does not trigger 
endocytosis. Since the secondary ligand cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGD) is 
tethered to shorter PEG-chains, it is initially “invisible” for the cell and can only bind 
to the secondary receptor (avβ3 integrin) if the NP is already in close proximity to the 
cell membrane. Binding to the secondary receptor will then trigger cellular uptake of 
the colloid.  
To implement this targeting strategy, there are several requirements towards the two 
ligands that have to be met. The primary ligand should be able to specifically bind to 
the primary AT1R with moderate affinity without inducing internalization. In contrast, 
the secondary receptor has to be shielded during the initial cell recognition to minimize 
ligand-receptor interactions with off-target cells. Furthermore, it has to be capable of 
binding to the secondary avβ3 integrin receptor with high affinity and trigger 
endocytosis upon receptor binding.  
In the first part of the study, two different ARBs (Exp3174 and Valsartan) were 
evaluated for their potential as primary ligand. Flow cytometry and confocal 
microscopy analyses were performed to assess AT1R binding and cellular distribution 
of NPs, whereas a calcium immobilization assay was used to evaluate the affinity loss 
of ARB ligands upon PEGylation. In the second part of the study, avβ3 integrin receptor 
binding and cellular uptake of NPs decorated with the secondary ligand was evaluated 
and the minimum PEG linker length required for ligand cloaking was assessed using 
avβ3 integrin receptor overexpressing off-target cells (U87MG). In the last part of this 
study, binding and uptake of dual-targeted heteromultivalent NPs into mesangial cells 
was assessed and compared to the respective single-targeted counterparts.
 
2 Materials and methods 
2.1 Materials 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) solution, anhydrous dichloromethane 
(DCM), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM), 3,6-Dimethyl-1,4-dioxane-2,5-dione (Lactide), CF™  647 amine, anhydrous 
dimethyl sulfoxide (DMSO), fluoresceinamine isomer I (FAM), 2-Mercaptoethanol 
(BME), methoxy poly(ethylene glycol) with a molecular mass of 5000 g mol-1 
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(MeO-PEG5k), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), N-hydroxy-
succinimide (NHS), N,N'-Dicyclohexylcarbodiimide (DCC), N,N-Diisopropyl-
ethylamine (DIPEA) and Resomer® RG 502 (PLGA) were received from Sigma-Aldrich 
(Taufkirchen, Germany). Losartan potassium and Valsartan were obtained from Santa 
Cruz (Heidelberg, Germany). Alexa Fluor™ 647 cadaverine, Dulbecco’s phosphate 
buffered saline pH 7.4 (DPBS; containing 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM 
KCl and 138 mM NaCl), fura-2AM and Leibovitz’s L15 medium were obtained from 
Invitrogen GmbH (Karlsruhe, Germany). Cyclic RGDfK (cRGD) was purchased 
from SynPeptide Co. Ltd (Shanghai, China). Hydroxyl polyethylene glycol carboxylic 
acid with molecular masses of 2000, 3500 and 5000 g mol-1 (COOH-PEG-OH) and 
hydroxyl poly(ethylene glycol) Boc-amine (Boc-NH-PEG5k-OH) with a molecular 
mass of 5000 g mol-1 were provided by JenKem Technology USA Inc. (Allen, TX, USA). 
All other materials were of technical grade and obtained from Merck KGaA 
(Darmstadt, Germany). Ultrapure water was obtained using a Milli-Q water 
purification system (Millipore, Schwalbach, Germany).  
 
2.2 Fluorescent labeling of PLGA  
PLGA was dissolved in anhydrous DMF and the carboxylic acid group was activated 
by addition of DMTMM for two hours. Afterwards, 0.1 equivalents of CF™ 647 amine 
or Alexa Fluor™ 647 cadaverine, or 3 equivalents of FAM were added and stirred 
overnight to yield PLGA-CF647, PLGA-Alexa647 and PLGA-FAM. To remove 
unreacted dye, fluorescently labeled PLGA was purified by several precipitation steps 
in methanol (2x) and water (1x), followed by dialysis against water. The purified 
polymer conjugate was lyophilized for 72 h.    
 
2.3 Synthesis of block copolymers  
PLA-PEG-OMe (10k-b-5k), PLA-PEG-COOH (10k-b-5k, 10k-b-3.5k, 10k-b-2k) and 
PLA-PEG-NH2 (10k-b-5k) block copolymers were synthesized by ring-opening 
polymerization as previously described by Qian et al. [170] with slight modifications. 
Prior to use, racemic 3,6-dimethyl-1,4-dioxane-2,5-dione (D,L-lactide) was purified by 
recrystallization from anhydrous ethyl acetate and dried under vacuum for at least 
12 h. Linear MeO-PEG-OH or Boc-NH-PEG-OH with a molecular mass of 5000 g mol-1 
and COOH-PEG-OH with a molecular mass of either 2000, 3500 or 5000 g mol-1 were 
used as macroinitiators for a ring-opening polymerization of cyclic rac-Lactide using 
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DBU as catalyst. After 1 h, the polymerization was quenched with benzoic acid. For 
cleavage of the Boc protection group of Boc-NH-PEG-PLA the respective polymer was 
dissolved in 50% (v/v) TFA in anhydrous DCM. After stirring for 30 minutes at room 
temperature, the solution was diluted with three volumes of anhydrous DCM and 
washed three times with saturated sodium bicarbonate solution and subsequently with 
ultrapure water.  The organic phase was dried over anhydrous sodium sulfate, filtered, 
and concentrated under reduced pressure. For purification, block copolymers were 
precipitated in diethyl ether and dried under vacuum at either 35 °C (PLA-PEG-NH2) 
or 45 °C (PLA-PEG-OMe, PLA-PEG-COOH). 1H-NMR spectroscopy (CDCl3, 300 Hz) 
was used to characterize the PLA-PEG polymers and calculate the molecular weight of 
the respective PLA block. 
 
2.4 Synthesis of Losartan carboxylic acid (Exp3174)  
Exp3174 (losartan carboxyclic acid) was prepared from losartan by oxidation with 
potassium permanganate (KMnO4). Briefly, losartan potassium was dissolved in 0.1 N 
sodium hydroxide (NaOH) solution and cooled down to 0 °C. KMnO4 (2 equiv.) was 
dissolved in ultrapure water, added dropwise to the losartan solution and stirred for 4 
h at room temperature. The reaction was monitored by thin layer chromatography 
(DCM/MeOH/HOAc 90/10/0.5). Losartan carboxylic acid was precipitated by stepwise 
addition of 1 N HCl until the supernatant turned pink. The precipitate, containing 
Exp3174 and manganese dioxide, was thoroughly washed with ultrapure water and 
the product was dissolved by addition of 2 N NaOH. Manganese dioxide was removed 
by centrifugation and subsequent filtration of the supernatant through a 5 µm 
Acrodisc® PES syringe filter (Pall GmbH, Dreieich, Germany). The pH of the filtered 
solution was adjusted to pH 3 using 1 N HCl to precipitate the product. The cloudy 
aqueous suspension was extracted three times with ethyl acetate. After ethyl acetate 
was removed by rotary evaporation, the residue was dissolved in ethanol and the 
solution was filtered through a 1.2 µm Acrodisc® PES syringe filter (Pall GmbH, 
Dreieich, Germany). The purified product was precipitated into 20 volumes of 
ultrapure water and lyophilized for 72 h. 
 
2.5 Synthesis of PLA-PEG-ARB conjugates  
The two AT1 receptor blockers (ARB) Exp3174 and Valsartan were covalently 
conjugated to amine-modified PLA-PEG block copolymers and MeO-PEG5k-NH2 by 
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DCC/NHS chemistry. MeO-PEG5k-NH2 was synthesized from its precursor 
MeO-PEG5k-OH using the Mitsunobu reaction as described previously [242].  First, 
ARBs were dissolved in DMF and the carboxylic group was activated by DCC and NHS 
for 1 hour at room temperature. Resulting urea byproducts were removed by 
centrifugation and subsequent filtration through a 0.45 µm Rotilabo® PTFE syringe 
filter (Carl Roth, Karlsruhe Germany). PLA10k-PEG5k-NH2 and DIPEA were added and 
stirred for 24 h to form a stable amide bond. Ligand-modified conjugates were purified 
by precipitation in diethyl ether/-methanol, and dialysis against 10% (v/v) ethanol in 
10 mM borate buffer (pH 8.5) to remove excess free ligand and reagents, followed by 
dialysis against ultrapure water to remove buffer salts. PLA-PEG-ARB conjugates were 
lyophilized for 72 hours. PEGylated ARBs were further purified and concentrated by 
ultrafiltration using Amicon Ultra-15 filter units (MWCO 3 kDa) and stored as solution 
until used. Ligand conjugation was confirmed using a fluorescamine assay [237].  
The content of PEG was quantified using a colorimetric iodine complexation 
assay [192] (IA) and the conjugation efficiency (CE) for each ARB-conjugate was 
calculated using equation 1. 
 
CE [%]= cPEG 
[µM] - cunreacted amines [µM]
cPEG [µM]
 ·100   (1) 
 
In addition, liquid chromatography mass spectrometry* (LC-MS) was used to confirm 
absence of free ligand in PEGylated ARBs. 
 
2.6 Synthesis of PLA-PEG-cRGD 
Cyclo(RGDfK) was covalently conjugated to carboxy-modified PLA-PEG block 
copolymers via the lysine residue of the cyclic peptide. In brief, PLA-PEG-COOH was 
dissolved in anhydrous DMF and the carboxylic acid function was activated by EDC 
and NHS for 2 hours. Then, BME was added to quench the reaction. DIPEA and 
cRGDfK were subsequently added and stirred for 24 hours to form a stable amide 
bond [60]. Ligand-modified copolymers were purified by several precipitation steps in 
diethyl ether/-methanol mixtures, followed by dialysis against water for 24 hours to 
___________________ 
___________________ 
*LC-MS analyses were performed by the Central Analytical Service (University of Regensburg) 
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remove excess free ligand and reactants. Conjugated cRGDfK was quantified using a 
9,10-phenanthrenequinone assay as described previously [83]. A colorimetric iodine 
complexation assay [192] (IA) was used to quantify the exact amount of PEG. The 
conjugation efficiency (CE) was calculated as the ratio of peptide molecules to PEG 
chains (equation 2). 
 
CE [%]= ccRGDfK 
[µM]
cPEG [µM]
 ·100    (2) 
 
2.7 Preparation of polymeric nanoparticles 
For the manufacture of non-targeted nanoparticles (ntNPs) consisting of 
PLA10k-PEG5k-MeO and fluorescently labeled PLGA, polymers were diluted with 
acetonitrile to a final polymer concentration of 10 mg mL-1. The copolymer mass ratio 
of PLA-PEG to PLGA was 70/30. The polymer mixture was then added dropwise into 
10 volumes of borate buffer (10 mM, pH 8.5) while stirring. NP dispersions were stirred 
for 3 hours to evaporate the organic solvent. The dispersant was changed to DPBS via 
ultracentrifugation at 2500 g for 15 min using Pall Microsep® filters (MWCO 100 kDa). 
To prepare NPs with different ligand densities and varying PEG linker lengths, a 
fraction of PLA-PEG-MeO was substituted with ligand-modified PLA-PEG 
copolymers. The copolymer ratio of PLA-PEG to PLGA was continuously adjusted to 
obtain particles with consistent molarities of PLA-PEG and PLGA, resulting in a 
constant molar ratio of PEG chains per fluorescence tags.  
 
2.8 Nanoparticle quantification by an iodine assay (IA) 
Three batches of non-targeted NPs consisting of PLA10k-PEG5k-MeO and PLGA were 
prepared in ultrapure water, purified and concentrated as described above. A 
colorimetric iodine complexation assay was used to quantify the amount of PEG [192]. 
The exact polymer concentration was determined gravimetrically after lyophilization 
(n=3) of the concentrated NP samples and plotted against the PEG content determined 
by the iodine assay. Since the PEG content was considered to be constant, from this 
point on, the PEG content of freshly prepared samples was determined against the 
mPEG5k standard and used to calculate the polymer concentration of non-targeted 
NPs. For different formulations with varying ligand densities and PEG linker lengths, 
the PEG content was analyzed and diluted to attain equal molarities of PEG. 
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2.9 Flow cytometry analysis 
Receptor binding of fluorescently labeled nanoparticles (PLGA-Alexa647, 
PLGA-CF647 or PLGA-FAM) was evaluated by flow cytometry. U87MG (αvβ3+), 
NCI-H295R (AT1+) or rat mesangial cells (rMC; αvβ3+ and AT1+) were seeded into 
24-well plates (Corning, Corning, NY, USA) at a density of 120,000, 150,000 or 60,000 
cells per well, respectively. For all experiments conducted with U87MG cells, wells 
were collagen-coated since binding of cRGDfK significantly impairs attachment of 
U87MG cells to uncoated wells [243]. Flow cytometry experiments were performed 
when 80 - 90% cell confluency was reached. Fluorescently labeled sample solutions 
were prepared in RGD binding buffer (20 mM TRIS, 150 mM NaCl, 2 mM CaCl2, 1 mM 
MgCl2, 1 mM MnCl2, 0.1% BSA) supplemented with 10% FCS and incubated for 15 min 
at 37 °C to induce the formation of a protein corona. Cells were washed with DPBS and 
subsequently treated with NP dilutions for 45 min at 37 °C. After incubation, cells were 
washed with DPBS, trypsinized and centrifuged at 200 g for 5 min and washed once 
again with DPBS. Cells were suspended in 200 µL DPBS and cellular fluorescence was 
analyzed with a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, 
USA). FAM and Alexa647/CF647 fluorescence was excited at 488 nm and 633 nm, 
respectively. Emission was measured using a 530/30 BP filter for PLGA-FAM and a 
661/16 nm BP filter for PLGA-Alexa647/CF647. To evaluate the fluorescence intensity 
distribution 10,000 events were gated and results were corrected for the negative 
control (untreated cells) unless otherwise stated. Data were evaluated using the 
Flowing Software v2.5 (Turku, Finland). 
 
2.10 Confocal Laser Scanning Microscopy (CLSM) 
To analyze the NP binding pattern on the cells confocal microscopy was conducted. 
U87MG (αvβ3+), NCI-H295R (AT1+) or rat mesangial cells (αvβ3+ and AT1+) were seeded 
into 8-well µ-slides (Ibidi, Martinsried, Germany) at a density of 15,000 (U87MG; 
collagen-coated wells) or 8000 (rMC and NCI-H295R) cells per well, respectively. After 
cells had adhered to the cell culture plastic, NP binding was assessed. Fluorescently 
labeled sample solutions were prepared in TRIS binding buffer (20 mM TRIS, 150 mM 
NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1% BSA) supplemented with 10% FCS 
and incubated for 15 min at 37 °C to induce the formation of a protein corona. Cells 
were washed with DPBS and treated with pre-warmed NP test solutions for 45 min at 
37 °C. After the incubation period, cells were vigorously washed with DPBS and cells 
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were analyzed in Leibovitz’s medium. Confocal fluorescence analysis of cells was 
conducted on a Zeiss Axiovert 200 microscope combined with an LSM 510 laser-
scanning device at 63-fold magnification. NP fluorescence was excited with an argon 
laser at 488 or 633 nm and the emission was recorded using a 530/30 nm bandpass (BP) 
or a 650 nm longpass filter for NPs labeled with PLGA-FAM or 
PLGA-Alexa647/-CF647, respectively. 
 
2.11 Binding of ARB-decorated nanoparticles to AT1R 
Binding to the AT1R expressed on NCI-H295R was assessed by flow cytometry and 
CLSM as described above. ARB-decorated NPs were manufactured by 
nanoprecipitation, using fluorescently labeled PLGA (FAM or Alexa647) and either 
PLA10k-PEG5k-Valsartan (NP-Val) or PLA10k-PEG5k-Exp3174 (NP-Exp). Non-targeted 
NPs served as control. NP concentration was 400 µg mL-1 (FAM-labeled) for CLSM 
experiments and 300 µg mL-1 (Alexa647-labeled) for flow cytometry analysis. To 
suppress specific NP-receptor interactions, cells were simultaneously incubated with 
NPs and an excess of the free ligand (500 µM). 
The antagonistic affinity of native and conjugated ARB ligands towards the AT1R was 
measured using the fluorescent fura-2 Ca2+ chelator method as recently described [54]. 
Briefly, suspensions of rat mesangial cells were incubated with 5 µM fura-2AM and 
0.05% Pluronics F-127 in Leibovitz’s L-15 medium for 1 hour at room temperature 
under light exclusion. After loading, cells were repeatedly washed by centrifugation 
(3x, 5 min, 200 g, RT) to remove excess fura-2AM and suspended in Leibovitz’s 
medium. Dilutions of native ARB ligands (Exp3174, Valsartan) or ligands conjugated 
to mPEG5k (mPEG-Val, mPEG-Exp), as well as dilutions of ligand-decorated NPs 
(NP-Val, NP-Exp) were pipetted into half-area 96-well plates (Corning, Corning, NY, 
USA) at 10 µL per sample and 45 µL of cell suspension (2x106 cells mL-1) were 
subsequently injected into each well. After 30 minutes of incubation, 45 µL of the EC80 
of the agonist angiotensin II (Bachem, Bubendorf, Switzerland) was injected into each 
well and the fluorescence signal was instantly recorded using a FluoStar Omega 
fluorescence microplate reader (BMG Labtech, Ortenberg, Germany) for 30 s. The EC80 
(concentration that leads to 80% of the maximum response) of angiotensin II was 
determined from sigmoidal fit of the agonist dose-response curve in rat mesangial cells 
using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). For time 
resolved ratiometric measurements 340/20 nm and 380/20 nm excitation filters were 
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used and fluorescence emission recorded using a 510/20 bandpass filter. Loaded cells 
incubated with 0.1% Triton X-100 and 0.1% Triton X-100 supplemented with 45 mM 
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) were used 
to determine the maximum (Rmax) and minimum (Rmax) ratio, respectively. Intracellular 
calcium concentrations were calculated based on the Grynkiewicz equation [244]. IC50 
values (concentration that leads to 50% inihibition) were determined with sigmoidal 
fitting (variable slope) of dose-response curves using GraphPad Prism 6.0 (GraphPad 
Software Inc., La Jolla, CA, USA). 
 
2.12 Binding of cRGD-decorated nanoparticles to αvβ3 receptors 
Binding of the secondary ligand (cRGD) to αvβ3 receptors as a function of ligand 
density was assessed by flow cytometry using U87MG cells. NPs with different ligand 
densities were prepared by varying the molar ratio of PLA10k-PEG5k-MeO to 
PLA10k-PEG5k-cRGD from 0/100 to 100/0, whereas the amount of PLGA-FAM was kept 
constant. U87MG cells were treated with NPs (200 µg mL-1) for 45 min. An excess of 
cRGDfK (200 µM) was used to suppress binding to the αvβ3 receptor. To analyze the 
binding pattern of NP-cRGD on U87MG cells confocal microscopy was conducted.  
 
2.13 Shielding of cRGD by tethering to shorter PEG chains 
To initially shield the secondary ligand, NPs were prepared with 50/50 molar ratios of 
PLA10k-PEGx-cRGD (x = 2k, 3.5k or 5k) and PLA10k-PEG5k-MeO. The copolymer ratio of 
PLA-PEG to PLGA was continuously adjusted to obtain particles with consitent 
molarities of PLA-PEG to PLGA, resulting in a constant molar ratio of PEG chains per 
fluorescence tags. NPs that were completely surface functionalized with cRGD 
conjugated to short PEG2k, medium PEG3.5k or long PEG5k-linkers served as 
reference and ntNP were used as control. Cellular-associated fluorescence of U87MG 
cells treated with CF647-labeled NPs (200 µg mL-1, or equivalents) for 45 min was 
quantified by flow cytometry.
 
2.14 Binding and uptake of heteromultiligand binding nanoparticles 
Dual-targeted NPs decorated with both ligands (NP-Exp/cRGD3.5k) were prepared 
using a 50/50 molar ratio of PLA10k-PEG3.5k-cRGD to PLA10k-PEG5k-Exp and a constant 
amount of PLGA-CF647. NPs comprising PLA10k-PEG5k-MeO and either 
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PLA10k-PEG3.5k-cRGD (NP-cRGD3.5k/MeO) or PLA10k-PEG5k-Exp3174 (NP-Exp/MeO) 
blended at a mass ratio of 50/50, as well as ntNPs served as reference. Rat mesangial 
cells were seeded at a density of 40,000 cells per well and cultured for 48 h. Cells were 
incubated with 300 µg mL-1 of CF647-labeled ntNPs (or NP equivalents) and receptor 
binding was investigated by flow cytometry and CLSM. 
 
2.15 Statistical analysis 
All results are presented as mean ± standard deviation, based on the data obtained 
from at least n = 3 samples. Statistical significance was determined by means of 
one-way ANOVA, followed by Tukey’s post-hoc test using GraphPad Prism 6.0 
(GraphPad Software Inc., La Jolla, CA, USA). Statistical significances were set as 
indicated.  
 
3 Results and discussion 
3.1 Dual-targeted nanoparticles  
For specific targeting of the AT1R, designated as the primary target, PLA-PEG 
copolymers were modified with Exp3174 and Valsartan moieties. Both ligands belong 
to the group of angiotensin receptor blockers (ARBs) and are widely applied to treat 
diabetic nephropathy as they can lower the intraglomerular pressure and therefore, 
slow down disease progression [245]. The cyclic pentapeptide cRGDfK was used to 
target the vitronectin receptor that was intended as secondary target in this study. The 
αvβ3 integrin receptor can be found on epithelial and endothelial cells at low expression 
levels, whereas high receptor densities are linked to the development and progression 
of several diseases, such as cancer [246,247] or diabetic kidney disease [158,248].  
As the targeting strategy aims at a time-shifted sequential binding of the primary (AT1) 
and the secondary (αvβ3 integrin) receptor, ligand presentation had to be optimized. 
Therefore, cRGD was conjugated to PLA-PEG block copolymers with different PEG 
linker lengths (Figure 2). Pre-modification of block polymers allows for precisely 
tuning NP composition, which was considered as a prerequisite for the preparation of 
heteromultiligand NPs. Successful conjugation of PLA-PEG-cRGD copolymers was 
confirmed using a 9,10-Phenanthrenequinone assay, whereas conjugation efficiency of 
PLA-PEG-Exp3174 and PLA-PEG-Valsartan was determined using a fluorescamin 
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assay. The conjugation efficiency was in the range of 97.9% to 99.7% for cRGD-modified 
block copolymers and between 98.4% and 99.0% for ARB-tethered PLA-PEG 
copolymer, respectively (Table 1). 
 
 
 
Figure 2. (A) Ligand moieties used in this study. (B) Angiotensin II receptor blockers (ARBs) Exp3174 and 
Valsartan were conjugated to amine-terminated PLA-PEG-NH2 via the carboxylic acid function. 
(C) c(RGDfK) was tethered to carboxy-terminated PLA-PEG-COOH via the lysine residue. 
 
 
 
Table 1. Conjugation efficiency of ligand-modified PLA-PEG copolymers. 
PLA-PEG Copolymer CE (%) [1] PLA-PEG Copolymer CE (%) [2] 
PLA10k-PEG2k-cRGD 99.7 ± 3.9 PLA10k-PEG5k-Valsartan 98.4 ± 0.1 
PLA10k-PEG3.5k-cRGD 98.8 ± 6.9 PLA10k-PEG5k-Exp3174 99.0 ± < 0.1 
PLA10k-PEG5k-cRGD 97.9 ± 3.9   
 
(1) As determined by PCA.  
(2) As determined by Fluram Assay.  
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3.2 Targeting the AT1R with ARB-decorated nanoparticles  
A major prerequisite for the primary ligand is its ability to specifically bind to the AT1R 
without initiating endocytosis of the nanocarrier. To evaluate the potential of Exp3174 
and Valsartan as primary ligand, ARB-decorated NPs were prepared by 
nanoprecipitation and receptor binding was assessed by flow cytometry using 
NCI-H295R cells, an adrenal gland carcinoma cell line with high expression levels of 
the AT1R [233]. Non-targeted NPs (ntNPs) served as control to evaluate nonspecific 
binding to the cells, whereas unmodified free ligand was added used to suppress 
specific NP-cell interactions. As shown in Figure 3A, cell-associated fluorescence was 
1.59-fold and 2.35-fold increased, when NCI-H295R cells were incubated with 
Valsartan- and Exp3174-decorated NPs, respectively, compared to cells treated with 
ntNPs. In contrast, fluorescence of cells that were simultaneous incubated with 
ARB-modified NPs and excess free ligand was significantly decreased (p < 0.001) to a 
level comparable to the ntNP control, confirming that the interaction between targeted 
NPs and NCI-H295R cells was receptor-mediated. Confocal microscopy was used to 
evaluate the NP distribution pattern on NCI-H295R cells after incubation with NP 
samples. As shown in Figure 3B, both ARB-decorated NP formulations displayed 
strong binding to the cell membrane, whereas cellular association of non-targeted NPs 
was only marginal. 
 
 
 
Figure 3. (A) Binding of Valsartan- and Exp3174-decorated NPs to AT1R expressing NCI-H295R cells was 
quantified by flow cytometry. Levels of significance are indicated as: (***) p < 0.001 (B) The cellular 
distribution pattern of NCI-H295R cells incubated with ARB-decorated NPs was analyzed by CLSM. 
ARB-decorated NPs accumulated on the cell surface and were not internalized via endocytosis. Specific 
AT1R binding could be suppressed by addition of excess free ligand (scale bar: 10 µm). 
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Neither NP-Val nor NP-Exp were internalized by the cells, which is in good agreement 
with previous studies demonstrating that binding of AT1R antagonists to the receptor 
do not trigger receptor-mediated endocytosis [249,250]. Targeted NPs were 
homogenously distributed on the cell surface, however, the NP binding pattern was 
characterized by multiple bright fluorescent spots indicating distinct membrane areas 
with local AT1R accumulation that allow for multivalent binding of ARB-decorated 
NPs. 
Since Exp3174 and Valsartan are not immediately internalized by the cells, they stayed 
adhered to the cell membrane where they could bind to neighboring receptors. 
Although native Valsartan and Exp3174 have comparable receptor affinities, 
Exp3174-decorated NPs displayed stronger binding to the AT1R expressing cells 
compared to NP-Val which might result from their different binding kinetics. Valsartan 
is a competitive antagonist, whereas Exp3174 is an insurmountable (noncompetitive) 
antagonist [251]. Insurmountable ARBs dissociate slowly from the receptor and have 
been reported not to dissociate under physiological conditions until the AT1R is 
recycled. Due to the slow dissociation rate, antagonistic effects of insurmountable 
ligands cannot be overcome by high concentrations of angiotensin II [252]. 
Furthermore, slow dissociation favors multivalent binding of several receptors, 
because NPs stay in close proximity to the cell membrane over a prolonged period of 
time.  
Hennig and colleagues [54] have previously demonstrated that PEGylation of AT1R 
antagonists leads to severe affinity loss that can be significantly counterbalanced by the 
multivalent binding of Exp3174-decorated Qdots. For that reason, ARB-decorated NPs 
were evaluated for their binding affinities and compared to native and PEGylated 
counterparts using a calcium immobilization assay. Activation of AT1R can be 
monitored by measuring the increase in cytosolic calcium using the fluorescent calcium 
chelator dye fura-2, whereas the angiotensin II induced receptor response is decreased 
after antagonist binding. Dose-response curves of native ARBs and their respective 
conjugates are depicted in Figure 4.  
Native Valsartan and Exp3174 both blocked angiotensin II signaling of the AT1R with 
low nanomolar affinity and IC50 values of 2.4 ± 0.3 nM (Valsartan) and 0.7 ± 0.1 nM 
(Exp3174), which is in agreement with literature [233,253]. 
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Figure 4. Affinity of (A) Valsartan and (B) Exp3174 towards AT1R expressed on rat mesangial cells was 
assessed using an intracellular calcium immobilization assay. The native ligands antagonized the AT1R 
with nanomolar affinity, whereas the receptor affinity was substantially decreased upon PEGylation and 
immobilization on polymeric NPs. When considering the whole NP as a targeting construct, the calculated 
affinity regained a nanomolar IC50 due to the high avidity of multivalent NPs. 
 
 
To investigate the affinity of ARBs after PEGylation, Valsartan and Exp3174 were 
tethered to MeO-PEG5k-NH2 with an equivalent molecular weight compared to the 
PEG5k linker used for ligand presentation on PLGA/PLA-PEG NPs. Compared to their 
native counterparts, the affinity of PEGylated Valsartan and Exp3174 was vastly 
decreased to 229.8 ± 38.9 nM and 66.3 ± 8.4 nM, respectively (Table 2). Binding of ARBs 
to the AT1R involves key acid-base interactions between acidic moieties of the ARB 
molecule and basic amino acid residues on the cognate receptor. Mire and colleagues 
have reported, that the carboxylic acidic group at the 5-position of the imidazole ring 
provides a crucial hydrogen-bonding point of attachment to the AT1R [254], which 
might be a contributing factor for the loss in affinity. However, Santella and colleagues 
have demonstrated that substitution of the carboxylic acid functional group at the 
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imidazole 5-position with amides and esters only marginally decreases affinity 
towards the AT1R but might have an impact on AT1/AT2 receptor selectivity [255]. 
Therefore, key factors for the substantial decrease in AT1R affinity are the increased 
size and the steric hindrance of ARB-PEG conjugates. On the one hand, the binding site 
for small ARBs is located deep in the seven transmembrane regions of the 
AT1R [237,256], it is hardly accessible for larger molecules. On the other hand, 
PEGylation attenuates intermolecular interactions between the ligand and the amino 
acid residues of the receptor, such as hydrogen bonding, hydrophobic and electrostatic 
interactions and π-π stacking, due to wrapping around the ARBs.  
 
 
Table 2. Binding affinities of ARBs and ARB-conjugates towards AT1R expressed on rMC. 
 
Conjugate # ARB ligands (1) Ligand affinity/(nM) Conjugate affinity (2)/(nM) 
Valsartan 1 2.4 ± 0.3 n.a. 
mPEG-Val 1 229.8 ± 38.9 229.8 ± 38.9 
NP-Val 2071 ± 23 3022.1 ± 140.4 1.5 ± 0.1 
Exp3174 1 0.7 ± 0.1 n.a. 
mPEG-Exp 1 66.3 ± 8.4 66.3 ± 8.4 
NP-Exp 919 ± 40 1515.9 ± 549.6 1.5 ± 0.8 
 
(1)  Conjugation of PEG-ARB was confirmed by MS.  
(2) Calculated based on the z-average size as determined by DLS and using a density of 
1.2 g cm-3. (NP-Val: 47.9 ± 0.2 nm; NP-Exp3174: 36.5 ± 0.5 nm) 
 
 
Compared to native ARBs, the calculated affinity of a single NP-bound PEG-Valsartan 
and PEG-Exp3174 was 1259- and 1516-fold increased to 3022.1 ± 140.4 nM and 
1515.9 ± 549.6 nM, respectively. This additional loss in affinity can be attributed to the 
fact that the interface between the flat cell membrane and the NP, which has a 
considerable surface curvature, is rather small compared to the surface area of the 
respective NP. As a consequence, only a small fraction of ligands can spatially interact 
with their cognate receptors, whereas the remaining ligands cannot reach the target 
receptors located on the cell membrane due to the spherical NP geometry. However, 
these ligands contribute to the overall ligand density on the NP surface and thus also 
dictate the number of ligands that are present on the NP-cell interface. The IC50 
calculated for ARB-modified NPs was drastically decreased to 1.5 ± 0.1 nM (NP-Val) 
and 1.5 ± 0.8 nM (NP-Exp) compared to their monovalent PEGylated counterparts due 
Results and discussion  
107 
to the higher avidity of targeted NPs which enables simultaneous binding of multiple 
receptors on the target cell.  
These results clearly demonstrate that both ARB ligands meet the requirements as 
primary ligand: a specific but moderate affinity towards the primary receptor and no 
induction of endocytosis upon receptor binding. However, Exp3174 was chosen for 
further experiments due to its slower binding kinetics that was considered highly 
beneficial for the sequential targeting approach. 
 
3.3 Binding of cRGD-decorated nanoparticles to the αvβ3 receptor  
NPs with different degrees of cRGD-modification (0 - 100%) were prepared and the 
influence of ligand density on binding to U87MG cells was investigated by flow 
cytometry. As shown in Figure 5A, a higher quantity of ligands on the particle surface 
led to an almost linear increase in cell-associated fluorescence, indicating an enhanced 
cellular association, while non-modified NPs displayed no receptor interaction at all 
(compared to the control cells).  
 
 
 
Figure 5: (A) Integrin binding of cRGD-decorated NPs as a function of ligand density quantified by flow 
cytometry. Specific integrin receptor binding could be suppressed with a surplus of free cyclo(RGD) 
peptide. Levels of significance are indicated as: (***) p < 0.001 compared to non-targeted NPs. 
(B) Endocytosis of NP-cRGD after binding to the αvβ3 receptor was confirmed by CLSM (scale bar: 10 µm). 
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Binding of NPs with the highest degree of modification (100%) were completely 
suppressed when an excess of cRGDfK was added, which served as an evidence that 
binding of ligand-decorated NPs was receptor-mediated. 
These data demonstrate, that even a low cRGD ligand density (e.g. of 20%) was 
sufficient to target the αvβ3 receptor. As confirmed by confocal microscopy, binding of 
cRGD-decorated NPs to the αvβ3 integrin receptor resulted in fast endocytosis of the 
nanocarrier (Figure 5B) and accumulation in vesicles within the cytosol. Simultaneous 
incubation of cells with NP samples and free ligand could efficiently inhibit specific 
NP uptake. 
To avoid binding of the secondary ligand to off-target cells expressing high levels of 
αvβ3 integrin receptor, cRGD was conjugated to block copolymers with different PEG 
lengths and was additionally blended with equimolar amounts of methoxy-modified 
PLA10k-PEG5k-MeO. U87MG cells were chosen for this experiment, since they are 
known for their exceptionally high αvβ3 integrin expression [23] and thus, shielding has 
to be highly efficient to successfully avoid receptor binding and uptake by these 
off-target cells. As shown in Figure 6, receptor binding was effectively suppressed 
when the secondary ligand was tethered to short PEG2k or medium PEG3.5k linker, 
whereas the shielding was not efficient if cRGD was conjugated to long PEG5k.  
 
 
 
Figure 6: Shielding of the secondary ligand (cRGD) tethered to either 2k, 3.5k or 5k PEG was investigated 
by flow cytometry. NPs were either prepared from cRGD-modified PLA-PEG copolymers or blends of 
PLA-PEG-cRGD (2k, 3.5k or 5k PEG) and PLA-PEG5k-MeO. Levels of significance are indicated as: 
(*) p < 0.05, (***) p < 0.001. 
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Moreover, uptake of NP-cRGD without additional MeO-PEG-blends significantly 
increased by using shorter PEG chains. On the one hand combination of high cRGD 
densities and short PEG linkers result in an increasing tendency of targeted NPs to 
form agglomerates which enhances NP-receptor interactions via cooperative binding 
of NP clusters [226]. On the other hand, the molecular weight of PEG plays a pivotal 
role in the formation of a protein corona [214]. In the case of shorter PEG linker, the 
stealth effect in serum containing media is less pronounced and thus, interactions 
between ligands and receptors are enhanced. 
In summary, polymeric NPs prepared with blends of PLA10k-PEG5k-MeO and 
PLA10k-PEG3.5k-cRGD were found as a good compromise between a sufficient stealth 
effect upon administration into the blood stream and an efficient shielding of the 
secondary ligand and were used for the final design of heteromultiligand-decorated 
NPs. 
 
3.4 Synergistic targeting of mesangial cells with dual-targeted NPs 
In a final experiment, dual-targeted heteromultivalent NPs (NP-Exp/cRGD3.5k), 
comprising PLA10k-PEG5k-Exp, PLA10k-PEG3.5k-cRGD and fluorescently labeled PLGA 
were evaluated for their targeting efficiency towards rat mesangial cells in comparison 
to the two respective single-targeted NPs, modified with either the primary or the 
secondary ligand (NP-Exp/MeO and NP-cRGD3.5k/MeO). Non-modified NPs (ntNPs) 
were used to determine the unspecific binding of polymeric NPs to target cells. 
Receptor binding and cellular uptake into mesangial cells were evaluated by flow 
cytometry and confocal microscopy, respectively. As shown in Figure 7, ntNPs 
displayed only minor association with rat mesangial cells which was attributed to 
unspecific binding to the cell membrane.  
Receptor binding of NP-Exp/MeO (347.7 ± 3.2 a.u.), was 3.7-fold increased compared 
to the control particles (93.8 ± 1.6 a.u.), but NPs were exclusively located on the cell 
surface not internalized by the cells as confirmed by confocal microscopy. The 
shielding effect of NP-cRGD3.5k/MeO towards αvβ3 integrin receptors was efficient and 
only a small fraction of the NP dose was internalized by mesangial cells. The 
fluorescence level of cells treated with a 50/50 mixture of single-targeted NP-Exp/MeO 
and shielded NP-cRGD3.5k/MeO (227.7 ± 10.0 a.u.) was slightly higher than of 
NP-cRGD3.5k/MeO (160.9 ± 11.3 a.u.). In contrast, NPs decorated with both, Exp3174 as 
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a primary ligand (PEG5k) and cRGD as a secondary ligand (PEG3.5k), displayed an 
enhanced cellular binding (546.3 ± 25.1 a.u.) compared to particles prepared with only 
a single type of ligand (NP-Exp/MeO, NP-cRGD3.5k/MeO). 
 
 
 
Figure 7. (A) Flow cytometry data for rat mesangial cells incubated with non-targeted NPs, single-targeted 
NPs, mixtures of both single-targeted NPs, or heteromultiligand binding NPs decorated with Exp3174 and 
cRGD. Non-targeted NPs and shielded cRGD-decorated NPs displayed only minor association to rat 
mesangial cells, whereas cellular associated fluorescence was 3.7- and 5.8-fold increased when cells were 
incubated with Exp3174-decorated and dual-targeted NPs, respectively. Levels of significance are 
indicated as: (***) p < 0.001 compared to non-targeted NPs. (B) Confocal microscopy confirmed, that 
cRGD-moieties were prerequisites for NP internalization. Exp3174-decorated NPs adhered to the cell 
surface, but were not internalized. To allow for comparison of all samples, the image contrast was adjusted 
and fluorescence (CF647) was displayed in false color (green) for better visibility. Scale bars indicate 
20 µm. 
Results and discussion  
111 
The specific binding of dual-targeted NPs (ΔF = 452.5 a.u.) as determined by 
subtracting the fluorescence levels determined for ntNPs was even 1.4-fold higher as 
the sum of NP-Exp/MeO and NP-cRGD3.5k/MeO (ΔF = 321.0 a.u.) and also enhanced by 
a factor of 1.7 compared to twice the value of the 50/50 mixture of NP-Exp/MeO and 
NP-cRGD3.5k/MeO (ΔF = 267.8 a.u.) corresponding to equal amounts of primary and 
secondary ligands. In addition, NP-Exp/cRGD3.5k did not only display synergistic 
binding to mesangial cells but were also endocytosed, indicating that the secondary 
ligand was able to bind to the integrin receptor after the particle was in close proximity 
to the cell surface.  
A summarized overview of the interaction of single- or dual-targeted NPs with 
mesangial cells is depicted in Figure 8. NPs solely decorated with the primary ligand 
(Exp3174) could bind to AT1R on mesangial cells but were not internalized by 
endocytosis. NPs carrying only the secondary ligand (cRGD) tethered to shorter 
PEG3.5 linkers displayed poor receptor binding due to cloaking. In contrast, 
dual-targeted polymeric NPs featured with both receptor ligands were able to target 
the AT1 and avβ3 receptor in a time-shifted manner and were subsequently internalized 
by mesangial cells. 
 
 
 
Figure 8. Summary of NP-cell interactions using single-targeted and heteromultivalent NPs. 
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As the αvβ3 integrin is an ubiquitous receptor, expressed inter alia in endothelial and 
vascular smooth muscle cells [257], the delayed visibility of the secondary receptor 
ligand is mandatory to avoid an interaction and uptake by off-target cells exclusively 
expressing the secondary receptor. These findings clearly demonstrate that, compared 
to other heteromultivalent binding NPs developed in recent years [258], these 
polymeric NPs acted in a virus-like fashion with sequential binding to the primary 
(AT1) and the secondary (αvβ3) receptor, which not only drastically enhanced specificity 
towards the target cell but also led to synergistic targeting efficiency compared to 
single-targeted NPs bearing only one of the two receptor ligands. 
 
4 Conclusion 
Dual-targeted polymeric NPs were able to target two different types of receptors (AT1 
and avβ3 integrin) in a time-shifted manner. The primary ligand Exp3174, which was 
conjugated to longer PEG linkers (5 kDa), displayed specific and moderate affinity 
towards the AT1R, but did not trigger internalization of the nanocarrier. The secondary 
ligand (cRGD), attached to shorter PEG linkers (3.5 kDa) with the intention to make the 
NP “visible” for the cell after a time delay efficiently bound to the avβ3 integrin receptor 
and triggered endocytosis into the target cells. In vitro experiments confirmed, that this 
strategy not only improved targeting efficiency, but also specificity towards rat 
mesangial cells since NP bearing only the primary ligand were not endocytosed, 
whereas NPs bearing only the secondary ligand (cRGD) tethered to shorter PEG linkers 
displayed poor receptor binding due to cloaking.  
In summary, heteromultiligand binding NPs can consecutively bind two types of 
receptor in a virus-like fashion and thus, possess high potential as advanced drug 
delivery systems.  
 
 113 
 
 
 
 
 
  Chapter 7 
 
 
Gold-tagged polymeric nanoparticles with 
spatially-controlled composition for 
enhanced detectability in biological 
environments 
 
Chapter 7: Hybrid nanoparticles with enhanced detectability 
114 
Abstract 
Nanoparticles made of organic materials offer the advantage of high biocompatibility 
for biomedical applications but suffer frequently from poor visibility in biological 
environments. Reliable and simultaneous qualitative and quantitative detectability in 
cells and tissues is a largely unmet need. While fluorescent labeling is convenient and 
allows for fast and extensive histological analysis, fluorescence imaging and 
quantitative analysis are limited by low resolution and significantly hindered by tissue 
auto-fluorescence. To overcome this restraint, 2.2 nm gold nanoparticles were 
introduced as a contrast agent at the interface between the hydrophobic 
fluorophore-loaded core and the hydrophilic shell of polymeric nanoparticles. Due to 
the spatially controlled stratified composition of polymer/gold hybrid nanoparticles, 
fluorescence quenching by gold was minimized to 15.1%, allowing for concomitant 
detection of both labels via confocal scanning fluorescence microscopy. Multilayered 
hybrid nanoparticles exhibited outstanding detectability in transmission electron 
microscopy without additional sample staining. Furthermore, they were capable of 
producing remarkable image contrast inside cells after gold or silver enhancement. The 
interfacial gold layer increased the hydrodynamic particle size only marginally from 
71.8 to 89.5 nm and had no negative impact on biocompatibility in vitro. The gold 
content (0.75% m/m) is sufficiently high for future quantification in tissues after 
systemic administration. With their superior detectability and their unique properties, 
multilayered hybrid nanoparticles constitute an outstanding blue print and tool for the 
development of nanomedicines 
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1    Introduction 
The detection of nanomaterials in biomedical applications is highly challenging. The 
use of organic materials for better biocompatibility results in poor detectability in cells 
and tissues. In histological sections polymeric colloids can per se not be localized with 
high resolution by transmission electron microscopy (TEM) or quantified in tissue after 
administration in vivo [259]. Because profound knowledge of pharmacokinetics and 
biodistribution [260] are key to the successful development of nanomedicines, 
additional labels are required to evaluate their in vivo performance and track their 
journey from the point of administration to the target site. Radioactive tags [261,262], 
organic fluorescent dyes [263,264] and inorganic “contrast” agents, such as 
nanocrystals [265,266] have frequently been used to facilitate the detection of organic 
nanoparticles (NPs). However, these labels suffer from significant limitations and 
drawbacks: Preparation, handling, and disposal of radioactive materials is expensive 
and requires strict safety precautions [267]. The incorporation of organic labels often 
results in significantly reduced drug loading capacity and unpredictable alteration of 
physicochemical properties [268]. Organic fluorescent tags are often quenched, 
degraded in a biological environment [269], or compromised in their detectability by 
the high auto-fluorescence of natural and fixed tissues [267].  
Gold nanoparticles (AuNPs) constitute an ideal contrast agent because AuNPs possess 
excellent electron scattering properties [270] and are detectable via TEM, the method of 
choice to reveal a NP’s whereabout in histological sections of cells and tissues [271]. In 
contrast to previous approaches [272], the use of small 2.2 nm gold tags would allow 
for labeling of polymeric NP without changing its structure or compromising the tag’s 
renal elimination after biodegradation of the labeled nanomaterial in vivo [21]. In 
histological samples, the size of gold tags could even be enlarged via silver or gold 
enhancement to increase visibility and permit detectability of hybrid NPs via optical 
microscopy [273,274]. Furthermore, AuNPs can be quantified by inductively coupled 
plasma optical emission spectroscopy (ICP-OES), which would allow for a quantitative 
evaluation of the labeled NP’s biodistribution [275]. However, random gold-tagging of 
fluorescently labeled nanomaterials can impede the concomitant detection of both 
labels because AuNPs are known to efficiently quench the emission of proximate 
fluorescent dyes, making the combination of a fluorescent label and a gold marker 
highly challenging [276]. In addition, most procedures to manufacture hybrid NPs lack 
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the ability to control the NP composition precisely, such as gold content or surface 
ligand density, which constitute a major drawback of such hybrid materials.  
To overcome these limitations, AuNPs were introduced at the interface between the 
lipophilic core and the hydrophilic shell of core/shell-type particles by covalently 
attaching them to a degradable lipophilic nanoparticle component. To this end, 
hydrophilic monoamine-functionalized small gold nanoparticles (AuNP-NH2) were 
covalently conjugated to the carboxy-end of hydrophobic poly(lactic-co-glycolic acid) 
(PLGA) polymers. The gold-grafted polymers were then blended with amphiphilic 
poly(lactic acid)-poly(ethylene glycol) block copolymers (PLA-PEG), which are known 
for their ability to self-assemble into core/shell structured NPs and which served as a 
model for this study. Due to their hydrophilic nature, gold tags were expected to be 
located at the core/shell interface where they would be sufficiently distant from a 
fluorescent label in the core to minimize quenching effects. 
In the first part of this studies, hybrid NPs were evaluated for their physicochemical 
properties and their cytotoxicity compared to nanoparticles consisting of unlabeled 
PLGA and PLA-PEG. In the second part, the dual detectability of particles labeled with 
gold and fluorescent tags in cells via TEM and confocal laser scanning microscopy was 
investigated. To enhance cellular uptake by αvβ3 integrin positive rat mesangial cells, 
hybrid NPs were additionally surface-decorated with cRGD ligands.  
  
2 Materials and methods 
2.1 Materials 
1,4-Diazabicyclo[2.2.2]octane hydrochloride (DABCO), 1,8-Diazabicyclo[5.4.0]undec-
7-ene (DBU) solution, anhydrous dichloromethane (DCM), 4-(4,6-Dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), 3,6-Dimethyl-1,4-dioxane-
2,5-dione (Lactide), anhydrous dimethyl sulfoxide (DMSO), fluoresceinamine isomer I 
(FAM), 2-Mercaptoethanol (BME), methoxy poly(ethylene glycol) with a molecular 
mass of 5000 g mol-1 (MeO-PEG5k-OH), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC), N-hydroxy-succinimide (NHS), N,N-Diisopropyl-
ethylamine (DIPEA), Resomer® RG 502 (PLGA) and the Silver Enhancer Kit (SE-100) 
were received from Sigma-Aldrich (Taufkirchen, Germany). Cyclic RGDfK (cRGD) 
was purchased from SynPeptide Co. Ltd (Shanghai, China). Hydroxyl polyethylene 
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glycol carboxylic acid with a molecular mass of 5000 g mol-1 (COOH-PEG5k-OH) was 
provided by JenKem Technology USA Inc. (Allen, TX, USA). GoldEnhance™ EM Plus 
was obtained from Nanoprobes Inc. (Yaphank, NY, USA). Monoamino gold 
nanoparticles (AuNP-NH2) with an average size of 2.2 nm were purchased 
from Nanopartz (Loveland, CO, USA). All other materials were reagent grade and 
obtained from Merck KGaA (Darmstadt, Germany). Ultrapure water was freshly 
prepared using a Milli-Q water purification system (Millipore, Schwalbach, Germany). 
 
2.2 Synthesis of gold-conjugated PLGA (PLGA-Au) 
AuNP-NH2 were lyophilized from an aqueous 3% (w/v) sucrose solution and 
reconstituted in anhydrous DMSO. PLGA was dissolved in anhydrous DCM and the 
terminal carboxylic acid group was converted to an NHS ester intermediate using 
50 equivalents (equiv.) of EDC and 50 equiv. of NHS [60]. After two hours of stirring 
at ambient temperature, DCM was removed under reduced pressure, and the activated 
PLGA intermediate was dissolved in DMSO. DIPEA (10 equiv.) and the AuNP-NH2 
(0.015 equiv.) were added subsequently, and the polymer solution was stirred for 
24 hours. PLGA-Au was precipitated into water, isolated by centrifugation, and 
lyophilized to yield a dark brown solid. 
 
2.3 Fluorescent labeling of PLGA (PLGA-FAM) 
PLGA was dissolved in anhydrous DMF and the carboxylic acid group was activated 
by addition of DMTMM (25 equiv.) for two hours. Afterwards, three-fold excess of 
FAM was added and stirred overnight to yield PLGA-FAM. Fluorescently labeled 
PLGA was purified by multiple precipitation steps in methanol (2x) and water (1x), 
followed by dialysis against water and subsequent lyophilization of the polymer 
conjugate. 
 
2.4 Synthesis of PLA-PEG-OMe and PLA-PEG-COOH 
PLA-PEG-OMe (10k-b-5k) and PLA-PEG-COOH (10k-b-5k) block copolymers were 
synthesized by a ring-opening polymerization as previously described in 
literature [170]. 1H-NMR spectra were recorded in CDCl3 at 295 K using a Bruker 
Avance 300 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany). 
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2.5 Synthesis of PLA-PEG-cRGD 
Cyclo(RGDfK) was covalently conjugated to carboxy-modified PLA-PEG block 
copolymers via the lysine residue of the cyclic peptide [60,80]. In brief, 
PLA-PEG-COOH was dissolved in anhydrous DMF and the carboxylic acid function 
was activated by EDC (25 equiv.) and NHS (25 equiv.) for 2 hours. Then, BME 
(30 equiv.) was added to quench the reaction. DIPEA (10 equiv.) and cRGDfK (3 equiv.) 
were subsequently added and stirred for 24 hours. The ligand-modified copolymer 
was purified by several precipitation steps in diethyl ether/-methanol mixtures, 
followed by dialysis against water for 24 hours to remove excess free ligand and 
reactants.   
 
2.6 Preparation of polymeric nanoparticles 
Polymeric NPs were prepared via bulk nanoprecipitation [165]. In general, PLA-PEG 
and PLGA were diluted with acetonitrile to a final polymer concentration of 
10 mg mL-1. The copolymer ratio of PLA-PEG to PLGA was kept constant at 
60/40 (m/m). The polymer mixture was then added dropwise into 10 volumes of stirred 
DPBS. NP dispersions were stirred for 3 hours to remove the organic solvent and 
concentrated by centrifugation using 30 kDa molecular weight cut off Pall Microsep® 
Advance centrifugal filters (Pall, Dreieich, Germany). 
 
2.7 Physicochemical Characterization 
Spectral properties of hybrid NPs were analyzed on a FluoStar Omega fluorescence 
microplate reader (BMG Labtech, Ortenberg, Germany). Spectra were recorded 
between 400 and 800 nm. A solution of AuNP-NH2 served as reference. Size and 
morphology of hybrid polymer/gold NPs were evaluated on a Zeiss Libra 120 electron 
microscope (Zeiss, Oberkochen, Germany). NP samples were applied onto 
carbon-coated nickel grids (300 mesh; Plano, Wetzlar, Germany) and incubated for 3 
minutes. Excess sample solution was removed with a filter paper and sample grids 
were dried and stored in a desiccator before use.  Dynamic light scattering (DLS) 
measurements of polymeric and hybrid NPs were performed with a Malvern Zetasizer 
Nano ZS (Malvern, Herrenberg, Germany) equipped with a 633 nm He-Ne laser and 
operating at an angle of 173° and a constant temperature of 25 °C using semi-micro 
PMMA disposable cuvettes (Brand, Wertheim, Germany). The position from the 
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cuvette wall was set to 4.65 mm and the attenuator was optimized by the device. Data 
were collected and analyzed using the Malvern Zetasizer software version 7.11 
(Malvern Instruments, Worcestershire, United Kingdom).  
 
2.8 Cytotoxicity 
To assess the cytotoxicity of hybrid gold/polymer NPs compared to plain polymeric 
NPs, a metabolic assay using the reagent 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was performed according to ISO 10993−5:2009 
(Biological evaluation of medical devices, part 5: Tests for in vitro cytotoxicity). In brief, 
mouse fibroblast L-929 cells were seeded in 96-well plates at a density of 10,000 cells 
per well and allowed to adhere for 24 hours. NP formulations were prepared under 
aseptic conditions and treated with UV-light prior to the experiment to reduce the 
microbial burden. Samples with polymer concentrations ranging from 30 to 1000 µg 
mL-1 were prepared in EMEM medium supplemented with 10% FCS and added to the 
cells. The gold content in hybrid colloids was not considered for quantification; hence, 
both NP formulations were adjusted to equal PEG molarities which were determined 
by an iodine complexation assay as described in literature [192]. SDS (0.1%) served as 
a positive control and pure medium as a negative control (n = 6). Cells were incubated 
with the test media for 24 h, 37 °C and 5% CO2. Afterwards, sample solutions were 
gently aspirated and replaced by 50 µL of a solution containing 1.0 mg mL-1 MTT in 
EMEM medium. After 2 h of incubation, the MTT solution was removed and 100 µL 
isopropanol were added to each well. After 30 min of incubation under gentle shaking 
and light exclusion, absorbance at 570 and 690 nm was measured for each well using a 
FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). 
The difference in absorbance at 570 and 690 nm was used to calculate the viability of 
cells. The viability of treated cells was normalized to the value of the control media 
samples. Microscope images were recorded with a Nikon SD-U1 camera (Nikon, 
Düsseldorf, Germany) connected to a Leica DM IRB microscope (Leica, Wetzlar, 
Germany). 
 
2.9 Confocal laser scanning microscopy (CLSM) 
To evaluate the enhanced detectability of hybrid NPs which were co-labeled with the 
gold tag and an additional fluorescent marker, uptake in rat mesangial cells was 
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assessed by CLSM. For this experiment, cRGD-decorated hybrid NPs consisting of 
PLA-PEG-cRGD, PLGA-Au and PLGA-FAM at a ratio of 60/26.7/13.3 (m/m) were 
prepared via bulk nanoprecipitation into 10 mM borate buffer (pH 8.5) and the 
dispersant was changed to DPBS during the ultracentrifugation step. Rat mesangial 
cells were seeded into 8-well Nunc® Lab-Tek® Chamber Slide™ systems (Nunc, Inc., 
Naperville, IL) at a density of 15,000 cells per well. After overnight incubation to allow 
time for cell adhesion, cells were washed with PBS and treated with pre-warmed NP 
test solutions (200 µg mL-1) for 45 min at 37 °C. To suppress specific NP-receptor 
interactions, cells were simultaneously incubated with NPs and excess free cRGD 
(500 µM). Untreated cells served as control. Then, cells were rinsed in DPBS, fixed with 
2% paraformaldehyde in DPBS for 10 min, washed twice with DPBS, permeabilized 
with 0.1% Triton X-100 in DPBS for 10 min, and washed extensively with DPBS. The 
silver enhancement of gold tags was conducted according to the manufacturer's 
specification. In brief, cells were thoroughly rinsed in ultrapure water, covered with 
staining solution and incubated for 3 minutes at room temperature. Cells were 
subsequently washed with water, fixed with a 2.5% sodium thiosulfate solution for 
2 min and washed with DPBS. Samples were embedded in Mowiol aqueous 
embedding medium supplemented with 2.5% (w/v) DABCO and analyzed with a Zeiss 
Axiovert 200 microscope combined with an LSM 510 laser-scanning device at 63-fold 
magnification. NP fluorescence was excited with an argon laser at 488 nm and the 
emission was recorded using a 530/30 nm bandpass (BP) filter. The brightfield channel 
was used to detect the NP-associated silver-enhanced gold tags.
 
2.10 Transmission electron microscopy to assess cellular uptake 
For TEM experiments, rat mesangial cells were seeded into 24-well plates at a density 
of 70,000 cells per well and cultivated for 24 h. Peptide-decorated hybrid NPs were 
diluted with RGD binding buffer (20 mM TRIS, 150 mM NaCl, 2 mM CaCl2, 1 mM 
MgCl2, 1 mM MnCl2, 0.1% BSA) supplemented with 10 % FCS and incubated for 15 min 
at 37 °C to induce the formation of a protein corona. The pre-warmed NP test solutions 
(300 µg mL-1) were pipetted onto the cells and incubated for 45 min at 37 °C. Then, cells 
were washed, fixed with 2.5% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M 
sodium cacodylate buffer for 2 hours at room temperature, and rinsed with cacodylate 
buffer. Samples were washed with a solution of 50 mM glycine in DPBS, rinsed with 
water, and permeabilized with 0.1% Triton X-100 in DPBS for 10 minutes. After 
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extensive washing steps with DPBS and water, samples were gold enhanced according 
to the manufacturer's specification. In brief, cells were thoroughly rinsed in ultrapure 
water, covered with staining solution and incubated for 6 minutes at room 
temperature. Cells were subsequently washed with water, fixed with a 2.5% sodium 
thiosulfate solution for 2 min and washed with DPBS. Postfixation was performed for 
30 min in 0.5% osmium tetroxide at 4 °C. After several washing steps with 0.1 M 
cacodylate buffer, samples were dehydrated in a graded series of ethanol (50, 70, 80, 
90, 99.5%). En-bloc staining with 2% uranyl acetate in ethanol 70% was performed after 
dehydration with 70% ethanol. Afterwards, samples were embedded in Epon. 
Ultrathin sections with a thickness of about 150 nm were imaged without further 
contrasting at 120 kV using a Zeiss Libra 120 electron microscope (Zeiss, Oberkochen, 
Germany). 
 
2.11 Determination of gold content by ICP-OES 
The gold content of the hybrid NPs was determined using ICP-OES. NP samples were 
prepared in ultrapure water, lyophilized, and weighed out. Samples were dissolved in 
freshly prepared aqua regia and diluted to 5 mL with ultrapure water. Polymer 
precipitates were removed by centrifugation at 5000 rpm for 10 min and subsequent 
filtration of the supernatant through a 0.45 µm PES filter. The Au3+ content of the 
solution was determined by ICP-OES analysis on a Spectro Flame-EOP (Analytical 
Instruments GmbH, Kleve, Germany). Gold(III) chloride solutions with concentrations 
of 1, 5, 10, 20 and 25 ppm were used for calibration. 
 
2.12 Statistical analysis 
All results are presented as mean ± standard deviation, based on the data obtained 
from at least n = 3 samples. Statistical significances between two groups were evaluated 
by Student's t-test using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, 
USA). Statistical significances were set as indicated.     
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3 Results and discussion 
3.1 Synthesis of block copolymers and preparation of nanoparticles 
Pre-modification of block copolymers with ligands, gold- or fluorescent tags enable the 
combination of different polymers during NP manufacturing and thus allow for 
precise control over gold content and NP composition. Figure 1A outlines the synthesis 
strategies of functionalized copolymers and conjugates. Hydrophilic AuNPs were 
covalently conjugated to hydrophobic PLGA by EDC/NHS chemistry [277]. In contrast 
to the highly water soluble AuNP-NH2, the PLGA-Au conjugate was soluble in organic 
solvents (Figure S9). 
 
 
 
Figure 1. (A) Synthesis of PLGA-Au, PLGA-FAM, PLA-PEG-OMe and PLA-PEG-cRGD (B) Preparation of 
different NP formulations by mixing various functionalized PLGA and PLA-PEG block copolymers.  
 
Results and discussion  
123 
For the preparation of fluorescently labeled PLGA a novel conjugation strategy was 
applied, using DMTMM which is already established as highly efficient coupling 
reagent [278]. In contrast to EDC/NHS activation, addition of DIPEA is not necessary 
since the reaction proceeds independently of pH. PLA-PEG-OMe and 
PLA-PEG-COOH block copolymers were synthesized by a ring-opening 
polymerization according to literature [170], and the carboxylic acid function was 
further modified with a c(RGDfK) ligand. Complete conjugation was confirmed using 
a 9,10-phenanthrenequinone assay [83]. 
In this work, three different NP formulations were prepared, as depicted in Figure 1B. 
Plain polymeric and polymer/gold hybrid NPs were composed of PLA-PEG-OMe and 
PLGA terminated with either free carboxylic acid groups or conjugated gold tags, 
respectively. These two formulations were analyzed and compared regarding their 
physicochemical properties and cytotoxicity towards L-929 cells. In contrast, 
cRGD-decorated hybrid NPs also contained an additional fluorescence tag inside the 
particle core and were further decorated with an ανβ3 integrin binding ligand to 
enhance cellular uptake. This particular NP formulation was used to demonstrate the 
advanced detectability of gold/polymer hybrid NPs in optical and transmission 
electron microscopy. 
 
3.2 Comparative characteristics of hybrid nanoparticles 
In principle, the resulting block copolymer NPs display a core/shell structure, with a 
hydrophobic core consisting of PLGA and PLA and a hydrophilic PEG shell. In the case 
of the gold-tagged hybrid NPs, TEM images revealed a stratified composition with an 
additional gold layer at the core/shell interface (Figure 2A). Due to this gold layer, 
nanoscaled hybrid colloids were detectable in TEM even without further staining. As 
PEG is highly radiation sensitive, it depolymerizes and evaporates rapidly in the 
electron beam. As a result, the hydrophilic particle shell is not visible without further 
staining [279]. Because gold nanoparticles display discrete spectral properties 
depending on their size and shape, the absorbance spectra of gold (AuNP-NH2) and 
hybrid NPs, which were assembled by nanoprecipitation of gold-tagged PLGA and 
PLA-PEG block copolymers, were recorded and evaluated regarding their absorbance 
maxima. AuNP-NH2 exhibited localized surface plasmon resonance (LSPR) absorption 
with a maximum at approximately 505 nm. Nonetheless, the intensity of the LSPR 
absorption was quite low, which is characteristic of AuNPs with a size smaller than 3 
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nm [280]. Compared to unconjugated 2.2 nm AuNPs, hybrid NPs displayed a slight 
red-shift of the absorbance maximum to 512 nm (Figure 2B). In the case of hybrid NPs, 
the small gold particles, which are embedded in the polymer matrix, are in close 
proximity to each other, pretending an aggregated state in the absorbance spectrum. 
Moreover, previous studies have reported that a red-shift of the LSPR band does not 
exclusively occur in case of aggregation, but also if the refractive index in the 
surrounding of the AuNP is increased [281].  
In a further experiment, physicochemical characteristics of hybrid and polymeric NPs, 
consisting of plain PLGA and PLA-PEG copolymers, were determined. Dynamic light 
scattering was used to evaluate the impact of incorporated nanogold on size and size 
distribution of hybrid NPs. 
 
 
 
Figure 2. (A) Unstained TEM images of hybrid NPs revealed a stratified composition with an additional 
gold layer at the core/shell interface. Scale bar indicates 100 nm. Black and white asterisks indicate 
magnified picture sections. (B) Absorbance spectra of AuNP-NH2 and hybrid NPs. Incorporation of 
AuNP-NH2 into the polymer matrix led to a slight red-shift of LSPR absorbance which was also confirmed 
by the optical appearance. (C) Hydrodynamic diameter and PDI, (D) intensity-weighted size distribution 
and (E) ζ-potential of plain polymeric NPs and gold/polymer hybrid NPs. Levels of significance are 
indicated as: (**) p < 0.01, comparing polymeric NPs and hybrid NPs. 
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Compared to polymeric NPs, hybrid NPs displayed a moderate increase in 
hydrodynamic size from 71.8 to 89.5 nm and a slight decrease in PDI from 0.244 to 0.223 
(Figure 2C). The average intensity-weighted size distribution of hybrid NPs was only 
slightly shifted towards larger particle sizes. In contrast to hybrid NPs, polymeric NPs 
showed an additional peak at around 10 to 20 nm, which could be attributed to a small 
fraction of polymeric micelles (Figure 2D). Although the increase in size could be 
explained by the introduction of an additional gold layer, it has to be considered that 
the hydrodynamic diameter, as measured by DLS, is also influenced by the particle 
charge and hydrophilicity of the surface which determines the extent of hydration. 
Nonetheless, these results indicate that the introduction of gold tags into the polymer 
matrix caused only minor changes in size and size distribution. Compared to polymeric 
NPs (-10.9 mV), hybrid NPs displayed less pronounced negative charge (-4.3 mV). This 
might be the result of amide bond formation via gold conjugation to the carboxylic acid 
groups of the PLGA polymer, leading to a less negatively-charged core of the 
polymeric particles (Figure 2E).  
 
3.3 Cytotoxicity 
Although, colloids consisting of biodegradable PLGA and PLA-PEG are considered 
biocompatible and safe for medical applications [282], insertion of gold tags can alter 
cytotoxicity of NPs. For instance, addition of the gold layer can influence particle 
integrity and thus, might trigger the release of amphiphilic polymer chains, which 
could then integrate into cell membranes and cause membrane damage and cell 
death [283,284]. To assess the cytotoxicity of the hybrid NPs in comparison to 
polymeric NPs, an MTT assay was performed in accordance with the ISO guideline 
10993−5:2009. Neither polymeric nor gold/polymer hybrid NPs exhibited considerable 
cytotoxicity (Figure 3A) or changes in cell morphology (Figure 3B) over the tested range 
of concentrations. Viability of L-929 cells treated with NP dispersions was above 70%, 
which is the threshold of biocompatibility after a 24 h incubation period according to 
the ISO guideline.  
As demonstrated in Figure 3, introduction of small 2.2 nm AuNPs into the colloidal 
system had no negative influence on cell viability (Figure 3A) or cell morphology 
(Figure 3B) at doses up to 1000 µg mL-1. Due to covalent conjugation to the core 
polymers, gold particles are located at the core/shell interface. As a result, the gold tags 
are efficiently covered by the PEG chains, which impede direct contact between gold 
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NPs and cell membranes and, furthermore, diminish nonspecific NP uptake. Although 
hybrid NPs can be considered non-toxic in vitro, the in vivo biocompatibility needs to 
be further assessed. 
 
 
 
Figure 3. L-929 cell viability after 24 h incubation with polymeric and hybrid NPs. (A) Cell viability after 
treatment with different NP concentrations. The dotted line indicates cytotoxicity according to the ISO 
guideline. Levels of statistical significance are indicated as: (*) p < 0.05, comparing polymeric NPs with 
hybrid NPs at equal polymer concentrations. (B) Morphology of untreated control cells and L-929 cells 
incubated with either 1000 µg mL-1 of polymeric or hybrid NPs. 
 
 
3.4 Simultaneous detection of fluorescence and gold tags in CLSM 
To evaluate enhanced detectability in optical microscopy, fluoresceinamine-labeled 
cRGD-decorated hybrid NPs were used for an uptake study in rat mesangial cells. After 
incubation with sample solutions, cells were further treated with a silver enhancer kit 
to induce particle growth of the gold tags to a visible size. Cellular uptake was 
investigated and detected by recording the fluorescence image for detection of the 
fluorescein tag, the bright-field image for detection of the silver enhanced gold label, 
and merged images to evaluate colocation of both imaging tags. Compared to the 
control, cells incubated with cRGD-decorated hybrid NPs displayed efficient uptake of 
NPs, which accumulated in endosomes (Figure 4). Addition of excess free ligand 
resulted in complete suppression of NP-cell interaction, demonstrating that the 
fluorescence and gold/silver signal could be attributed to the specific integrin 
receptor-mediated uptake and did not derive from non-specific adhesion to the cellular 
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membrane. This receptor-mediated endocytosis pathway of cRGD-modified colloids 
has been reported in previous studies [217]. Interestingly, this NP uptake could be 
simultaneously detected by fluorescence and transmitted light microscopy. 
Furthermore, overlays of the fluorescence and the bright field channels demonstrated, 
that gold/silver precipitates were clearly colocalized with the fluorescence signals, 
indicating that the particles were still intact and that the gold/silver signals were not 
derived from nonspecific auto-nucleation of silver ions on the well surface. This 
observation was confirmed by the control cell sample, which was also treated with the 
silver enhancer and exhibited no auto-nucleation of the silver ions as well. 
 
 
 
Figure 4. CLSM images of untreated control cells (left) and rat mesangial cells after incubation with 
cRGD-decorated hybrid NPs (middle). Excess free cRGD was used to suppress specific NP-receptor 
interaction (right). Cells were subsequently fixed, permeabilized and silver enhanced. Scale bars indicate 
20 µm. 
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These results are particularly interesting because previous studies have shown, that the 
combination of fluorescent dyes and AuNPs often results in strong quenching of 
fluorescence emission due to nonradiative energy transfer from the energy donor 
(e.g. a fluorescein derivative) to the gold particle, which acts as an energy 
acceptor [285-287]. In the case of AuNPs, two mechanisms for the energy transfer have 
been extensively discussed, fluorescence resonance energy transfer (FRET) and 
nanometal surface energy transfer (NSET). In both cases, the energy transfer is strongly 
distance dependent with d-6 and d-4 correlations, respectively, where d is the 
center-to-center distance between the fluorophore and the metal NP [288,289]. Since 
FRET requires a distinct LSPR band [290], it is the predominant process for samples 
containing gold particles larger than 5 nm, while NSET prevails for smaller NPs with 
a low intensity or even absence of the LSPR [280]. While AuNPs are located at the 
core/shell interface of the hybrid NPs due to their hydrophilic properties, fluorescein 
becomes more hydrophobic after grafting to the PLGA polymer and, as a result, is 
assumed to be localized in the particle core. Hence, most of the fluorophores inside the 
polymeric core are spared from quenching because the distance is too far for efficient 
energy transfer (Figure S10). Since the small AuNPs only exhibited weak LSPR 
absorbance, FRET will probably not occur. Emission spectra of hybrid NPs revealed 
that the maximum fluorescence intensity was reduced by only 15.1% upon 
introduction of AuNPs compared to fluorescein-labeled hybrid NPs with no gold tag 
(Figure S11).  
This uptake experiment demonstrates the advanced detectability of hybrid NPs in 
optical microscopy, since fluorescence and enlarged AuNPs can be detected at the same 
time. 
 
3.5 Enhanced detection of cRGD-decorated hybrid NPs in TEM  
Gold particles have become an important tool for immunostaining of tissue sections 
because they display excellent contrast in TEM images due to their high electron 
density and allow for localization of cellular nanostructures by conjugating the gold 
tags to primary or secondary antibodies. Since TEM analysis provides a higher 
resolution compared to conventional fluorescence analysis, it is commonly used to 
investigate uptake of AuNPs into cells or biodistribution in tissues after systemic 
administration. In contrast, TEM visualization of polymeric NPs in tissue sections often 
requires a lot of effort and time, and is only feasible for NPs bearing a fluorescent tag 
Results and discussion  
129 
used for the photoconversion of a substrate to an electron-dense precipitate after 
embedding samples in epoxy and acrylic resins [291]. Therefore, cRGD-decorated 
hybrid NPs were utilized to evaluate the enhanced detectability in TEM (Figure 5). 
Uptake of cRGD-decorated hybrid NPs was again investigated using rat mesangial 
cells, followed by treatment with a gold enhancer kit. In contrast to the silver 
enhancement, particle growth of the gold enhancement proceeds in a slower and more 
controlled manner. Besides, the additional gold layer which is formed around the 
AuNP has a lower propensity to dissolve upon fixation and staining with osmium 
tetroxide compared to the silver enhanced counterparts [292]. Due to the gold 
enhancement, enlarged gold-tagged hybrid NPs were clearly visible even at lower 
magnifications and had a size in the range of 80 to 150 nm. For gold enhancement, 
samples were incubated for six minutes which was expected to increase the gold tags 
to a single particle size of approximately 5 nm. 
 
 
 
Figure 5. TEM images of rat mesangial cells treated with cRGD-decorated hybrid NPs and subsequent 
gold enhancement. Picture sections A-D show magnifications of gold-enhanced hybrid NPs within 
vesicles. Images were acquired at 6300-fold magnification. Scale bar indicates 1000 nm. 
 
 
Since NPs are multi-tagged with numerous AuNPs at the core/shell interface, hybrid 
NPs are not only enlarged, but display excellent contrast in this biological setting. As 
depicted in Figure 5, cRGD-decorated hybrid NPs were internalized by the cells and 
accumulated in intracellular vesicles, which were homogeneously distributed in the 
cytoplasm. In contrast, untreated control cells did not form intracellular vesicles and 
showed no formation of gold deposits caused by nonspecific auto-nucleation of the 
gold enhancement (Figure S12). 
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3.6 Quantification of gold content by ICP-OES 
ICP-OES was used to quantify the gold content of both NP formulations that were used 
for in vitro studies. For hybrid NPs consisting of 40% (m/m) PLGA-Au, the gold content 
was (0.75 ± 0.01)%. For preparation of cRGD-decorated hybrid NPs, 13.3% (m/m) of 
PLGA-Au were substituted by PLGA-FAM, resulting in a lower gold content of 
(0.50 ± 0.01)% (Table 1). A detailed list of single results and calculations of the gold 
content can be found in the supplemental information (Table S3). These results clearly 
demonstrate that the gold content can be adjusted using different amounts of 
PLGA-Au during NPs manufacturing. To further increase the gold content, a higher 
stoichiometric ratio of monoamine gold NPs to PLGA can be used in the conjugation 
reaction. Depending on the gold content, as well as the dose applied, hybrid NPs might 
even enable quantitative biodistribution analysis by inductively coupled plasma mass 
spectrometry (ICP-MS) after systemic administration. For instance, laser ablation 
inductively-coupled plasma mass spectrometry (LA-ICP-MS) has already been used to 
quantify the distribution of 2 nm monolayer-protected AuNPs in tissues after 
intravenous injection into mice. The total dose of injected gold was as low as 4000 ng 
per mouse and even small gold amounts of approximately 10 ng g-1 (i.e. 10 ppb) could 
be quantified in tissue sections [293].  
 
 
Table 1: Gold content of hybrid NP formulations with different copolymer ratios measured by ICP-OES.  
 
Formulation Copolymers Polymer Ratio (m/m) Au content/ % 
Hybrid  NPs PLA-PEG/PLGA-Au 60/40 0.75 ± 0.01 
cRGD-decorated 
hybrid NPs 
PLA-PEG-cRGD/ 
PLGA-Au/PLGA-FAM 
60/26.7/13.3 0.50 ± 0.01 
 
 
Since polymeric NPs are generally utilized at polymer quantities up to 5 mg for 
intravenous administration in mice [294], the dose of gold present in the hybrid NPs is 
considered high enough for this experimental design. Henceforth, it would be of great 
interest to evaluate the in vivo biodistribution of hybrid NPs after systemic 
administration in the future. 
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4 Conclusion 
In this study a multifunctional self-assembling nanocarrier system was developed in 
which targeting ligands and fluorescently labeled polymers can be combined with an 
additional gold tag. Introduction of small gold nanoparticles had only minor impact 
on particle size and no effect on the biocompatibility compared to plain polymeric NPs. 
Hybrid NPs exhibited only a weak LSPR, allowing combination with an additional 
fluorescent tag and the concomitant detection of both labels by optical microscopy. 
Furthermore, targeted hybrid NPs could be localized and detected after 
receptor-mediated internalization in cells by transmission electron microscopy after 
enlargement of gold tags via gold enhancement. The gold content incorporated into 
hybrid NPs was high enough to enable future quantification in tissue after systemic 
administration, e.g. via (LA)-ICP-MS. Pre-modification of polymers with gold or 
fluorophores, as well as conjugation of targeting ligands enables precise control of 
physicochemical properties, such as size, PEG density, ligand modification, and the 
content of gold and fluorescent tags. With their superior detectability, hybrid 
gold/polymer NPs open up new paths of detection for polymeric colloids. Since they 
can be further loaded with hydrophobic drugs or surface-decorated with multiple 
types of ligands, hybrid NPs represent an outstanding nanocarrier system for 
biomedical applications which require both, tunable drug targeting abilities and 
excellent imaging properties.  
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8.1 Summary 
The use of conventional small-molecular drugs is often accompanied by undesired side 
effects derived from their intrinsic toxicity and their non-specificity. As introduced in 
Chapter 1, colloidal drug delivery systems have outstanding potential to deliver 
therapeutics more safely and more efficiently [9]. In particular, receptor-mediated 
targeting can be used to direct nanoparticles (NPs) to the site of disease and trigger 
their endocytosis [11]. This approach holds great promise to treat a variety of severe 
diseases. Among those, diseased kidneys are particularly promising targets since the 
renal filter integrity is often impaired in the diseased state. However, a myriad of 
parameters have to be taken into account when designing colloidal delivery systems 
for renal targeting [12]. This complexity explains why effective renal targeting remains 
an unmet medical need. 
The targeting ability of NPs is largely determined by target-ligand interactions. 
However, the extent of interaction is governed by various particle attributes. Besides 
ligand density, NP size and shape are without doubt both essential key factors since 
they determine the interfacial contact area between a particle and its target site [65,212]. 
Therefore, manufacturing of NPs with uniform shape and size is mandatory to ensure 
successful and reliable targeting. To this end, microfluidic NP synthesis was evaluated 
and compared to the standard procedure in the field: bulk nanoprecipitation. It was 
found that nanoprecipitation generally results in formation of larger particles with a 
wide size distribution, whereas microfluidic synthesis allowed for the manufacturing 
of highly monodisperse NPs of defined size. Among the critical process parameters of 
microfluidic manufacturing, the flow rate ratio was identified to be the key 
determinant for tuning the size distribution, whereas particle size was mainly 
controlled by the total flow rate. In summary, is was demonstrated that the microfluidic 
synthesis of NPs is clearly superior to nanoprecipitation and has outstanding potential 
for the scalable preparation of NPs with reproducible attributes (Chapter 3). 
While physicochemical characteristics certainly play a pivotal role for the NPs' 
performance as a delivery vehicle, their influence on the interactions with their 
environment in vivo should not be overlooked. For example, serum proteins are known 
to be deposited at the NP surface resulting in formation of a protein corona which has 
a major impact on the in vivo performance of colloidal drug delivery systems [29]. For 
instance, adsorption of opsonins on the colloidal surface substantially enhance NP 
sequestration by the reticuloendothelial system and can severely compromise colloidal 
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stability. Therefore, it is truly surprising how little is known about the influence of NP 
characteristics on the interaction with serum proteins. In order to gain a better 
understanding in this area, the impact of particle charge (negative, positive, 
zwitterionic) and hydrophobicity (non-charged) on the interaction with serum proteins 
was studied. Due to strong attractive electrostatic interactions, positively charged NPs 
formed the most distinct protein corona, followed by uncharged and negatively 
charged NPs, and finally zwitterionic NPs with the lowest amount of deposited 
protein. This enhanced interaction with serum proteins significantly impaired the 
colloidal integrity since the lipophilic cargo was continuously leached out of the 
hydrophobic NP core. In summary, these findings highlight the critical influence of 
protein-particle interactions on NP integrity and colloidal stability (Chapter 4). 
Although there is a large number of studies available evaluating the therapeutic 
efficacy of targeted polymeric NPs, little is known about the critical attributes that can 
further influence their uptake into target cells. In literature, the degree of 
functionalization [59] is widely considered the main determinant for controlling uptake 
efficiency of targeted colloids while the linker length is often overlooked. In order to 
gain a deeper understanding of the combinational influence of both parameters the 
impact of varying cRGD ligand densities and poly(ethylene glycol) (PEG) spacer 
lengths on the specific receptor binding of core/shell structured polymeric NPs was 
investigated. When NPs with complete surface functionalization and short versus long 
linkers were compared, short PEG chains displayed a significantly higher tendency to 
form colloidal clusters which facilitated cooperative binding to integrin receptors on 
the cell membrane. In contrast, the use of longer and more flexible PEG chains 
enhanced the chance of ligand shrouding which significantly impeded ligand-receptor 
interactions. These results highlight the importance to consider the role of the linker 
length when designing targeted NPs (Chapter 5).  
There are numerous examples where nature has inspired researchers to create high 
performance materials for medicine, engineering and other fields. For targeted 
delivery, viruses could serve as blueprints to optimize selective targeting of NPs. In 
order to mimic the binding sequence of viruses and utilize this selective targeting 
strategy for the treatment of renal diseases, polymeric core/shell structured 
nanocarriers were prepared and decorated with two mesangial cell-specific targeting 
ligands. In this system, the primary ligand (AT1R blocker) was used for the first 
recognition of the target cell via binding to the AT1R, whereas the secondary ligand 
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(cRGD) was initially “invisible” for the cell and interacted with the secondary receptor 
(avβ3 integrin) in a time-shifted manner, following endocytosis of the colloid. Laser 
scanning confocal microscopy and flow cytometry experiments confirmed that 
dual-targeted NPs displayed synergistic targeting effects with enhanced selectivity as 
compared to NPs decorated with a single type of targeting ligand. Consequently, such 
virus-inspired heteromultivalent NPs offer a versatile platform for delivering 
therapeutic cargos to a target site with significantly improved specificity and targeting 
efficiency (Chapter 6).  
All previous chapters were focused on generating a better understanding for factors 
that can impact the performance of targeted NPs and use this knowledge to create 
optimized colloidal delivery systems. However, in order to proof a NP´s efficacy in vivo 
its fate after intravenous injection has to be tracked precisely. In this context it should 
be mentioned that the simultaneous qualitative and quantitative detection of polymeric 
NPs in cells and tissues is a largely unmet need which is owed to their poor visibility 
in biological environments [259]. As this is a main factor which compromises the 
transition of polymeric NPs from preclinical research to clinical trials, NPs that can 
both be visualized with transmission electron microscopy and fluorescence imaging 
were developed. Small gold NPs were attached to poly(lactic-co-glycolic acid) 
(PLGA-Au) and introduced as a contrast agent into poly(lactic acid)-poly(ethylene 
glycol) (PLA- PEG) block-copolymer NPs. Due to their unique stratified composition 
with a hydrophobic PLA/PLGA core, a single gold layer at the core/shell interface and 
an outer PEG shell, these hybrid NPs exhibited outstanding detectability by 
transmission electron microscopy, even without the addition of contrast agents. 
Combination with an additional fluorescence label resulted in a negligible degree of 
fluorescence quenching which allowed for concomitant detection of the gold and the 
fluorescent label by optical microscopy. Moreover, the gold content of hybrid NPs is 
sufficiently high for the quantification in tissues after systemic administration. Due to 
their superior detectability and their unique properties, hybrid PLGA-Au/PLA-PEG 
NPs constitute an outstanding blueprint and tool for the development of 
nanomedicines (Chapter 7).  
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8.2 Conclusion 
In this study, various novel concepts have been established that will facilitate the 
development of effective nanomedicines or improve existing delivery strategies. For 
example, the gained knowledge about protein corona formation should be applied to 
develop polymeric NPs with reduced serum protein deposition, which can circumvent 
impairment of the in vivo performance. Sequential binding of dual-targeted 
nanocarriers has been demonstrated to enhance targeting specificity and efficiency and 
therefore, can be of high value for the development of advanced drug delivery systems 
with significantly reduced systemic toxicity. Finally, gold/polymer hybrid NPs could 
serve as s powerful instrument to track polymeric NPs after administration and thereby 
contribute to gain a better understanding for their biodistribution. Future studies 
should be focused on applying these concepts in preclinical studies to assess their 
potential in animal models. In particular, drug loaded polymeric NPs with 
virus-mimetic binding should be employed in combination with a disease models of 
diabetic nephropathy to investigate their therapeutic potential.  
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Supplementary Data 
 
A) Supplementary data to chapter 4 
 
 
Figure S1. Determination of the NP concentration by an iodine assay. The linear correlation of PEG content 
and total polymer concentration of (A) NP510C, (B) NP510N, (C) NP510CN and (D) NP510m allows for 
an absorbance based quantification of PLA-PEG/PLGA NPs.  
 
 
 
 
 
 
Figure S2. Particle size and PDI of NP510N in either DPBS pH 7.4 (diamonds) or DPBS supplemented with 
45 mg mL-1 BSA (circles). NP samples were incubated at 37 °C for up to 12 hours and size was measured 
in 0.5 h intervals. 
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B) Supplementary data to chapter 5 
 
 
Figure S3: Determination of NP concentration using an iodine complexation assay. (A) Absorbance 
intensity as a function of PEG content (1-50 µg mL-1). (B) The linear correlation of polymer concentration 
in formulated NPs (PLA-PEG-COOH, 10k-b-5k and PLGA at a mass ratio of 70/30) and PEG content allows 
for a quantification of the NP concentration. Since NPs with different block copolymers (PLA-PEG-COOH, 
10k-b-3.5k and 10k-b-2k) were prepared using a constant ratio of PLA-PEG to PLGA molarity, NP 
concentrations of NP-cRGD-5k, NP-cRGD-3.5k and NP-cRGD-2k were adjusted to equal PEG molarities 
(based on Mw(PEG) provided by material specification sheets). 
 
 
 
 
Figure S4: TEM image of cRGD-decorated NPs with different PEG-linker lengths: (A) 2 kDa, (B) 3.5 kDa, 
(C) 5 kDa. Particle size and aggregation tendency increased with decreasing PEG-linker length. Scale bar 
indicates 200 nm.  
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Figure S5. Number-weighed particle size distribution of (A) NP-cRGD-2k, (B) NP-cRGD-3.5k and 
(C) NP-cRGD-5k with different ligand densities (0-100 %) determined by DLS. Preparation of targeted NPs 
with shorter PEG-linkers resulted in an increase in nanoparticle size and a broader particle size 
distribution. 
 
 
 
 
 
 
 
Figure S6. Quantification of targeted NP surface composition. (A) Estimated ligand density expressed as 
number of ligands per µm² and (B) estimated number of ligands per NP or cluster. Values were calculated 
based on the number of functionalized-PEG molecules of each formulation and the z-average size of NPs 
and colloidal clusters. 
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Figure S7. Cellular uptake of NPs consisting of a constant amount of PLGA and different ratios of 
PLA-PEG-COOH and PLA-PEG-OMe. The charged carboxylic acid groups were gradually substituted by 
uncharged methoxy-groups leading to control NPs with varying surface charge. All NP formulations were 
prepared and handled as described for cRGD-decorated NPs. Independent of their charge, all five control 
NP formulations did not bind to integrin receptor on U87MG cells. 
 
 
 
 
 
 
 
 
Figure S8. Mean cell-associated fluorescence as a function of ligand density of (A) NP-cRGD-2k, 
(B) NP-cRGD-3.5k and (C) NP-cRGD-5k. The ligand density was calculated based on the grafting density 
of non-modified NP-cRGD0-2k, NP-cRGD0-3.5k and NP-cRGD0-5k multiplied with the respective surface 
functionalization degree (%) as determined by PCA. Changes in particle size and rearrangement of PEG 
linkers upon cluster formation were not taken into consideration. Data were fitted with a first (dotted light 
grey line) and second order (solid dark grey line) polynomial. 
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Table S1: Absolute ligand densities (number per µm2) of different NP formulations were correlated with 
corresponding cell-associated fluorescence levels. Data were fitted with second order polynomial.  
 
NP formulation First order polynomial fit R² 
NP-cRGD-2k y = -2.054 + 0.0003116x 0.9970 
NP-cRGD-3.5k y =  2.498 + 0.0001645x 0.9732 
NP-cRGD-5k y =  3.332 + 0.0001995x 0.9877 
 
 
 
Table S2: First order polynomial fit of uptake kinetics.  
 
NP formulation 
First order polynomial 
15-120 min 
R² 
First order polynomial 
15-180 min 
R² 
NP-cRGD100-2k y = 33.36 + 4.745x 0.9999 y = 57.37 + 4.255x 0.9925 
NP-cRGD100-3.5k y = 24.48 + 1.195x 0.9998 y = 32.15 + 1.038x 0.9873 
NP-cRGD100-5k y = 11.11 + 0.9720x 0.9998 y = 24.34 + 0.7014x 0.9230 
NP-cRGD0-5k y = 0.2965 + 0.04739x 0.9985 y = 0.4018 + 0.04523x 0.9982 
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C) Supplementary data to chapter 7 
 
 
Figure S9. Partitioning of AuNP-NH2 before (left) and after (right) covalent conjugation to PLGA in water 
and dichloromethane. Unconjugated AuNP-NH2 were primarily present in the aqueous phase, whereas 
PLGA-Au conjugates were primarily present to the organic phase. 
 
 
 
 
Figure S10. Scheme illustrating the structure of fluorescent and gold labeled NPs. The grey area indicates 
the maximum distance of energy transfer. Most of the fluoresceinamine molecules inside the NP core are 
spared from quenching due to the long distance from the gold particles. 
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Figure S11. Fluorescence intensity of fluorescein-labeled NPs as a function of gold content. The contents 
of PLA-PEG-MeO and PLGA-FAM were kept constant at 60.0% and 13.3% (m/m), respectively, whereas 
PLGA-Au (27.7%) was gradually replaced by unlabeled PLGA (0, 25, 50, 75, 100% referring to PLGA-Au) 
to manufacture NP with gold contents of 0, 0.13, 0.25, 0.38, 0.50 wt%. NP-associated fluorescence was 
excited at 460 nm and spectra were recorded between 485 and 620 nm. Spectra smoothing was performed 
using a Savitzky-Golay polynomial. 
 
 
 
Figure S12. TEM image of untreated rat mesangial cells after gold enhancement. Control cells did not form 
intracellular vesicles and showed no formation of gold deposits caused by nonspecific auto-nucleation 
during gold enhancement. Scale bar indicates 500 nm.  
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Table S3: Calculation of the relative gold content in different hybrid NP formulations determined by 
ICP-OES.  
 
NP 
formulation 
Gold content NP content 
Mass (Au) per 
mass (NP) 
Gold 
content 
ppm (1) mg mL-1 (2) mg (3) mg mL-1 (4) µg mg-1 (5) % (6) 
Polymeric 
NPs 
(no gold) # 
0.12 0.00012 7.92 1.58 0.07 0.01 
0.11 0.00011 7.92 1.58 0.07 0.01 
0.12 0.00012 7.92 1.58 0.07 0.01 
0.13 0.00013 7.92 1.58 0.08 0.01 
0.09 0.00009 7.92 1.58 0.06 0.01 
Hybrid NPs 
13.67 0.01367 9.15 1.83 7.47 0.75 
13.62 0.01362 9.15 1.83 7.44 0.74 
13.73 0.01373 9.15 1.83 7.50 0.75 
13.74 0.01374 9.15 1.83 7.51 0.75 
13.92 0.01392 9.15 1.83 7.61 0.76 
cRGD-
decorated 
polymeric 
NPs 
(no gold) # 
0.19 0.00019 8.05 1.61 0.12 0.01 
0.17 0.00017 8.05 1.61 0.11 0.01 
0.14 0.00014 8.05 1.61 0.08 0.01 
0.14 0.00014 8.05 1.61 0.09 0.01 
0.12 0.00012 8.05 1.61 0.07 0.01 
cRGD-
decorated 
hybrid NPs 
 
5.60 0.00560 5.73 1.15 4.89 0.49 
5.66 0.00566 5.73 1.15 4.94 0.49 
5.76 0.00576 5.73 1.15 5.03 0.50 
5.83 0.00583 5.73 1.15 5.09 0.51 
5.73 0.00573 5.73 1.15 5.00 0.50 
 
(1) Determined by ICP-OES, (2) Calculated as gold concentration in 1 mL of sample solution, 
(3) Weighed out after lyophilization, (4) Calculated as NP concentration in 5 mL of sample 
solution, (5) Calculated as mass of gold per mass of NP, (6) Gold content in NP formulation.
# Unlabeled NPs were used as blanks to determine the background signal of respective hybrid 
NP samples. 
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Abbreviations 
 
ACN   acetonitrile 
ANOVA  analysis of variance 
Anx   anginex 
APS   ammonium persulfate 
ARB   angiotensin receptor blocker 
AT1R   angiotensin II receptor type I 
AuNP   gold nanoparticle 
BME   2-Mercaptoethanol 
BP   band pass 
BSA   bovine serum albumin 
CDCl3   deuterated chloroform 
CE   conjugation efficiency 
cyclo(RGDfK)  cyclo(Arg-Gly-Asp-D-Phe-Lys) 
CLSM   confocal laser scanning microscopy 
DABCO  1,4-Diazabicyclo[2.2.2]octane hydrochloride 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM   dichloromethane 
DLS   dynamic light scattering 
DiD 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine 
perchlorate  
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DiI 1,1’-Dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate 
DiO   3,3’-dioctadecyloxacarbocyanine perchlorate 
DIPEA   N,N-Diisopropylethylamine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF   N,N-Dimethylformamide 
DMSO   dimethyl sulfoxide 
DN   diabetic nephropathy 
D2O   deuterium oxide 
DPBS   Dulbecco’s phosphate buffered saline 
EC50   half maximal effective concentration 
EC80   concentration that leads to 80% of the maximum response 
EDC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride 
EGF epidermal growth factor 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic 
acid 
EMEM Eagle’s minimal essential medium 
EPR enhanced permeation and retention 
ESRD end-stage renal disease 
FACS fluorescence activated cell sorting 
FAM fluoresceinamine 
FCS fetal calf serum 
FRET fluorescence resonance energy transfer 
FRR flow rate ratio 
GBM  glomerular basement membrane
GFB  glomerular filtration barrier 
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GPCR  G protein-coupled receptor
HA   hemagglutinin 
HC   hard corona 
IA   iodine complexation assay 
IC50   half maximal inhibitory concentration 
LA-ICP-MS   laser ablation inductively-coupled plasma mass spectrometry 
ICP-MS  inductively coupled plasma mass spectrometry 
ICP-OES  inductively coupled plasma optical emission spectroscopy  
LP long pass 
LSPR localized surface plasmon resonance 
mAb monoclonal antibody 
MPS mononuclear phagocyte system 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW   molecular weight 
NA   neuraminidase 
NHS   N-hydroxysuccinimide 
NP   nanoparticle 
NSET   nanometal surface energy transfer 
ntNP   non-targeted nanoparticles 
PC   protein corona 
PCA   9,10-phenanthrenequinone assay 
PDI   polydispersity index 
PEG   poly(ethylene glycol) 
PFA   paraformaledhyde 
PLA   poly(lactic acid) 
PLGA   poly(lactic-co-glycolic acid) 
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ppb   parts per billion 
ppm   parts per million 
PVP   polyvinylpyrrolidone 
RAAS   renin-angiotensin-aldosteron system 
Re   Reynold’s number 
RES   reticuloendothelial system 
RGD   (Arg-Gly-Asp) 
RT   room temperature 
SC   soft corona 
SDS   sodium dodecyl sulfate  
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
SFD   surface functionalization degree 
SPR   surface plasmon resonance 
TEM   transmission electron microscopy 
TEMED  tetramethylethylendiamin 
TFA   trifluoroacetic acid 
TFR   total flow rate 
TMS   tetramethylsilane 
TMSP   3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt 
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